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Abstract 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease (AD) affecting about 1-2% of the population over 65 years of age 
(Farrer, 2006). The pathological hallmarks of PD are the loss of dopaminergic neurons in 
the substantia nigra pars compacta (SNpc) and the presence of intracellular 
proteinaceous inclusions called “Lewy bodies” (LB) in surviving neurons (Damier et al., 
1999; Frank et al., 2007). The etiology of PD is unknown, with a complex relationship 
between environmental and genetic factors, and aging being a required factor. The 
majority of cases, about 90-95%, is sporadic, while the remaining 5-10% can be 
explained by mutations in single genes (Van Den Eeden et al., 2003). The discovery of 
PD-related genes holds the potential to shed light into disease treatments, since the 
sporadic and familial forms are likely to share common pathogenic mechanisms and 
compromised pathways (Lesage and Brice, 2012). To date, five genes have been 
conclusively associated to familial PD, with both autosomal-dominant and autosomal-
recessive modes of inheritance (Valente et al., 2004; Lakshminarasimhan et al., 2008; 
Nemani et al., 2013; Singleton et al., 2013; Kuang et al., 2013). Accordingly, several 
studies focused on the physiological role of PD-related proteins and on how pathogenic 
mutations cause the pathology. In 2004, two studies found that mutations in Lrrk2 
(PARK8) are responsible for a familial form of PD (Paisan-Ruiz et al., 2004; Zimprich et 
al., 2004) and, currently, mutations in this gene represent the most common genetic 
cause of PD (10%). Lrrk2 encodes leucine-rich repeat kinase 2 (LRRK2), a large multi-
domain protein with both GTPase and kinase activities (Marín et al., 2008). The majority 
of LRRK2 pathological mutations are located within the enzymatic core of the protein, 
and they can affect LRRK2 activity causing impaired cellular functions and cytotoxicity. 
Among all, the G2019S mutation is the most frequent (Gilks et al. 2005), thus the most 
studied. This mutation lies in the kinase domain and increases LRRK2 kinase activity 
(Greggio and Cookson, 2009). Several studies support a role for LRRK2 in synaptic vesicle 
trafficking, although the exact mechanism is unclear. Thus, understanding which 
pathways are compromised in pathological conditions is fundamental to develop 
efficient strategies against synaptic impairment in PD. While LRRK2 pharmacological 
II 
 
inhibition may block the PD-related LRRK2 phenotypes, the use of LRRK2 inhibitors has 
been shown to cause severe side-effects on peripheral organs (Baptista et al., 2013; 
Luerman et al., 2014). Thus, alternative therapeutic strategies may be directed toward 
other proteins that take part in LRRK2 pathways. In this scenario, identifying putative 
LRRK2 substrates at the presynaptic site, among the plethora of possible interactors, is 
fundamental to understand the downstream effects related to LRRK2 pathological 
mutations. Previous studies showed that LRRK2 can modulate synaptic vesicle trafficking 
through phosphorylation of components of the exo- endocytic machinery (Heo et al., 
2010; Matta et al., 2012; Yun et al., 2013). For this reason, an outstanding question is to 
identify physiologically relevant, substrates of LRRK2 kinase activity and the effects of 
LRRK2 PD-related mutations on substrate phosphorylation. In this thesis, we focused on 
N-ethylmaleimide Sensitive Fusion protein (NSF) and Rab7L1. These two proteins have 
been previously indicated as LRRK2 interactors in neurons (Piccoli et al., 2011; MacLeod 
et al., 2013, Beilina et al., 2014). Here, our aim was to test whether they are also 
substrates of LRRK2 kinase activity. 
NSF is an AAA+ (ATPases Associated with various cellular Activities) and its function is 
pivotal at the presynaptic site for proper synaptic vesicle recycling. More in detail, NSF 
uses the energy produced from ATP hydrolysis to disassemble SNARE proteins (Soluble 
N-ethylmaleimide Attachment protein REceptors), together with its adaptor protein 
alpha-SNAP (Soluble NSF Associated Protein), allowing them to another fusion cycle 
(Zhao and Brunger, 2015). NSF displays a homo-hexameric structure, where each 
monomer is composed by three different domains: the N-terminal domain (N-ter) 
required for alpha-SNAP:SNARE complex interaction, the D1 domain with an ATP-binding 
site necessary for the ATPase activity and a D2 domain with another ATP-binding site 
required for oligomerization (Zhao et al., 2015). Since NSF has been largely studied using 
non-human orthologous proteins (Chang et al., 2012; Cipriano et al., 2013; Vivona et al., 
2013; Zhao et al., 2015), we set up a protocol to purify human Flag-tagged NSF from 
HEK293T mammalian cells. Firstly, we investigated the biochemical properties of NSF 
and subsequently its interaction with LRRK2. We demonstrated that the purified protein 
is an active ATPase and is able to interact with LRRK2. In particular, data obtained from 
pull-down assays revealed an interaction between NSF D2 domain and LRRK2. 
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Moreover, we demonstrated that NSF is also a substrate of LRRK2 kinase activity and 
this phosphorylation preferentially occurs at Thr-645 in the D2 domain. We confirmed 
this result by measuring the 33P incorporation with kinase assays incubating NSF non-
phosphorylatable mutants (NSF-T645A, T646A and S647A) together with LRRK2 G2019S. 
Kinetic studies of NSF ATPase activity revealed that NSF is 2-fold more active upon 
LRRK2 G2019S phosphorylation. Noteworthy, NSF-T645A, which resulted in a 50% 
reduction of 33P incorporation compared to wild-type, abolishes LRRK2-mediated 
increased ATPase activity. In addition, we demonstrated that NSF disassembles the 
SNARE complex at a higher rate after phosphorylation by LRRK2 G2019S. Taken 
together, these results highlight a possible regulatory mechanism in which LRRK2 is 
involved in synaptic vesicle recycling through phosphorylation of NSF. Importantly, NSF 
ATPase activity could be compromised by excessive phosphorylation due to LRRK2 
G2019S pathological mutation. 
As mentioned, an important aspect in the development of PD may be linked to impaired 
synaptic vesicle trafficking, which may trigger neurodegeneration at early stages. A 
major class of proteins orchestrating vesicle sorting inside the cell are Rab proteins. Rabs 
constitute a large family of monomeric small GTPases associated with all cellular 
compartments (Grosshans et al., 2006). There are more than 60 different Rab proteins in 
humans (Schwartz et al., 2007; Pereira-Leal et al., 2001) and a switch between the GTP- 
(active) and GDP- (inactive) bound form regulates the interactions with their effectors. 
To date, several studies highlight a possible interaction between LRRK2 and a number of 
Rabs (MacLeod et al., 2013; Gomez-Suaga et al., 2014; Dodson et al., 2014; Waschbusch 
et al., 2014).  Here, we tested whether different Rab proteins are also substrates of 
LRRK2 kinase activity. We performed kinase experiments on Rab7, Rab7L1, Rab9, Rab11 
and Rab32. Kinase assays revealed that, among them, only Rab7L1 is a substrate of both 
LRRK2 wild-type and G2019S kinase activity. Rab7L1 is located within the PARK16 locus, 
a non-familial PD risk-associated locus, and Rab7L1 has been found to associate with 
LRRK2 to regulate the degradation of trans-Golgi derived vesicles (Beilina 2014). Mass 
spectrometry analysis revealed that phosphorylation by LRRK2 G2019S preferentially 
occurs on Rab7L1-T21, a residue localized in the highly conserved region responsible for 
GTP binding (P-loop region). In addition, we detected Rab7L1-S22 as a less probable 
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phosphorylation site. To test which residue was phosphorylated, we generated Rab7L1-
T21A and S22A mutants. Kinase assays indicate that Rab7L1 likely possesses additional 
sites, other than T21 or S22, able to be phosphorylated by LRRK2 G2019S. 
In summary, this work identified two novel substrates of LRRK2 kinase activity in vitro 
with potential relevance for disease. Our studies revealed an increased NSF ATPase 
activity upon LRRK2 G2019S phosphorylation and highlighted a novel regulatory 
mechanism that might be compromised in PD. In addition, we found that Rab7L1 is 
another substrate of LRRK2 kinase activity. Future studies should uncover whether NSF 
and Rab7L1 are substrates of LRRK2 also in the cellular context and whether pathological 
phosphorylation is relevant for PD. 
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Riassunto 
La malattia di Parkinson (PD) è la seconda malattia neurodegenerative più comune dopo 
la malattia di Alzheimer (AD) e colpisce circa l’1-2% della popolazione oltre I 65 anni 
(Farrer, 2006). Gli elementi caratteristici del morbo di Parkinson sono la perdita dei 
neuroni nella sustantia nigra pars compacta (SNpc), e la presenza di aggregati proteici 
intracellulari denominati corpi di Lewy (LB) nei neuroni che sopravvivono (Damier et al., 
1999; Frank et al., 2007). L’eziologia della malattia di Parkinson è sconosciuta, con una 
complessa correlazione tra fattori ambientali e genetici, e fattori legati 
all’invecchiamento. La maggior parte dei casi, circa 95%, è di origina sporadica, mentre il 
rimanente 5-10% può essere collegato a mutazioni in singoli geni (Van Den Eeden et al., 
2003). La scoperta di geni collegati al morbo di Parkinson ha messo in luce possibili 
trattamenti terapeutici, dato che la forma sporadica e quella familiare hanno in comune 
molti meccanismi patologici e pathway compromessi (Lesage and Brice, 2012). Ad oggi, 
cinque geni sono stati associati alla forma familiare del morbo di Parkinson, sia ad una 
forma genetica autosomica dominante che recessiva (Valente et al., 2004; 
Lakshminarasimhan et al., 2008; Nemani et al., 2013; Singleton et al., 2013; Kuang et al., 
2013). Per questo motivo, numerosi studi si sono focalizzati sul ruolo fisiologico delle 
proteine collegate alla malattia di Parkinson e come le mutazioni patologiche causino la 
patologia. Nel 2004, due studi hanno identificato come mutazioni nel gene Lrrk2 (PARK8) 
siano causa della forma familiare di morbo di Parkinson (Paisan-Ruiz et al., 2004; 
Zimprich et al., 2004) e, ad oggi, mutazioni all’interno di questo gene rappresentano la 
più comune causa genetica di malattia di Parkinson (10%). Lrrk2 Questo gene codifica 
per la proteina leucine-rich repeat kinase 2 (LRRK2), una grande proteina composta da 
vari domini con attività GTPasica e chinasica (Marín et al., 2008). La maggior parte delle 
mutazioni sono localizzate all’interno del core enzimatico della proteina, e possono 
colpire l’attività di LRRK2 causando un danno alle funzioni cellulari e citotossicità. Tra 
tutte, la mutazione G2019S è la più frequente (Gilks et al. 2005), quindi la più studiata. 
Questa mutazione avviene all’interno del dominio chinasico e aumenta l’attività 
chinasica di LRRK2 (Greggio and Cookson, 2009). Numerosi studi sostengono un ruolo di 
LRRK2 a livello del traffico delle vescicole sinaptiche, anche se il meccanismo esatto non 
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è ancora chiaro. Perciò, capire quali pathway sono compromessi in condizioni 
patologiche è fondamentale per sviluppare strategie efficienti contro i danni provocati 
dalla malattia di Parkinson. Mentre l’inibizione farmacologica di LRRK2 potrebbe 
bloccare il fenotipo patologico, l’uso di inibitori di LRRK2 ha mostrato effetti secondari 
gravi a livello degli organi periferici (Baptista et al., 2013; Luerman et al., 2014). Per 
questo motivo, strategie terapeutiche alternative potrebbero essere dirette verso altre 
proteine che sono coinvolte all’interno dei pathway di LRRK2. In questo scenario, 
l’identificazione di substrati di LRRK2 a livello presinaptico, tra tutti i possibili interattori, 
è fondamentale per capire gli effetti a valle relativi a mutazioni patologiche di LRRK2. 
Studi precedenti hanno dimostrato che LRRK2 può modulare il traffico delle vescicole 
sinaptiche attraverso la fosforilazione di componenti facenti parte dei processi di eso- ed 
endocitosi (Heo et al., 2010; Matta et al., 2012; Yun et al., 2013). Per questa ragione, una 
domanda ancora senza risposta è quella di identificare possibili substrati dell’attività 
chinasica di LRRK2, rilevanti a livello fisiologico, e gli effetti che le mutazioni di LRRK2 
associate al morbo di Parkinson hanno sulla fosforilazione. In questa tesi, ci siamo 
focalizzati sulla proteina N-ethylmaleimide Sensitive Fusion (NSF) protein e Rab7L1. 
Queste due proteine sono state precedentemente indicate come interattori di LRRK2 nei 
neuroni (Piccoli et al., 2011; MacLeod et al., 2013, Beilina et al., 2014). In questo lavoro, 
il nostro scopo era quello di testare se queste due proteine siano anche substrati 
dell’attività chinasica di LRRK2. 
NSF è classificata come proteina AAA+ (ATPases Associated with various cellular 
Activities) e la sua funzione è fondamentale a libello presinaptico per un corretto riciclo 
delle vescicole sinaptiche. In dettaglio, NSF usa l’energia prodotta dall’idrolisi dell’ATP 
per disassemblare le proteine del complesso SNARE (Soluble N-ethylmaleimide 
Attachment protein REceptors), insieme alla sua proteina adattatrice alpha-SNAP 
(Soluble NSF Associated Protein), consentendo un nuovo ciclo di fusione (Zhao and 
Brunger, 2015). NSF mostra una struttura omo-esamerica, dove ogni monomero è 
composto da tre differenti domini: l’N-terminale (N-ter) necessario all’interazione con 
alpha-SNAP ed il complesso SNARE, il dominio D1 con un sito di legame dell’ATP 
necessaria per l’attività ATPasica, ed un dominio D2 con un altro dito di legame per l’ATP 
richiesta all’oligomerizzazione (Zhao et al., 2015). Dato che NSF è stato largamente 
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studiato usando una proteina ortologa non umana, abbiamo messo a punto un 
protocollo per purificare NSF umano con un Flag-tag da cellule di mammifero HEK293T. 
Per prima cosa, abbiamo deciso di studiare la biochimica di NSF e successivamente la sua 
interazione con LRRK2. Abbiamo dimostrato che la proteina purificata è attiva ed è in 
grado di interagire con LRRK2. In particolare, i risultati ottenuti attraverso esperimenti di 
pull-down rivelano una interazione tra il dominio D2 di NSF e LRRK2. Inoltre, abbiamo 
dimostrato che NSF è anche un substrato dell’attività chinsica di LRRK2 e questa 
fosforilazione avviene preferenzialmente nella treonina-645 all’interno del dominio D2. 
Abbiamo confermato questo risultato misurando l’incorporazione di 33P con saggi 
chinasici incubando dei mutanti non-fosforilabili di NSF (NSF-T645A, T646A and S647A) 
insieme a LRRK2 G2019S, Studi cinetici sull’attività ATPasica di NSF hanno rivelato che 
NSF è due volte più attivo dopo la fosforilazione da parte di LRRK2 G2019S. E’ 
importante notare che il mutante NSF-T645A, dove l’incorporazione di 33P risulta essere 
il 50% in meno rispetto al wild-type, non presenta un aumento dell’attività ATPasoca 
dovuto alla fosforilazione ad opera di LRRK2 G2019S. Inoltre, abbiamo dimostrato che 
NSF dopo essere stato fosforilato da LRRK2 G2019S disassembla il complesso SNARE più 
velocemente. Tutti questi risultati evidenziano un possibile meccanismo regolatorio in 
cui LRRK2 è implicato all’interno del riciclo delle vescicole sinaptiche attraverso la 
fosforilazione di NSF. L’attività ATPasica di NSF potrebbe quindi essere compromessa da 
una sua aumentata fosforilazione ad opera del mutante patologico G2019S. 
Come illustrato precedentemente, un aspetto importante nello sviluppo della malattia di 
Parkinson potrebbere essere collegato ad un danno nel traffico delle vescicole, che 
potrebbe far scaturire la neurodegenerazione a stadi precoci (Fernandez-Chacon et al., 
2004; Burre et al., 2010). La principale classe di proteine che governa l’organizzazione 
delle vescicole all’interno della cellula, è composta dalle proteine Rab. Esse costituiscono 
una vasta famiglia di piccole GTPasi monomeriche associate a tutti i compartimenti 
cellulari (Grosshans et al., 2006). Nell’uomo ci sono più di 60 tipi di Rab ((Schwartz et al., 
2007; Pereira-Leal et al., 2001)) che passando da una forma attiva, legata al GTP, ad una 
forma inattiva, legata al GDP, regolando la loro interazione con proteine effettrici. Ad 
oggi, numerosi studi hanno evidenziato una possibile interazione tra LRRK2 e varie 
proteine Rab (MacLeod et al., 2013; Gomez-Suaga et al., 2014; Dodson et al., 2014; 
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Waschbusch et al., 2014). Nel nostro lavoro, abbiamo testato se alcune proteine Rab 
siano anche substrati dell’attività chinasica di LRRK2. Abbiamo eseguito saggi chinasici 
con varie Rab, su Rab7, Rab7L1, Rab9, Rab11 e Rab32. I saggi chinasici hanno rivelato 
che, tra tutte, solamente Rab7L1 è un substrato di LRRK2, sia wild-type che G2019S. Il 
gene Rab7L1 è localizzato all’interno del locus PARK16, un locus associato al richio di 
insorgenza della forma di malattia di Parkinson non-familiare, Rab7L1 è stato trovato 
associato a LRRK2 nella regolazione della degradazione delle vescicole a livello 
dell’apparato del Golgi (Beilina 2014). Analisi di spettrometria di massa hano rivelato 
comee la fosforilazione ad opera di LRRK2 G2019S avvenga preferenzialmente sulla 
treonina-21 di Rab7L1, un residuo localizzato nella regione altamente conservata 
responsabile del legame col GTP (P-loop). In aggiunta, abbiamo individuato come meno 
probabile sito di fosforilazione la serina-22. Per testare quale residuo fosse quello 
fosforilato, abbiamo generato i mutati non fosforilabili Rab7L1-T21A ed S22A. I saggi 
chinasici ci hanno indicato che Rab7L1 possiede verosimilmente siti di fosforilazione 
aggiuntivi, oltre la T21 e la S22, che possono essere fosforilati da LRRK2 G2019S. 
Riassumendo, questo lavoro ha identificato due nuovi substrati dell’attività chinasica di 
LRRK2 in vitro con una potenziale rilevanza a livello della malattia. I nostri studi hanno 
rivelato un aumento dell’attività ATPasica di NSF successivamente alla fosforilazione da 
parte di LRRK2 G2019S ed hanno evidenziato un nuovo meccanismo regolatorio che 
potrebbe essere compromesso nella malattia di Parkinson. In aggiunta, abbiamo trovato 
che Rab7L1 è un altro substrato dell’attività chinasica di LRRK2. Studi futuri sono 
necessari per scoprire se NSF e Rab7L1 siano substrati di LRRK2 anche in un contesto 
cellulare, e se la fosforilazione in condizioni patologiche è rilevante nel morbo di 
Parkinson. 
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Chapter I Introduction 
1. Parkinson’s Disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease (AD) and affects about 1-2% of the population over 65 years old 
(Farrer, 2006). This percentage increases to 4% over the age of 85 (Fahn, 2003). The 
mean age of onset is 60, but 4% of the patients show an early-onset before 50 years old. 
Being that the development of the disorder is strongly associated with aging (de Lau and 
Breteler, 2006), the fraction of population affected is expected to increase parallel with 
the increasing life expectancy. The etiology of PD has unknown causes, with a complex 
relationship between environmental and genetic factors. The environmental hypothesis 
is based on toxins able to mimic clinical and pathological characteristics of PD. The 
sporadic form of the disease has been linked to herbicide (paraquat) and insecticide 
(rotenone) largely used in agriculture, and chemical compounds toxic to mitochondria 
(such as, MPTP), as discussed below. Although this is the most common form of the 
disease, 10-15% of PD cases are linked to pathogenic mutations in single genes (Sherer 
et al., 2002). The discovery of PD-related genes holds the potential to shed a light into 
disease treatments since the sporadic and familial forms are likely to share common 
pathogenic mechanisms and compromised pathways. Several studies are focused on the 
physiological role of PD-related proteins and how mutations cause the development of 
the pathology. Of interest, besides genetic and environmental causes, there are 
additional predisposing factors that lead to an increased risk of PD. For example,  
estrogens seem to have a beneficial effect on dopaminergic neurotransmission and 
protect neurons via antioxidant effects (Behl et al., 1997). For this feature, men and 
women without hormone replacement have an increased risk of 25% to incur in this 
pathology (Popat et al., 2005; Lees et al., 2009). 
 
1.1 Clinical Features 
Clinical characteristics can be summarized with the acronym TRAP: Tremor at rest, 
Rigidity, Akinesia (or bradykinesia) and Postural instability. These motor dysfunctions 
contribute to diagnose the disease. Symptoms derive from loss of dopaminergic neurons 
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Chapter I Introduction 
in the substatia nigra pars compacta (SNpc) of the midbrain (Damier et al., 1999). These 
neurons are part of the circuitry of the basal ganglia which controls motor functions. The 
depletion in the dopamine (DA) level is considered the starting point of motor 
impairment in PD and the onset of symptoms is caused by a progressive worsening of 
neuronal dysfunction that ends with cell death. The main problem is that a definitive 
diagnosis of this disease can only be made with a post-mortem detection of neuronal 
loss in patient brains with resulting in the depigmentation of the substantia nigra and 
the presence of intracellular proteinaceous inclusions called “Lewy Bodies” (LBs) in 
surviving neurons (Fig.1.1.1). Several proteins have been described in aggregates and α-
synuclein (aSyn) is the major component (Spillantini et al., 1998). Although LBs are a 
typical feature of PD, they are not specific for this disease and they can be also found in 
AD and “dementia with LB” (Gibb and Lees, 1988). The mechanism underlying PD remain 
an open question, but one hypothesis is that intracellular protein aggregates may 
represent the starting point of toxicity. Aggregates, or misfolded proteins, could cause 
directly injury interfering with intracellular pathways or recruit proteins that are 
important for cellular mechanisms: this leads to the hypothesis of a strong correlation 
between inclusion formation and neurodegeneration. 
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Fig.1.1.1 | Hallmarks of Parkinson’s disease (PD). Images of the SNpc  in the midbrain that 
highlight its depigmentation due to the loss of the dopaminergic neurons and the presence of 
Lewy bodies (LB) as pathological hallmarks of the disease (Frank et al., 2006). 
 
1.2 Etiology Of PD 
To date, the etiopathogenesis of PD is unclear. About 90-95% of PD cases are classified 
as sporadic and only 5-10% of the patients present a familial form of the disease. The 
sporadic form of the disease is likely caused by a complex interaction between genese 
and environment, with aging being a required factor. An early evidence that exposure to 
environmental toxins may cause parkinsonism came in 1980s. MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine), an additive in the heroin preparation, was identified to be 
the cause of an irreversible motor disorder with symptoms of PD among heroin users 
(Langston et al., 1983). The most important feature is that MPTP is able to cross the 
blood-brain barrier (BBB) and in glial cells it can be oxidized and deprotonated to MPP+, 
which is the active toxic species (Kopin, 1987). In addition, epidemiological studies 
identified how compounds used in agriculture, such as paraquat (herbicide) and 
rotenone (insecticide), can induce mitochondrial dysfunction at complex I (Betarbet et 
al., 2000), and, a long term exposure, the typical PD phenotype. Another hypothesis is 
that the preferential loss of dopaminergic neurons in the substantia nigra pars compacta 
could be ascribed to the chemical properties of DA. An impairment in the storage of this 
neurotransmitter could cause cytotoxicity and this could be one of the aspects that 
 6 
 
Chapter I Introduction 
explain why DA neurons are preferentially involved in this pathology (Bisaglia et al., 
2013). DA is normally stored within large dense core synaptic vesicles where the low pH 
stabilizes the neurotransmitter. However, if the concentration of cytosolic DA arises, DA 
can undergo autoxidation. The oxidized forms of DA, the quinones (DAQs), are highly 
reactive species that can react with and damage several cellular components, such as 
lipids, proteins and DNA, and generate DA adducts (Berman and Hastings, 1999; Bisaglia 
et al., 2010; Girotto et al., 2012). For this reasons, cytosolic accumulation of DA may 
promote dopaminergic neuron degeneration. As discussed, even though the majority of 
PD cases have an unknown etiology (idiopathic PD), about 5-10% of cases are caused by 
mutations in single genes. The discovery of PD-related genes has been crucial for 
understanding the intracellular pathways compromised in PD, since sporadic and familial 
forms of the disease share most of the clinical aspects (Lesage and Brice, 2012). Among 
them, five genes have been associated to familial PD both autosomal-dominant (SNCA 
coding for α-synuclein and Lrrk2 coding for leucine-rich repeat kinase 2, LRRK2) and 
autosomal-recessive (PARKIN, PINK1 and DJ-1). PD is rarely the result of mutations in 
single genes and the PD onset is influenced by polymorphic genetic variations shared 
between PD and AD, as highlighted through genome wide association studies (GWAS). 
 
1.3 Dominant Form Of PD 
Mutations in genes that cause autosomal-dominant forms of PD can have different 
effects on protein function. Neurotoxicity could derive from a “gain of existing function” 
where the activity of the PD protein is abnormally high (this is thought to underlie the 
pathogenic mechanism of mutant LRRK2) or it can originate from a “gain of a novel 
function”. This last mechanism has been proposed for aSyn, that, when mutated, is 
prone to form neurotoxic oligomers and aggregates typical of PD. 
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1.3.1 Alpha-Synuclein (PARK1/4) 
α-Synuclein (aSyn) is a natively unfolded protein of 140 amino acids with a molecular 
weight of 14,5 kDa. Duplication and triplication of the aSyn gene (SNCA) cause 
autosomal dominant form of PD. aSyn is abundantly expressed in mammalian brain in 
nerve terminals (Fortin et al., 2004) and it is the major component of the LBs and Lewy 
Neurites (LNs) (Spillantini et al., 1998), the hallmark of PD and other neurodegenerative 
disorders called “synucleinopathies”. Even if the precise function of aSyn is still under 
investigation, its presynaptic localization argues for a role in neurotransmitter release 
and synaptic plasticity (Burré et al., 2010; Diao et al., 2013). Given that, impairment in 
the physiological role of aSyn due to aggregates formation, might be one of the starting 
point of neurodegeneration (Nemani et al., 2010). Several studies showed that this 
protein can bind lipid bilayers through its N-terminal region and acquire an alpha-helix 
conformation (Davidson et al., 1998; Ulmer and Bax, 2005; Burré et al., 2013) which has 
been proposed to stabilize the curvature of synaptic vesicles (Nuscher et al., 2004). 
Interestingly, aSyn knockout mice show defects in neurotransmission, confirming that 
this protein is important for synaptic function (Greten-Harrison et al., 2010). aSyn is the 
major component of Lewy bodies and multiple lines of evidence indicate that the 
protein can aggregate in vitro and in cells. In the oligomerization process, that ends with 
the formation of toxic fibrils, aggregates are organized in β-sheets (el-Agnaf and Irvine, 
2002). Additional studies identified point mutations that increase the propensity of aSyn 
to aggregate (Hardy et al., 2009) and post-translational modification of aSyn result in 
increased oligomerization or alteration in lipid binding. To date, A53T (Polimeropoulos 
et al., 1997), A30P (Krüger et al., 1998), E46K (Zarranz et al., 2004), H50Q (Proukakis et 
al., 2013) and G51D (Lesage et al., 2013) point mutations have been associated to 
familial PD. Even though the exact mechanism of aggregation process and how these 
aggregates are harmful to neurons is unclear, several studies observed that aSyn 
aggregates can induce neuroinflammation and oxidative stress to neurons resulting in 
neurodegeneration (Béraud et al., 2011). 
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1.3.2 LRRK2 (PARK8) 
The Lrrk2 gene encodes a protein of 286 kDa, which, in 2004, was identified as the gene 
responsible for PARK8-linked PD (Zimprich et al., 2004; Paisan-Ruiz et al., 2004). 
Autosomal dominant mutation in LRRK2 are the most common genetic cause of late-
onset PD, since LRRK2 mutations affect approximately 10% of patients with familial PD 
(Singleton et al., 2013). Despite more than ten years after this discovery and the 
impressive amount of research conducted on LRRK2, it is still unclear how mutation 
cause neurodegeneration. Several studies have been focused on understanding LRRK2 
pathobiology, because LRRK2-linked PD and sporadic are clinically and pathologically 
very similar. Therefore, understanding the pathways altered by LRRK2 could shed light 
into the pathogenic mechanisms of the more common idiopathic disease and disclose 
novel therapeutic strategies. Among all the mutations, the G2019S is the most diffuse in 
North American and European populations where it may account for 30-40% of all PD 
cases (Gilks et al., 2005), but other pathogenic mutations (R1441C, R1441G, Y1699C, and 
I2020T) have been identified in a number of families (Nichols et al., 2005). As discussed 
in the next paragraph, depending on their position these mutations can affect LRRK2 
kinase and/or GTPase activities, which may cause an impairment of the downstream 
signaling pathways and, in turn, induce neurodegeneration. Of interest, LRRK2 has been 
shown to physically and/or functionally interact with the products of MAPT (microtubule 
associated protein tau gene) (Golub et al., 2009) and Rab7L1 (MacLeod et al., 2013; 
Beilina et al., 2014), two risk factor for PD. 
 
1.4 Recessive Forms Of PD 
Mutations in Parkin, PINK1 and DJ-1 cause a recessive form of PD, characterized by an 
early onset of the disease and a slow progression. Of interest, all these three proteins 
are involved in common pathways protecting mitochondria and cells against reactive 
oxygen species and oxidative stress. 
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1.4.1 PARKIN (PARK2) 
Parkin is a cytosolic E3 ubiquitin-protein ligase (Shimura et al., 2000) of about 51 kDa 
containing an N-terminal ubiquitin-like domain followed by four zinc fingers domains. 
Mutations in this gene account for 50% of all recessive PD forms. This protein is involved 
in the protein ubiquitination pathway and impairments in mitochondrial activity and loss 
of mitochondrial membrane potential cause Parkin recruitment on the outer 
mitochondrial membrane to initiate mitophagy (Narendra et al., 2008). The involvement 
of Parkin in the maintenance of healthy mitochondria and other cellular processes 
(Winklhofer, 2014) suggests that a “loss-of-function” mutation of this protein may cause 
accumulation of toxic substrates (including mitochondria) with consequent 
dopaminergic degeneration (Kuang et al., 2013). 
 
1.4.2 PINK1 (PARK6) 
Mutations in PINK1 gene are the second most common cause of autosomal-recessive 
form of PD (Valente et al., 2004). PINK1 is a serine-threonine protein kinase of about 63 
kDa that act as a neuroprotective agent against oxidative stress (Wang et al., 2006). 
PINK1 is localized on the inner mitochondrial membrane and is normally subjected to 
protease degradation under normal conditions. When the mitochondrial potential is 
lost, these proteases are inactivated and PINK1 accumulates on the mitochondrial 
surface where it phosphorylates Ubiquitin, which then acts as a receptor for Parkin. 
Upon additional phosphorylation events, Parkin is activated and can attach ubiquitin to 
key proteins on the mitochondrial outer membrane to initiate mitophagy, a process of 
elimination of damaged mitochondria through autophagy (Beilina and Cookson, 2015). 
Thus PINK1 and Parkin cooperate to maintain mitochondrial homeostasis and mutations 
in both genes are thought to compromise this process, with consequent accumulation of 
damaged mitochondria, and, in turn, neurodegeneration. 
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1.4.3 DJ-1 (PARK7) 
DJ-1 encodes for a protein of 189 aa which is active in a dimeric conformation The exact 
biological function of DJ-1 is still unclear. At present, the most corroborated function of 
DJ-1 is its neuronal protective role against oxidative stress (Cookson, 2012). 
Overexpression of DJ-1 has a neuronal cytoprotective effect against oxidative damages 
(Taira et al., 2004; Martinat et al., 2004), whereas DJ-1 deficiency leads to increased 
oxidative stress-induced cell death (Kim et al., 2005; Meulener et al., 2005; Lavara-
Culebras and Paricio, 2007). Nevertheless, how exactly this function is exerted is not 
clear. As for other proteins involved in recessive forms of PD, pathogenic DJ-1 mutations 
have been described to cause a loss of protein function. As many mutations induce a 
loss of protein thermal stability, a possible explanation for the loss of the protective 
function relies on structural perturbations induced by the mutations 
(Lakshminarasimhan et al., 2008; Malgieri and Eliezer, 2008). This is clearly the case of 
the L166P mutant which is highly and globally unfolded (Malgieri and Eliezer, 2008). 
Nevertheless, as some mutant retains biophysical properties that make these proteins 
structurally indistinguishable from wild-type DJ-1 (Lakshminarasimhan et al., 2008; 
Malgieri and Eliezer, 2008; Ramsey and Giasson, 2008), some other mechanism should 
exist. 
 
1.5 Therapeutic Strategies 
To date, no therapeutic treatments can block the cell loss and the development of the 
pathology. The current therapeutic strategies are only symptomatic and whilst they can 
improve the quality of life, they cannot halt or slow disease progression. Since the DA 
depletion is the main cause of motor symptoms, this deficit can be attenuated by a DA 
replacement therapy. The most effective compound levodopa (L-DOPA), the precursor 
of dopamine, which is able to cross the BBB while the neurotransmitter itself is not. 
Restoring the physiological level of DA by L-DOPA administration attenuates the motor 
symptoms of the disease and this was considered the perfect therapy for many years. L-
DOPA remains the most efficient therapy to be used early in the development of the 
disease and was widely distributed for its easy oral administration. However, despite the 
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positive effects of this therapy, L-DOPA does not reduce the rate of neuron cell loss and 
the disease progression. Moreover, long term treatment induces dyskinesia (Heumann 
et al, 2014), a particular motor fluctuations associated with intermittent stimulation of 
dopamine receptors in association with a gradual decline of clinical efficiency (Davie, 
2008). For these reasons, other classes of drugs have been developed: dopamine 
receptor agonists and inhibitors of enzymes responsible of dopamine-metabolism, such 
as monoamine oxidase-B (MAO-B) and catechol-O-methyltransferase (COMT) (Olanow 
and Schapira, 2013). These new drugs were introduced to attenuate symptoms in the 
later stage of the disease, but evidences highlight the development of both peripheral 
effects and psychiatric symptoms due to chronic use as secondary effects (Smith et al., 
2012). Starting from these, novel therapies were developed to fight against the disease: 
surgical therapies based on deep brain stimulation (Coune et al., 2012) or less invasive 
treatments, such as gene and cell replacement, which are under investigation. Adeno-
associated virus (AAV) or lentivirus vectors to improve DA synthesis and expression of L-
DOPA-converting enzyme AADC offer a new potential therapy, against PD. However, 
clinical trials did not bring the expected results (Bartus et al, 2014). Cell replacement is 
also considered a great potential therapeutic strategy in PD (Loewenbruck and Storch, 
2011; Badger et al., 2014), and intense research is directed toward the development of 
such therapies. 
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2. Leucine-rich repeat kinase 2 
(LRRK2) 
In 2004, two back-to-back studies identified that mutations in the Lrrk2 (PARK8) gene 
cause a familial form of Parkinson's disease (PD) (Paisan-Ruiz et al., 2004; Zimprich et al., 
2004). This gene encodes for a large multi-domain protein of about 286 kDa (2527 
amino acids) with two enzymatic functions (Marín et al., 2008). LRRK2 belongs to a 
family of proteins called ROCO (Ras Of COmplex), characterized by two conserved 
domains (Gotthardt et al., 2008; Marín et al., 2006; Civiero et al., 2014): a Ras of 
complex (Roc) GTPase domain followed by a C-terminal of ROC (COR) domain. The Roc-
COR domain is then followed by a serine/threonine kinase domain at the C-terminal. The 
GTPase/kinase enzymatic core is surrounded by protein-to-protein interaction domains 
both at N- and C-terminal of LRRK2 (Fig.2.1): the armadillo, ankyrin and leucine-rich 
repeat (LRR) domains at N-terminal (Marín et al., 2006), and the WD40 at the C-
terminal, which seems to control LRRK2 function and kinase activity (Rudenko et al., 
2012). 
 
 
Fig.2.1 | Schematic representation of domain structure of LRRK2. LRRK2 has a multi-domain 
structure with an enzymatic core composed by a Roc-COR domain (GTPase activity) and Kinase 
domain (kinase activity), surrounded by protein-to-protein interaction domains. ARM (armadillo 
repeats), ANK (ankyrin-like repeats), LRR (leucine-rich repeats) and WD40 domains are shown 
(Adapted from: Civiero and Bubacco, 2012). 
 
The kinase domain of LRRK2 is predicted to belong to the class of mitogen-activated 
protein kinase kinase kinase (MAPKKK), such as RAF (Gloeckner et al., 2009), and one 
feature of these kinases is the formation of dimers. A major challenge in the 
investigation of LRRK2 tertiary and quaternary structure is due to the technical hurdle of 
isolating sufficient high-quality/quantity LRRK2 full-length and/or domains. Therefore, 
structural information on full-length LRRK2 is still missing and clues on LRRK2 quaternary 
structure come from indirect evidence. It has been shown that highly purified full-length 
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LRRK2 proteins are capable of forming dimers in solution as revealed by immune-gold, 
looking at the distribution of distances among metal particles imaged by transmission 
electron microscopy (Civiero et al., 2012). Published in 2008, the first structure of the 
isolated human ROC domain (amino acids 1333-1516) in complex with GDP revealed a 
dimeric GTPase (Deng et al., 2008). Although the proposed model describes a canonical 
GTPase fold, the catalytic core of LRRK2-ROC adopts an unusual topology due to domain 
swapping, in which the N-terminal of one monomer interacts with the C-terminal of the 
second monomer, thereby forming a constitutive dimer. Two follow-up studies 
investigated the quaternary structure of isolated ROC in solution using size exclusion 
chromatography. Liu et al. showed that the ROC construct, which crystalizes as swapped 
dimer, purifies as a mixture of dimers and monomers and ROC phosphorylation by 
LRRK2 or Roco4 enhances the proportion of monomers (Liu et al., 2016). Of interest, the 
GTPase activity of monomers and dimers are nearly identical. A second study by Liao 
and collaborators (Liao et al., 2014) purified an extended ROC construct (amino acids 
1329-1520) that resulted highly stable and exhibited two chromatographic peaks 
corresponding to the apparent size of a dimer and a monomer. The authors further 
demonstrated that the dimeric fraction can be converted into monomers by addition of 
guanine nucleotides (Liao et al., 2014). Therefore, the existence of both dimers and 
monomers in solution suggests that isolated ROC may not form a constitutive dimer and 
that the swapped 3D model might be a crystallographic artifact.  
One important consideration to make is that the ROC domain always occurs in tandem 
with the C-terminal of ROC (COR) domain, and the ROC-COR module is conserved across 
species. Thus, it is likely that ROC-COR represents a single functional unit and structural 
and biophysical studies should be focused on this fragment rather than on isolated ROC. 
However, the difficulty of purifying sufficient amounts of stable recombinant human 
ROC-COR has hampered its structural investigation. Important structural information on 
the role of COR in ROC dimerization comes from studies with related ROCO proteins 
from bacteria. In 2008, a crystallographic study of the ROC-COR unit from the 
thermophilic green bacteria Chlorobium tepidum disclosed a dimeric organization of 
ROCO proteins. However, in contrast to the previously determined structure of human 
ROC domain, the structural analysis of bacterial ROC-COR revealed a canonical G protein 
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domain where dimerization is mediated by the C-terminal half of the COR domain and 
by highly conserved residues on the ROC-COR interface (Gotthardt et al., 2008). That 
COR is a stable dimerization device serving as a scaffold for the ROC domain was also 
confirmed by a more recent study in which site-direct spin labeling was used to evaluate 
by pulse EPR the distances defined by the constrains that govern dimerization (Rudi et 
al., 2015). 
Notably, there are evidences that suggest the importance of the dimeric structure on 
both GTPase and kinase activity of LRRK2 (Sen et al., 2009; Berger et al., 2010). 
 
2.1 GTPase And Kinase Activities Of LRRK2 
A major feature of LRRK2 is the presence of a dual enzymatic core where the activity of 
one domain may influence the function of the other. The GTP-binding site of ROC 
possesses a region highly conserved among GTPases called P-loop (residues 1341–1348, 
GNTGSGKT) (Ito et al., 2007). This domain is responsible for nucleotide binding, while 
another important region, called Switch II motif (residues 1394–1398, DFAGR), 
contributes to LRRK2 capacity to hydrolyze GTP. Similar to other GTPases, the nucleotide 
binding changes the state of the protein that cycle from an active (GTP-bound) to an 
inactive state (GDP-bound). The presence of dual activities, kinase and GTPase, within 
the enzymatic core suggests that they may influence each other. There are some 
evidences that the GTPase activity of LRRK2 may regulate its kinase activity. In particular, 
addition of guanine nucleotide in the kinase reaction has been shown to increase LRRK2 
autophosphoryaltion (Smith et al., 2006). Another study however was not able to 
replicate this result and proposed that GTP can increase LRRK2 kinase activity via an 
indirect mechanism (Taymans et al., 2011).  
However, artificial mutations in the P-loop region (K1347A and T1348N) compromise the 
kinase activity possibly by altering the folding and produce a kinase dead form of the 
protein (Smith et al., 2006, West et al., 2007, Taymans et al., 2011). Altogether, these 
findings suggest that GTP binding to ROC may not directly affect kinase activity, but a 
correctly folded ROC (possibly in the dimeric conformation) is important for kinase 
 15 
 
Chapter I Introduction  
activity. The LRRK2 interactors ARHGEF7 and ArfGAP1 have been proposed as LRRK2 
guanine nucleotide exchange factor (GEF) and GTPase Activating protein (GAP) protein, 
respectively (Haebig et al., 2010; Xiong et al., 2012). Of note, ArfGAP1 is also a substrate 
of LRRK2 kinase activity and this phosphorylation compromises its GAP activity, 
suggesting a reciprocal regulation of the two proteins with consequences on activity and 
cytotoxicity (Xiong et al., 2012). As discussed, LRRK2 is thought to function as a dimer 
and an alternative hypothesis is that LRRK2 may be activated by nucleotide-dependent 
dimerization thus functioning as a GAD (G proteins activated by nucleotide dependent 
dimerization). This mechanism of activation would eliminate the dependence on 
regulatory GAPs and GEFs proteins (Gasper et al., 2009). 
Other studies reported that the cross-talk could be from the kinase to the GTPase 
domain. Supporting this notion, the majority of autophosphorylation sites within LRRK2 
map in the Roc domain (Greggio et al., 2009; Gloeckner et al., 2010). Thus, the kinase 
domain may act intra-molecularly to regulate GTP binding and hydrolysis via 
phosphorylation of ROC. Of note, whilst several putative LRRK2 kinase substrates have 
been proposed (Yun et al., 2013; Martin et al., 2014), the most consistently reported and 
validated substrate of LRRK2 in vivo is LRRK2 itself (Sheng et al., 2012). Accordingly, a 
number of serine and threonine residues have been identified as autophosphorylation 
sites in vitro. Autophosphorylation of Ser1292 has been proven also in vivo (Sheng et al., 
2012). The majority of the studies focused on kinase activity rather than GTPase activity 
as kinases are ideal pharmacological targets. An early study showed that pathological 
LRRK2 mutations (I1122V, R1441C or Y1699C) on a kinase-dead background resulted in a 
reduced formation of cytoplasmic inclusion bodies and cell death (Greggio et al., 2006). 
Moreover, LRRK2 pharmacological inhibition in vivo in rodent brains protects from 
neuronal cell death (Lee et al., 2010). To date, a number of selective and potent LRRK2 
inhibitors have been developed and LRRK2 inhibition has been proven effective at 
reducing pathological phenotypes in the rodent brain (Daher et al., 2015). However, 
chronic administration of LRRK2 inhibitors in rodents and non-human primates results in 
lung toxicity (Tong et al., 2012; Baptista et al., 2013). Thus, more research is necessary to 
understand whether inhibition of LRRK2 can be translated in the clinics as a future cure 
for PD. 
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2.2 LRRK2 Localization 
LRRK2 is expressed in different tissues and organs including kidneys, liver, lung, heart 
and, in the brain, within neurons, astrocytes and microglia (Miklossy et al., 2006). This 
ubiquitous pattern of expression suggests a role of this protein in different intracellular 
processes. In the cell, LRRK2 has been found associated with intracellular membranous 
structures including mitochondria (Hatano et al., 2007), the endo-lysosomal system 
(Alegre-Abarrategui et al., 2009), the endoplasmatic reticulum (ER) (Gloeckner et al., 
2006) and the Golgi (Biskup et al., 2006). Postmortem human brain tissue from normal 
and PD patients shows LRRK2 localization in the cerebral cortex, striatum, cerebral 
cortex, hippocampus, cerebellum and, at low levels, in the substantia nigra (Higashi et 
al., 2007). In pathological conditions, LRRK2 was found associated with LBs (Zhu et al., 
2006) and LNs (Giasson et al., 2006), although not as major component of this inclusions. 
Accumulating evidence indicates that impairment of autophagy-lysosomal pathways is 
as a major pathogenic event in neurodegenerative diseases, including PD (Dehay et al., 
2013). Of interest, there is robust evidence that links LRRK2 with endolysosomal-
autophagy processes (Rivero-Ríos et al., 2015). An increased lysosomal compartment 
was observed in primary cortical neurons (MacLeod et al., 2006) and SHSY-5Y cells 
expressing pathological LRRK2 mutations (Plowey et al., 2008). Moreover, in 
pathological brains LRRK2 was found colocalized with Rab7B, a late endosomal marker, 
and LAMP-2, a lysosomal marker (Higashi et al., 2009).  
Multiple lines of evidence indicate that LRRK2 localization is controlled by 14-3-3 
proteins. Specifically, 14-3-3s bind a cluster of serine residues at the N-terminal of LRRK2 
(including S910 and S935) and this binding is thought to be important to maintain LRRK2 
in the cytosol (Nichols et al., 2010; Dzamko et al., 2010). S910/S935 phosphorylation 
level is tuned by cellular activity, possibly through activation of PP1 phosphatases and/or 
inhibition of kinases such as CK1alpha and IKKs (Dzamko et al., 2012; Lobbestael et al., 
2013; Chia et al., 2014). Dephosphorylation of S910/S935 results in LRRK2:14-3-3 
complex dissociation (Nichols et al., 2010; Dzamko et al., 2010) with consequent 
relocalization of LRRK2 into defined cellular compartments including cytoskeletal 
elements and centrosomes (Nichols et al., 2010; Mamais et al., 2014). One striking 
feature of the majority of LRRK2 pathogenic mutations is that they all display moderate 
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to severe loss of S910/S935 phosphorylation in cell models, suggesting that LRRK2 
cellular phosphorylation is an important biomarker for monitoring LRRK2 pathological 
state. An additional role of LRRK2:14-3-3 interaction could be the regulation of LRRK2 
association with late endosomes and extracellular release via exosomes. The 
identification of LRRK2 within exosomes isolated from urine or cerebral spinal fluid (CSF) 
suggests a possible use of LRRK2 as a biomarker in clinical studies (Fraser et al., 2013). 
Interestingly 14-3-3 proteins have been linked to numerous neurological disorders 
including PD (Berg et al., 2003; Chen et al., 2005; Plotegher et al., 2014). 
 
2.3 PD-Associated Mutations 
Many of the pathological mutations of LRRK2 are located within the enzymatic core of 
the protein (Fig.2.3.1). Among all, the G2019S pathological mutation is the most 
frequent. For this reason is one of the most studied: it lies in the DXG motif (DYG in 
LRRK2) in the activation loop of the kinase domain, and is characterized by a “gain-of-
function” effect on LRRK2 kinase activity that produce a hyperactive form of LRRK2 with 
2-3 fold increased activity compared to the wild-type (Greggio and Cookson, 2009) and 
its overexpression in neurons is toxic (Greggio et al.,  2006; Smith et al., 2006). Of 
interest, the fact that LRRK2 mutations cause familial PD and common variations in the 
Lrrk2 locus increase life-time risk (Dächsel and Farrer, 2010), suggest a link between 
sporadic and inherited PD with LRRK2 being a common player (Lee et al., 2012). 
 
 
Fig.2.3.1 | LRRK2 pathological mutation. A focus on LRRK2 PD-related mutations and their 
localization inside LRRK2 different domains (Adapted from Greggio, 2012). 
 
Mutations laying in the Roc (R1441C/G/H) and COR (Y1699C) domain have been shown 
to decrease GTP hydrolysis  (Lewis et al., 2007; Li et al., 2009; Liao et al., 2014), 
suggesting a prolonged active state (GTP-bound) of LRRK2 and, hence, an abnormally 
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activated downstream signaling. The effect on kinase activity is variable, but integrating 
different studies there seems to be no consistent effect on this activity (Greggio and 
Cookson, 2009). One study addressed the effect of the Y1699C mutation within the COR 
domain on human ROC-COR dimerization (Daniëls et al., 2011). The authors found that 
the intra-molecular ROC:COR interaction is favoured over ROC:ROC dimerization. The 
pathogenic Y1699C mutation, situated at the ROC:COR interface, strengthens the intra-
molecular ROC:COR interaction, weakening the dimerization of LRRK2 at the ROC-COR 
tandem domain and resulting in decreased GTPase activity (Daniëls et al., 2011). In C. 
tepidum ROC-COR, the Y804C PD mutation in the COR domain analogous to the Y1699C 
human mutation, and the two L487V and Y558A mutations in the ROC domain, 
analogous to the I1371V and R1441G/C PD mutations, have much lower GTPase activity 
but similar dimerization properties (Gotthardt et al., 2008). Taken together, the ROC-
COR PD mutations seem to severely affect GTPase activity, whereas the effect on 
dimerization is unclear.  
Only recently identified mutation in the Roc domain is the N1437H and its 
overexpression in cells enhances the phosphorylation on Ser1292 similar to what 
observed for R1441G/C, G2019S and I2020T (Sheng et al., 2012). As a consequence, 
LRRK2 associated cytotoxicity does not depend simply to an alteration on its kinase 
activity (Fig.2.3.2). The fact that the kinase domain phosphorylates ROC, it is possible 
that ROC is the important pathological site, with the G2019S mutation impacting GTPase 
activity via abonormal phosphorylation of ROC. Indeed, a decreased GTPase activity by 
20% has been reported for the G2019S mutant (Herzig et al., 2011).  Overall, LRRK2 PD 
mutations may promote decreased GTPase activity, which results in a prolonged active 
state of the protein. 
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Fig.2.3.2 | Schematic representation of LRRK2 associated cytotoxicity. Increase in LRRK2 kinase 
activity enhances the phosphorylation on Ser1292, thus an increased  phosphorylation of LRRK2 
substrates (left). Moreover, the kinase domain may regulate GTP binding and hydrolysis via 
phosphorylation of ROC domain (right). These alterations in the normal function of LRRK2 lead 
to cytotoxicity inside neurons (image courtesy of Dr. Mark Cookson). 
 
Using yeast as model organism, altered GTPase activity was suggested to promote 
impairment in the endocytic vesicular trafficking and autophagy (Xiong et al., 2010). 
Several animal models have been generated to understand how Lrrk2 mutations affects 
the cellular processes in vivo. In particular, a number of LRRK2-mouse models have been 
generated, but only one of the LRRK2 transgenic mice models expressing G2019S 
mutation reproduces age-dependent loss of dopaminergic neuron (Ramonet et al., 
2011). However, different mutant LRRK2 rodent models display neurotransmission 
defects (Tong et al., 2009; Melrose et al., 2010; Beccano-Kelly et al., 2014; Belluzzi et al., 
2012), and, accordingly, several lines of evidence support a role of LRRK2 at the 
presynapse (Shin et al., 2008; Piccoli et al., 2011; Matta et al., 2012; Belluzzi et al., 2012; 
Migheli et al., 2013; Cirnaru et al., 2014; Beccano-Kelly et al., 2014). As discussed below, 
there are good molecular evidences linking LRRK2 kinase activity and regulation of 
synaptic vesicle trafficking, with pathogenic mutations impairing this process. 
 
2.4 LRRK2 And Regulation Of Vesicles Dynamics 
As described above, several studies showed an association between LRRK2 and vesicle 
structures in the mammalian brain suggesting a regulation in vesicles trafficking 
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(MacLeod et al., 2006; Stafa et al., 2012). Overexpression of wild-type or G2019S mutant 
leads to fragmentation of the Golgi complex (Lin et al., 2009). Furthermore, LRRK2 
overexpression provokes an impairment of microtubule dynamics, Golgi organization, 
and the ubiquitin-proteasome pathway enhancing alpha-synuclein mediated cytotoxicity 
(Lin et al., 2009). In addition, an alteration in LRRK2 expression show an impairment in 
synaptic vesicle regulation This regulatory mechanism derived from the interaction 
between LRRK2 and small GTPases Rab protein, associated to all cellular compartments, 
regulating in the endosome maturation (Zerial and McBride, 2001). One example is 
Rab5, a regulator of vesicles transport from plasma membrane to EE compartment: 
Rab5 functional defects have been reported to compromise endocytosis 
(Wucherpfennig et al., 2003) and its over-expression can rescue the altered phenotype 
due to LRRK2 overexpression or knock-down (Shin et al., 2008). Recent studies 
demonstrate that Rab5b is a substrate of LRRK2 kinase activity in vitro and its GTPase 
activity is enhanced upon phosphorylation (Yun et al., 2015). Rab5 is not the only small 
GTPase found to interact with LRRK2: an interaction was also found with Rab7L1 (also 
called Rab29), which is associated with the TGN and mediate the retrograde trafficking 
(Wang et al., 2014). Recent studies showed how Rab7L1 interacts with LRRK2 to regulate 
retromer function and lysosomal pathways to modify intraneuronal protein sorting and 
PD risk (MacLeod et al., 2013). In addition, genome-wide association studies (GWAS) 
highlight a genetic interaction between Rab7L1 and LRRK2 (Beilina et al., 2014). Of 
interest, other studies show that LRRK2 phosphorylates EndophilinA (EndoA). EndoA is 
an evolutionary conserved protein known to drive vesicle formation through membrane 
interactions (Ringstad et al., 1997). EndoA “loss-of-function” causes defects in synaptic 
vesicle endocytosis and transmission (Milosevic et al., 2011). In Drosophila, LRRK2 was 
shown to phosphorylate EndoA at Ser-75 decreasing its affinity for the membranes 
(Matta et al., 2012). 
From a screening of possible LRRK2-interacting proteins, LRRK2 has been also proposed 
to participate in the exo- and endo-cytic pathways by phosphorylating Snapin (Yun et al., 
2013). Snapin is a SNAP-25-binding protein associated with the SNARE complex (Ilardi et 
al., 1999). Studies on Snapin knock-out mice show altered calcium exocytosis and 
impairment in SNAP-25:Synaptotagmin-1 binding (Tian et al., 2005), instead this 
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association is increased by protein kinase A (PKA) phosphorylation on Ser-50 (Thakur et 
al., 2004). LRRK2 was found to interact with and phosphorylates Snapin at Thr-117: 
phosphorylation rate is higher in the presence of LRRK2-G2019S pathological mutation 
and results in a decreased association of synaptotagmin-1 to the SNARE proteins (Yun et 
al., 2013). This suggests that the negative regulation of Snapin by LRRK2 may underlie 
the defects in synaptic transmission. 
LRRK2 interacts with several presynaptic through its WD40 domain (Piccoli et al., 2014), 
which is important for both LRRK2 physiological and toxic role (Sheng et al., 2010). The 
PD-risk variant in the WD40 domain, G2385R, was found in Asian population (Funayama 
et al., 2007) and several presynaptic proteins, such as the N-ethylmaleimide Sensitive 
Fusion protein (NSF) later discussed, were shown to differentially interact with mutant-
WD40 compared to wild-type-WD40 (Piccoli et al., 2014). In addition, LRRK2 kinase 
activity has been shown to be crucial for proper SV trafficking (Cirnaru et al., 2014). 
 
2.5 LRRK2 And Cytoskeleton 
Several studies support a role for LRRK2 in regulating cytoskeleton dynamics through 
differential protein-protein interactions. In particular, LRRK2 has been shown to interact 
with α/β tubulin heterodimers and microtubules (Gandhi et al., 2008; Law et al., 2014). 
Moreover, β-tubulin is a substrate of LRRK2 kinase activity in vitro and this is enhanced 
by 3-fold in presence of G2019S mutation (Gillardon, 2009). There are different 
hypotheses on the nature of LRRK2 interaction with microtubules: it may interact 
directly on microtubules, with microtubules-associated proteins or microtubules may 
localize LRRK2 within the cell by serving as scaffold for LRRK2 signaling. Interestingly, 
mutations in the Roc-COR domain (R1441C and Y1699C) cause impaired axonal transport 
and acetylation (Godena et al., 2014), as LRRK2 binding to tubulin is responsible of its 
stability (Law et al., 2014). Moreover, LRRK2 is able to phosphorylate tau protein only in 
the presence of tubulin altering its binding to microtubules (Kawakami et al., 2012). 
Since microtubule transport is critical for intracellular vesicle trafficking, the role LRRK2 
in this mechanism may cause the trafficking deficits seen in PD and neurodegenerative 
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disorders. Taken together, these results suggest a possible mechanism compromised in 
PD that could serve as  possible target against neurodegeneration. 
 
2.6 LRRK2 And Autophagy 
Deregulated neuronal autophagy can lead to Parkinson’s disease phenotypes in rodent 
models (Komatsu et al., 2006; Hara et al., 2006; Zhu et al., 2007) and it may underlying 
the accumulation of ubiquitinated proteins that results in Lewy bodies. Knockdown of 
autophagy proteins attenuates the toxicity of LRRK2-G2019S in SH-SY5Y cells, 
accompanied by neurite shortening (Plowey et al., 2008). Moreover, the LRRK2-R1441C 
mutant causes an accumulation of abnormal Multivesicular bodies (MVBs) and 
autophagic vacuoles (AVs) and it is localized on autophagosomal and autolysosomal 
membranes (Alegre-Abarrategui et al., 2009). A link between LRRK2 and autophagy  in 
vivo comes from a study where Lrrk2 -/- mice display accumulation and aggregation of 
proteins, including a-syn, in the kidneys (Tong et al., 2010). In addition, kidneys from 
Lrrk2 -/- mice display an altered level of lysosomal proteins and an accumulation of 
autolysosomes with an impairment of normal protein degradation pathways (Tong et al., 
2012), suggesting a  relationship between LRRK2 and protein degradation pathways in 
PD. However, the mechanism by which pathogenic LRRK2 alters autophagy is still an 
open question. 
 
2.7 LRRK2 And Mitochondria 
A number of studies described a role of LRRK2 in mitochondria. Over-expression of wild-
type LRRK2 has been shown to induce mitochondrial fragmentation in SH-SY5Y cells and 
this effect was increased in the presence of pathogenic R1441C and G2019S mutations 
(Wang et al., 2012). In addition, co-expression of LRRK2 and DLP1, dynamin-like protein 
1, caused DLP1 to translocate to mitochondrial membrane promoting mitochondrial 
clearance and induced oxidative stress (Niu et al., 2012). Another study proposed that 
wild-type LRRK2 can act as a neuroprotective agent against cell death caused by H2O2 in 
HEK293 and SH-SY5Y cells (Liou et al., 2008). On the other hand, G2019S-LRRK2 cells 
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were found to be more sensitive to ROS (Nguyen et al., 2011) and this could be due to 
the altered  mitochondria morphology observed in fibroblasts from PD patients carrying 
this pathological mutation (Mortiboys et al., 2010). Over-expression of LRRK2-G2019S in 
SH-SY5Y cells causes mitochondrial uncoupling and a higher oxygen consumption 
(Papkovskaia et al., 2012). Mitochondrial damage has also been showed in transgenic 
mice carrying the G2019S mutation (Ramonet et al., 2011), whereas double transgenic 
mice with both G2019S-LRRK2 and A53T-aSyn mutations display impaired mitochondrial 
activity (Lin et al., 2009). Of note, inhibition of dynamin-related protein 1, DRP1, is able 
to rescue mitochondrial fragmentation due to G2019S-LRRK2 mutation in HEK293 and 
fibroblast (Su and Qi, 2013). All these evidences support a strong relationship between 
LRRK2 and mitochondrial damage, although it is still unclear if this represent an initial 
step in the development of the pathology, or if it is a secondary effect of LRRK2 toxicity. 
In fact, evidence supporting a direct role of LRRK2 in maintaining mitochondria 
homeostasis is currently missing. 
 
2.8 LRRK2 As A Potential Therapeutic Target 
At present, Parkinson’s disease therapies can alleviate symptoms by administration of 
levodopa or dopamine receptors agonists, but cannot halt or slow the inexorable 
neurodegenerative process. Thus, disease-modifying approaches are urgently needed to 
cope with the high social and economic burden of the disease. Being LRRK2 a kinase, it 
has attracted much attention over the past ten years, since kinase inhibitors have been 
largely exploited in the clinic, especially for cancer therapies. Initial studies highlighted a 
central role of LRRK2 kinase activity in mediating the observed toxic phenotypes in cell 
models, providing the rationale to invest in the development of specific inhibitors. In 
particular, kinase dead mutants of LRRK2 exhibit reduced neuronal toxicity (Greggio et 
al., 2006; Smith et al., 2006), rescue of the neurite shortening phenotype observed with 
pathogenic mutations as well as reduced accumulation of tau-positive inclusions 
(MacLeod et al., 2006).   
To date, over 100 hundred LRRK2 inhibitors have been described (reviewed in Taymans 
and Greggio, 2015). The early inhibitors (i.e. H1152 and sunitinib) had several unspecific 
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targets and the first molecule with good selectivity and potency was the LRRK2 inhibitor 
1 (IN-1), which was capable of abrogating LRRK2 Ser910/Ser935 phosphorylation in cells 
(Dzamko 2010; Deng et al., 2011). However, the reduced blood brain barrier penetration 
limited its subsequent use in vivo  (Kuss et al., 2014). Further studies identified the 
Glaxo-Smith-Kline inhibitor GSK2578215A as a better candidate for LRRK2 kinase 
inhibition (Reith et al., 2012).The recent Pfizer inhibitor PF06447475 is one of the most 
potent and selective molecules against LRRK2 kinase activity. Recent studies, however, 
have highlighted potential safety liabilities with LRRK2 inhibition. In particular, knock-out 
mice exhibit side pathologies on lung, liver and kidney (Baptista et al., 2013), whereas 
chronic treatment of non-human primates with the potent and selective MLi2 inhibitor 
results in lung pathology (Fuji et al., 2015). Thus, more research is needed to clearly 
understand whether LRRK2 inhibition can become a therapeutic strategy to combat PD. 
These observations also support the idea of investigating LRRK2 interactors and 
substrates to define the entire LRRK2 cellular pathways compromised during disease 
and, thus, identify alternative candidates rather than direct LRRK2 inhibition. 
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3. Synaptic Vesicle Trafficking 
Accumulating evidence suggests that synaptic dysfunction and impaired 
neurotransmitter release may be one of the aspects that trigger neurodegeneration at 
early stages (Fernandez-Chacon et al., 2004; Burré et al., 2010), although the causes of 
this dysfunction remains unclear. Several studies focused on the presynaptic site to 
identify the mechanisms involved in synaptic vesicles (SV) recycling and 
neurotransmitter release and addressing how pathological mutations may affect the 
exo- and endocytic machinery.  
 
3.1 Synaptic Vesicle Pools 
SV are generally categorized in relation to their localization at the presynapse, their 
availability and stimulus needed for release. Different pools have been classified in 
relationship with their proximity to the Active Zone (AZ), a portion of the presynaptic 
membrane where fusion between vesicles and membrane occurs. SV are classified as 
the Ready Releasable Pool (RRP), the Recycling Pool (RP) and the Resting/Reserve Pool 
(RtP) (Südhof, 2004; Dittman and Ryan, 2009) as shown in Fig.3.2.1 A: 
1. RRP. Vesicles belonging to this group are immediately available after a low 
stimulation and their highest fusion probability, in association with a fast 
recycling property, allow them to play the major role in neuronal transmission. 
Most of them are docked (“pre-primed”) or in close proximity to the AZ and 
represent 1-2% of the total number of vesicle (Hanse and Gustafsson, 2001; 
Schikorski and Stevens, 2001). 
2. RP. Vesicles located here require a strong stimulation to be released and 
translocate into the RRP (Stevens and Wesseling, 1998). However, they display a 
high mobility necessary to replace SV in the RRP upon neurotransmitter release 
and they are continuously recycled and refilled from the RtP (Südhof, 2004). SV 
in the RP represents a higher fraction of vesicles, about 10-20% of the total 
number. 
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3. RtP. This pool is defined as a class of vesicles that substantially remains 
unreleased except after strong activity and stimulation (Richards et al., 2000; 
Denker et al 2009). This is considered as a stock pool of vesicles and represents 
80-90% of total synaptic vesicles. 
The number of vesicles that compose these three pools differs due to the type of 
junctions. Moreover, synaptic vesicle are located among the three different 
compartment to be prone for release and refilled at a specific rate. Neurotransmitter 
release is regulated by Ca2+ and the release probability depends on Ca2+ affinity of 
sensors, which denotes the recruitment of a specific pool (Wen et al., 2010). The peak 
depends on the duration of the action potential that modulates neurotransmitters 
release (Qian and Saggau, 1999), the open probability of Ca2+ channels and the Ca2+ 
concentration when they are opened since residual Ca2+ during repetitive action 
potentials causes short-term plasticity of release (Zucker and Regehr, 2002). However, 
the release probability per peak of Ca2+ concentration depends on the number of 
vesicles in the RRP and their responsiveness to the stimulus, pool size and kinetic: this 
feature differs from synapses (Xu-Friedmann et al., 2001) and changes in the long-term 
potentiation (LTP). 
 
3.2 Synaptic Vesicle Composition 
Vesicles have different forms of release during presynaptic activity and a different lipid-
protein composition in association with their role and pathway inside the cell (Fig.3.2.1). 
SV are small vesicles with a diameter between 30-40 nm, are composed by a lipid bilayer 
and a 60% protein to lipid ratio (Takamori et al., 2006): over 400 different protein can be 
found both on the surface and inside the SV membrane (Grønborg et al., 2010). A 
different protein composition denotes the SV specialization (Poudel and Bai, 2014). All 
types of vesicles contain transport and trafficking proteins involved in neurotransmitters 
uptake and in the interactions with membranes in both exocytosis and endocytosis 
processes. The presence of additional proteins in addition to the basic components 
provides information on their different functional properties (Dittman and Ryan, 2009). 
Purified SV possess: 
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 Proteins. Among the hundreds of proteins described, few of them have been 
extensively characterized. The relative abundance of SV proteins differs and the 
stoichiometry between proteins is not well established across individual vesicles. 
Essential proteins that have a clear function on vesicles include synapsin I, a 
molecular marker for vesicles in the RP that theaters actin filaments with SV 
(Denker et al., 2011). When the RP needs to be mobilized, synapsin I is 
phosphorylated and loses affinity for SV (Verstegen et al., 2014). Moreover, the 
proton pump (vacuolar ATPase) whose functional role is necessary for 
neurotransmitter uptake through its transporter (Edwards, 2007), synaptotagmin 
I which acts as a calcium sensor essential for fast exocytosis (Chapman, 2008) 
and synaptobrevin2/VAMP2, later discussed, for the formation of the SNARE 
complex (Rizo and Rosenmund 2008); 
 Lipids. SV were firstly described as composed by phosphatidylcoline, 
phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and 
cholesterol (Benfenati et al., 1989). 
 
 
Fig.3.2.1 | The synaptic vesicle: (A) RRP is the more distant from the AZ, but is composed by 80-
90% of the total vesicles, than the RP 10-20% and the RRP 1-2% (Rizzoli and Betz, 2005); (B) 
Proteins and their copy numbers identified through proteomic analysis on purified SV. (Dittman 
and Ryan, 2009). 
 
Inclusion of distinct sensors and proteins to the SV membrane could characterize 
different presynaptic pathways with different release models and dynamics within the 
SV cycle. 
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3.3 Neurotransmitters Release And SV Cycle 
Synaptic transmission begins when the action potential (AP)-mediated membrane 
depolarization reaches the axon terminal from the cell body. The change in membrane 
potential triggers neurotransmitters release from the presynaptic site into the synaptic 
cleft: AP stimulates the open of voltage Ca2+ channels increasing the amount of calcium 
inside the cell leading to fusion of SV to the membrane where exocytosis starts (Katz and 
Miledi, 1968). The membrane of the SV fuses with the cell membrane, aided by multiple 
membrane proteins. The fused area forms a pore and neurotransmitter diffuse across 
the gap into the synaptic cleft to bind with membrane receptors on the postsynaptic 
cell. When neurotransmitters bind to their receptors, the signal is transferred into the 
postsynaptic cell. After exocytosis, SV undergo endocytosis and are recycled inside the 
cell and refilled with neurotransmitters to be available for another fusion round. 
Synaptic vesicles undergo a particular cycle in nerve terminal that can be divided into 
five steps:  
1. Neurotransmitters are transported inside the synaptic vesicles; 
2. SV cluster close to the active zone; 
3. Vesicles in the RRP dock at the active zone; 
4. Vesicles are pre-primed; 
5. Ca2+ triggers the fusion-pore opening. 
More than 40 years ago, different studies showed that after exocytosis, vesicles are 
rapidly refilled with neurotransmitters and that a number of vesicles recycled locally 
very fast. At the same time, data obtained from the neuromuscular junction highlight 
another fast way of vesicles recycling without a clathrin-coated intermediate (Ceccarelli 
et al.,1973), whereas an extensive stimulation produce a slow endocytosis of vesicles far 
from the synaptic terminal (Heuser and Reese, 1973). On the basis of these observations 
three vesicles pathways were proposed after neurotransmitters release in the synaptic 
cleft (Fig.3.3.1): 
a) Vesicles are refilled with new neurotransmitters without undocking, thus 
remaining in the RRP (“kiss-and-stay”); 
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b) Vesicles undock, but remains in close to the active zone and recycle locally (“kiss-
and-run”); 
c) Endocytic pathway through clathrin-coated pits, reacidify and refilled directly 
with neurotransmitters; 
d) Instead of directly, neurotransmitters are refilled through an endosomal 
intermediate. 
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Fig.3.3.1 | Synaptic vesicle endocytic pathways: The three different pathway proposed in which 
vesicle remains in the RRP and refilled immediately with neurotransmitters (“kiss-and-stay”), a 
local recycling pathway within the RP  (“kiss-and-run”) and a clathrin-mediated endocytosis via 
endosomal recycling (Südhof, 2004). 
 
 
These processes can be classified into “fast pathways” (a and b) or “slower pathway” (c 
and d) and a different fusion event can occurs: in the fast pathway vesicles probably 
utilize a transient fusion pore, whereas in the slow pathway the recycling involves a full 
fusion of the vesicle with the plasma membrane. 
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3.4 Trafficking Impairments In PD 
As discussed previously, PD causes severe motor impairments due to a progressive 
degeneration of dopaminergic neurons in the substantia nigra pars compacta. A number 
of studies on familial forms of the disease revealed alterations in several cellular 
processes, but the link between mutations and neurodegeneration remains unclear. To 
this regard, growing evidence suggests that PD genes regulate presynaptic activity. 
Specifically, a study by Burré and co-workers reported that alpha-synuclein regulates the 
release of neurotrasmitters by promoting the assembly of the SNARE complex (Burré et 
al., 2010). Furthermore, alpha-synuclein knockout mouse exhibits an increase of evoked 
dopamine (DA) release, suggesting that alpha-synuclein is an activity-dependent 
negative regulator of DA neurotransmission (Abeliovich et al., 2000). Interestingly, also 
DJ-1 and PINK1 knockout mice exhibit reduced DA overflow and impaired striatal 
synaptic plasticity (Kitada et al., 2009). Finally, severe neurotransmission defects have 
been repeatedly observed in different LRRK2 rodent models (Belluzzi et al., 2012). Thus, 
defective neurotransmitter release could arise as a prodromal phase of the disease, 
contributing to the early stage symptoms of PD. Thus, one process that appears to be 
deregulated in different PD models is SV trafficking (Fig.3.4.1). However, genes 
implicated in PD are widely expressed and the main unanswered question is why the 
dopaminergic neurons are more prone to neurodegeneration (Zarow et al., 2003). One 
explanation seems to be that perturbation in SV trafficking causes an altered DA 
homeostasis, resulting in increased cytosolic levels of DA toxic which is toxic to the cell. 
This idea is supported by the finding that overexpression of aSyn leads to an higher 
cytoplasmatic DA level (Mosharov et al., 2006). Also other PD models, show a DA-
dependent degeneration of DA neurons. Thus, the cellular impairments that affect SV 
trafficking may relate to deregulated DA storage/uptake, which in turn causes ROS 
increase leading to cytotoxicity and contributing to neurodegeneration (Bisaglia et al., 
2013). 
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Fig.3.4.1 |Proteins associated to PD at the presynapse: (A) Schematic representation of vesicle 
trafficking at the presynaptic site.  Vesicles filled with neurotransmitters move from the RP to 
the AZ. After docking and priming they are recycled inside the cell for another fusion event. (B) 
Effects of proteins related to PD at the presynaptic site in which an altered function produce a 
higher DA level allowing cytotoxicity. (Esposito et al., 2012). 
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4. Endocytic pathways 
4.1 Organization And Function 
Endocytosis is a cellular mechanism that allows internalization of extracellular 
components inside the cells and an important way of inter-cellular communication. 
Internalization of macromolecules and particles through an invagination of the plasma 
membrane is an essential step for maintenance of the intracellular framework and 
interaction with the environment (Mercer et al., 2010). In this scenario, endocytosis 
represents an important tuner of intra- and extra-cellular regulation and requires several 
elements necessary to reuse components or digest macromolecules through a recover 
or degradative system, respectively (Fig.4.1.1). The first step of the endocytic machinery 
is early endosomes (EEs) maturation, in which vesicles are directed to recycling, back to 
plasma membrane, or to late endosomes (LEs) maturation (Mayor and Pagano, 2007). 
EEs play a key role in determining the following sorting events such as recycling, 
degradation in LEs or lysosomes or delivery to the trans-Golgi network (TGN). In this 
regard, vesicles possess different morphology, localization, composition and function 
(van Meel and Klumperman, 2008). The maturation into LEs takes place from the EE 
compartment. During this maturation, vesicles communicate with the TGN (Bonifacino 
and Rojas, 2006) and this continuous vesicle sharing between these two compartments 
is a process extensively studied to unravel both vesicles destination and composition. 
LEs formed can fuse together and finally bind lysosomes to form bigger structures called 
endolysosomes (Luzio et al, 2007) that can be degraded through lysosomes. All those 
pathways provide a dynamic and continuous exchange mechanism and contribute in the 
maintenance of intracellular environment. The maturation process is characterized by 
changes in membrane components and the whole process is driven by regulating factors 
recruited at the surface of vesicle. 
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Fig.4.1.1 | The endocytic pathway: Endocytic vesicles move to the early endosome (EE) 
compartment, then can directly go back to the plasma membrane or moving towards to 
perinuclear space through microtubules (MT). Vesicles undergo several changes both on surface 
and in the lumen, acquiring more ILVs, and they deliver to lysosomes. At its final steps, vesicle 
fuses prior with a lysosome (endolysosome) in which components starts to be degradated, and 
then is converted into a lysosome (Huotari and Helenius, 2011) 
 
4.2 Rab Proteins 
Intracellular trafficking events are mediated by Rab proteins, a large family of 
monomeric small GTPases. Rabs are distributed in all cellular compartments (Fig.4.2.1) 
with multiple roles orchestrating organelles transport to regulate vesicle sorting inside 
the cell (Novick et al., 1997), therefore playing a major role in endocytic and vesicle 
trafficking also in neurons (Ng and Tang, 2008). 
In humans, there are more than 60 Rab proteins localized on membranes (Schwartz et 
al., 2007; Pereira-Leal et al., 2001) and the regulatory principle is based on their GTP- 
and GDP- bound form: since they use GTP to explain their role, it is possible to 
distinguish between an active (GTP-bound state) or inactive (GDP-bound state) 
conformation of the protein. The interconversion between these two states is a label of 
their physiological function as molecular switches and it is characterized by 
conformational changes in specific regions: the structural basis of the Rab molecular 
switch can be defined as two portions of the proteins called Switch I and II regions, as for 
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Ras proteins (Pfeffer, 2005). The cycle between active and inactive state depends on the 
rates of nucleotide exchange and hydrolysis. Intrinsic GTPase activity of Rab proteins is 
low, but GTP hydrolysis is catalyzed by GAPs (Haas et al., 2007) and this function 
activates specific effectors involved in each transport step of vesicles maturation. At the 
same time, the GDP dissociation inhibitor (GDI) was identified as an important factor 
that prevent GDP-release from Rabs due to stabilize the inactive form (Matsui et al., 
1990). To became active, they need to be recruited to membranes where GDI is 
removed and GDP replaced by GTP through GEF. An interesting feature is the different 
localization inside the cell of Rab proteins: this is mediated by the GDI displacement 
factors (GDFs) that plays a key role in Rab-GDP specific binding facilitating their specific 
association to membranes (Jovic et al., 2010). When they are in the active state, Rab 
proteins interact with a series of downstream effectors to modulate different pathways 
in vesicle maturation: Rab effector proteins control numerous steps providing a 
regulatory mechanisms complementary to SNARE proteins, further described. Each 
organelle has different Rabs on its surface that lend specificity on intracellular transport 
events, maintaining the specificity of interactions.. As mentioned before, the recycling 
vesicle through endocytosis is the main way to maintain the correct intracellular 
composition. During endosome maturation, EEs moved along microtubules (van Dam et 
al., 2002) acquiring components that manage their fate to specific compartments or 
vesicles could be immediately recycled back to the plasma membrane. At this point, 
Rab5 is the most important marker and a switch between it and other Rab proteins 
determines next events: Rab4 or Rab11 (Seaman et al., 2012) replaces Rab5 in the 
recycling endosome compartment (Schmidt and Haucke, 2007) for a fast or slow, 
through the perinuclear endosomal recycling compartment (ERC), vesicle fusion back to 
plasma membrane respectively (Stenmark, 2009). 
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Fig.4.2.1 | Representative Rab proteins localization: The endocytic pathway (red arrows) from 
the plasma membrane (PM) involved several Rab proteins that acts in all different compartment 
through both for anterograde transport (green arrows) and EE recycled to PM and trans-Golgi 
Network (TGN, black arrows) (Adapted from Chua et al., 2015). 
 
A number of studies showed how phosphorylation may regulate Rabs GTPase activity by 
direct phosphorylation or through phosphorylation of Rabs cofactors (Mattera et al., 
2006; Chavez et al., 2008; Bailly et al., 1991). Previously in the introduction, LRRK2 has 
been described to associate with Rab5 proteins in the regulating synaptic vesicle 
endocytosis. Of interest, other studies identified also a relationship between PINK1-
dependent phosphorylation and Rab proteins: PINK1 regulates Rab8A, 8B and 13 
phosphorylation on Ser-111 and this phosphorylation impairs Rab:GEF interaction, in 
particular between Rab8A and Rabin8 (Lai et al., 2015).  
All these findings highlight a potential novel regulatory mechanism altered in pathogenic 
conditions. An impairment of Rab GTPase-mediated signaling could alter the normal 
endocytic pathway and neurotransmitters release, thus representing an important 
mechanism compromised in PD.  
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4.3 Early Endosome (EE) Compartment 
The first step of the internalization process requires maturation of vesicles to early 
endosomes (EEs), which is a crucial point that determines the fate of the proteins and 
lipids internalized. This maturation process begins with clathrin-dependent or -
independent pathways. Molecules internalized could be either recycled back to the 
plasma membrane or undergo degradation in late endosome and then lysosome. The EE 
compartment receives vesicles directly from the plasma membrane and it is a structure 
with a high propensity to homotypic fusion (Gruenberg et al., 1989). It is characterized 
by the presence of regions with tubular extensions and multi-vesicular appearance 
(Gruenberg, 2001) that are important in vesicle sorting. It was demonstrated that the 
recycling pathway requires a step on the tubular membranes, whereas the multi-
vesicular elements are responsible of addressing vesicle to the degradation pathway. In 
this scenario, most of the present ligands and molecules are degraded, conversely 
receptors are recycled back to the plasma membrane. 
Intracellular fusion and trafficking events are mediated by specific soluble NSF-
attachment receptors (SNAREs). These phenomena are specific and orchestrated by a 
class of proteins through the vesicular transport pathway. The regulation occurs at all 
the steps of vesicle maturation and a critical component is the small class of Rab GTPase 
proteins: these small enzymes bind GTP and became physiologically active. Upon 
activation, they can interact with other effector proteins with roles and functions that 
will be discussed later. 
 
4.4 Late Endosomes (LEs) 
The maturation process of EEs into late endosomes (LEs), which is in junction with the 
trans-Golgi network (TGN), requires several changes and transformations until 
endosomes fuse with lysosomes as a dead-end point. LEs formed move to the 
perinuclear region of the cell where they fuse with each other (Luzio et al., 2007). 
Through this process, different changes take place and only few components are 
rescued, such as receptors and SNARE proteins. The most important regulation step 
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from EE to LE allows the “Rab switch”(Carroll et al, 2001; Behnia and Munro, 2005): this 
process requires the exchange in membrane marker where Rab5, an essential factor for 
clathrin-mediated endocytosis, is converted to its GDP-bound form, dissociated from the 
vesicle and replaced by Rab7 (Rink et al., 2005, Poteryaev et al., 2010). The Rab5/Rab7 
switch provides the most important regulation step from EE to LE maturation and 
organelles transport to lysosomes (Behnia and Munro, 2005; Carroll et al, 2001). Rab5 is 
on vesicle surface in its GTP-bound state, active, with its GEF Rabex-5; in this state 
Rabapitin-5, an effector of Rab5, binds the complex starting the dissociation of Rabex-5 
from membrane (Lippé et al., 2001). Active Rabs can recruit additional effectors into 
these domains: this generates a loop resulting in Rab5 inactivation and dissociation 
through GAP inactivation in which Rab7 is recruited. At this point, Rab7 in the active 
state replaces Rab5 on vesicle (Grosshans et al., 2006). Apart from the “Rab switch”, the 
lipid composition during vesicle maturation changes too: PtdIns(3)P on EE recruits the 
phosphatidylinositol 3-phosphate 5-kinase PIKfyve which converts it into PtdIns(3,5)P(2) 
on LE (Vicinanza et al., 2008). PIKfyve is also involved in the formation of intraluminal 
vesicles (ILVs), an important feature in the maturation process for further sorting events: 
the ESCRT complex (composed by ESCRT-0, -I, -II, -III) (Hurley and Hanson, 2010) and 
accessory proteins, such as VPS4 and Alix, are the main responsible of ILVs formation. 
The role of ESCRT machinery is to find the Ub-tags in the cytosolic domains of 
membrane proteins, which are subsequently removed. Their depletion results in a fewer 
ILVs formation, altered morphology and accumulation of cargo in endosomes (Razi and 
Futter, 2006). The acidification is another important aspect: EEs have a pH between 6.8 
and 6.1 that decreases gradually down to 6.0-4.8 in LEs (Maxfield and Yamashiro, 1987). 
In addition, the lumen environment changes in Cl-, Ca2+, Na+ and K+ concentrations. Once 
LEs arrive in the perinuclear area they can fuse each other or with lysosomes 
(endolysosomes). The latter brings to a dead-end pathway since lysosomes are the 
degradative organelles in eukaryotic cells. Even if the LEs are mainly degraded in the 
lysosomal compartment, they can also be transferred to membrane diffusing their 
contents in the extracellular space through exosomes. Of interest, some components 
can be saved from degradation through the retromer complex (Bonifacino and Hurley, 
2008; Seaman, 2012). 
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4.5 SNARE Proteins 
In eukaryotic cells, exo- and endo-cytosis pathways and in general all intracellular fusion 
processes are mediated by specific interaction of proteins located on membrane 
surfaces. Vesicles are carried to the their destination moving to the target site that ends 
with docking and membranes fusion. Intracellular fusion events are mediated by a class 
of proteins called SNAREs (Soluble N-ethylmaleimide-sensitive factor Attachment 
protein REceptors) that guarantee the specificity of the interaction. The term SNAREs 
was firstly introduced in 1993 (Söllner et al., 1993) and since then more than a hundred 
different SNARE proteins have been discovered in several organisms, with 38 of them 
known to exist in humans (Malsam et al. 2008). The hallmark of all of them is the heptad 
repeat sequence: a conserved domain of about 70 amino acids (SNARE motif) with a 
propensities to form the coiled coils necessary for their interaction (Sudhof and 
Rothman, 2009). Monomeric SNAREs are unstructured, but their motif spontaneously 
form a stable four-bundle helical complex when they interact together (Fasshauer et al., 
1997). The interaction is known as “zipper” model and starts from the N-terminal region 
to the membrane C-terminal of SNAREs and brings the two membranes in close 
proximity triggering membrane fusion (Hanson et al., 1997; Lin and Scheller, 1997). Due 
to this different localization inside the cells, SNARE proteins are divided into v-SNAREs 
(on vesicle) and t-SNAREs (target membrane) (Hong, 2005). Based on domain structure, 
all mammalian SNAREs have been classified as members of those three families. 
However from a structural point of view SNAREs can be classified also in R-SNAREs 
(arginine) or Q-SNAREs (glutamine) based on the key residue in the center of the SNAREs 
(Fasshauer et al., 1998). Generally, most R-SNAREs are members of the v-SNAREs and 
most of Q-SNAREs are t-SNAREs. The specificity of interaction leads to the formation of a 
coiled-helical bundle, highly stable and SDS-resistant (Poirier et al., 1998) complex with 
transmembrane domains (Chen and Scheller, 2001). This step is also characterized by a 
change in the SNARE structure that goes from a trans-SNARE complex to a cis-SNARE 
complex. In lipids fusion experiments it was demonstrated that two t-SNAREs and one v-
SNAREs are required for membrane tethering and fusion (McNew et al., 2000). 
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4.6 The SNARE Complex 
The crystal structure of the complex has been characterized and reveals a four-stranded 
coiled-coil assembly (Fig.4.6.1). In this conformation, the two membranes are in closed 
proximity and the binding among SNAREs triggers the membrane fusion (Zimmerberg et 
al., 1993). Biochemical studies reveal that the SNARE complex is high stable, up to 90°C 
(Hayashi et al., 1994), and SDS-resistant (Yang et al., 1999). Given this stability, the 
complex will not spontaneously disassemble, but this must be a mechanic process. 
However, the dissociation constant in vivo have not yet been described since the kinetic 
mechanism depends on SNARE concentration and membrane architecture, suggesting 
that additional protein are involved, such as SM (Sec1/Munc18-related) (Südhof and 
Rothman, 2009). In the nervous system, vesicle fusion to the pre-synaptic membrane, a 
calcium-dependent process (Heidelberger et al., 1994; Peters and Mayer, 1998), is an 
essential step in synaptic transmission. Neurotransmitters are released in the synaptic 
cleft: the neuronal SNAREs that mediate synaptic vesicle binding to the membrane are 
Synaptobrevin/VAMP (vesicle-associated membrane protein) protein and the plasma 
membrane SNAP-25 (synaptosomal-associated protein of 25 kDa) (Oyler et al., 1989) 
and Syntaxin-1 (STX-1) (Bennett et al., 1992) proteins. Therefore, neuronal SNARE core is 
composed by one coil of STX-1 and VAMP with two coils of SNAP-25 which constitutes 
the minimal functional unit of the SNARE complex in vitro. Regions that are not involved 
in the complex formation have also an important regulatory function: the C-terminal 
regions are involved in membrane interactions, and N-terminal regions might function as 
recruitment domains for SM-associated proteins (Jahn and Scheller, 2006). To date,  a 
number of studies show that the N-terminal of STX-1 forms a “closed” conformation that 
competes with the others SNARE motifs for its binding in a negative regulation 
(Nicholson et al., 1998) and can recruit Munc-18, a chaperone that facilitates complex 
assembly (Hata et al., 1993). The loop region of SNAP-25 not involved in complex 
assembly is useful for membrane fusion, and thus crucial for synaptic transmission 
(Scales et al., 2000); the N-terminal region of VAMP probably is not involved in 
membrane fusion, but if depleted exocytosis is compromised (Scales et al., 2000) 
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Fig.4.6.1 | The SNARE complex: Crystal structure of the SNARE complex composed by 
Synaptobrevin/VAMP (red), STX-1 (yellow) featuring its Habc domain (orange) and both SNAP-25 
N-terminal (blue) and C-terminal (green) (Rizo and Südhof, 2002). 
 
After membrane fusion and neurotransmitters/molecules release, the complex could be 
disassembled to be reused inside the cells and synaptic vesicles undergo recycling 
through the endocytotic pathway. Since it is a high stable complex, ATP is needed to 
dissociate SNARE components: the disassembly process is carried out by the ATPase N-
ethylmaleimide sensitive fusion (NSF) protein with its adaptor αSNAP (soluble NSF 
attachment protein). 
 
4.7 The N-Ethylmaleimide Sensitive Fusion Protein (NSF) 
In eukaryotic cells, intracellular trafficking requires SNARE proteins, therefore this 
complex needs to be disassembled after membranes fusion to make individual proteins 
available to be reused (Jahn et al., 2003). Spontaneous SNARE complex disassembly is 
slow, so this reaction is catalyzed by the N-ethylmaleimide Sensitive Fusion (NSF) protein 
that, with its adaptor protein αSNAP (Soluble NSF attachment protein) (Clary et al., 
1990), binds the SNAREs and disassembles the four helix-bundle complex using the 
energy of ATP hydrolysis (Whiteheart et al., 2001).  
NSF was firstly described in studies focused on TGN pathways (Block et al., 1988) as a 
regulatory factor in vesicle trafficking. NSF belongs to AAA+ (ATPases Associated with 
various cellular Activities), a wide family of ATPases found in all organisms. The hallmark 
of these proteins is the ATP binding domain of 200-250 amino acids characterized by 
 42 
 
Chapter I Introduction 
two conserved motifs: the Walker-A and Walker-B that mediate nucleotide binding 
(Ogura and Wilkinson, 2001; DeLaBarre and Brunger, 2003). AAA+ enzymes assemble 
into oligomers upon nucleotide binding and this is the biologically active conformation. 
In this state, they participate in several cellular processes by promoting conformational 
changes or remodeling of target proteins. The processes are proteolysis, protein 
disaggregation or protein-complex disassembly (Hanson and Whiteheart, 2005). This last 
function in eukaryotes is carried out by NSF itself to maintain intracellular network 
pathways, in which the disassembly of the SNARE complex is the main vesicle fusion 
regulation event. NSF is present in all tissues, but it is highly expressed in the nervous 
system, where it is responsible for synaptic transmission. Similar to other ATPases, NSF 
has two different ATP binding domain: one is necessary for conformational change from 
a monomeric structure to a homo-hexameric cylindrical quaternary structure; the 
second one is responsible for its ATPase activity. From a structural point of view, each 
subunit of NSF is composed by three different domains: the N-terminal domain (N, 1-
205) necessary for interaction with αSNAP:SNAREs (Whiteheart et al., 2001), the D1 
domain (206-477) with the ATP-binding domain necessary to disassemble the SNARE 
complex and the D2 (478-744) domain with the other ATP-binding domain necessary for 
hexamerization (Matveeva et al., 1997). The X-ray crystal structure of the N-terminal 
domain (May et al., 1999; PDB code: 1QDN) and D2 domain are well characterized 
(Lenzen et al., 1998; PDB code: 1NSF), but the structure of D1 domain lacks. Both D1 and 
D2 domains have the typical AAA+ structure for nucleotide binding with two subdomain 
called α and α/β motifs. When bound, αSNAP triggers the disassembly of the SNARE 
complex: prior to ATP hydrolysis the complex composed by SNAREs:αSNAP:NSF is called 
20S, referred to its sedimentation constant, and the dissociation can start. Also this 
complex was well characterized by NMR and cryo-electron microscopy using all the 
structures of the single proteins available in the protein data bank (Chang et al., 2012; 
PDB code: 3J98). 
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4.7.1 NSF quaternary structure 
Structural studies on NSF started when the protein was found in association with TGN 
trafficking (Balch et al., 1984). Further characterization demonstrated that the active 
state of NSF presents a homo-hexameric structure of 480 kDa (Hanson et al., 1996). Both 
the ATP- and ADP- bound state are organized into the three different layers one over the 
other referred to the three different domains of NSF described above (Fig.4.7.1.1): D2 
domains at the bottom, D1 domains in the middle and N-terminal domains on top. This 
last mentioned domain has a different distribution between the two nucleotide-bound 
state and forms a layer of six or four domains for ATP- or ADP-bound state respectively 
(Zhao et al., 2015). To better describe the two different conformations, the chain with 
the closest distance between D1 and D2 domain is named Chain A in the D1 domain, 
then there are chains from B to F as distance increases. Active NSF is when the protein is 
in the D2 ATP-bound state. 
The 3D reconstruction of NSF was obtained through cryo-EM density maps that well 
describe the distribution of the different domains. In the ATP-bound form, the D2 
domain has a six-fold symmetry; however, D1 domain presents a chain stepping of 5 Å 
as showed by the position of the helix. In this conformation there is a step down from 
chain A to F and, being the F chain the one available at the lower structural resolution. 
This means that it is probably the more flexible part with a more open conformation of 
the D1 ring. In this state the diameter is about 112 Å for both D1 and D2 domains.  
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Fig.4.7.1.1 | Full-length NSF structures obtained with Cryo-EM: Side views of ATP- and ADP-
bound state of NSF obtained from Cryo-EM density maps using cristal structures available from 
the Protein Data Bank (PDB) (Zhao and Brunger, 2015). 
 
A difference between these two states is the α subdomain correlated to the different D1 
conformation: D1 ring in ATP-state has a more compact structure, on the other hand in 
the ADP-bound has a more relaxed structure. On top there are the N-terminal domain 
(up conformation), and the lower density of this domain is probably due to its flexibility. 
This suggests a nucleotide-dependent movement of the flexible N-terminal domain and 
the different positions depend on NSF ATPase activity. The central hole has a dimeter of 
about 20 Å for D1 and near 24 Å on top to 7 Å at the bottom describing a more shaped 
structure of the D2 domain (Chang et al., 2012). For ADP-bound NSF, the D1 domain has 
a more expanded and planar conformation compared to its ATP-bound state, with a 
large opening between chain A and F that correspond to the gap in the D2 domain. The 
main difference is the position of the N-terminal domains that are allocated around the 
side (down conformation). Studies indicate the presence of four different N-terminal 
domains on top in this state (Zhao et al., 2015), despite previous data that placed all the 
six domains around the D1 (Chang et al., 2012). The D1 different conformation instead is 
related to a rotation of chains A and B and changes in their N domains.  
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Placing this structural information in the context of the 20S architecture (Fig.4.7.1.2), 
above NSF, there are the SNAREs and four different αSNAP that, with the N-terminal 
domains, surround the complex in a four-fold rotational symmetric arrangement. 
Moreover, αSNAP has a different twist compared to SNAREs: right and left-handed 
respectively. The SNARE proteins are in the center of the structure with a tighter 
conformation of D1 domain of NSF compared to the same domain alone in the ATP-
state. The position of these proteins is located close to chains E and F near the small gap 
in D1 domain suggesting an interaction between these two parts. Previous findings 
indicate that trans-SNARE complex before membrane fusion is resistant to NSF activity 
(Weber et al., 2000) and the αSNAP-SNARE complex is not able to form until the “zipper” 
conformation has formed (Vivona et al., 2013). At this step NSF uses the energy derived 
from ATP hydrolysis to torque and pulling the SNAREs. Taken together, these forces 
disassembly the complex into individual proteins that are now available to reuse inside 
the cell. 
 
 
 
Fig.4.7.1.2 |3D density map of the 20S supercomplex: Schematic representation of the 20S 
supercomplex composed by NSF (N-ter, red, D1 domain, light blue, and D2 domain, pink), alpha-
SNAP (yellow) and SNARE complex (green) (Zhao et al., 2015). 
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4.8 The SNARE Complex Disassembly 
The working model of NSF-mediated SNARE complex disassembly is based on structures 
obtained with cryo-EM. Models are based on neuronal SNAREs, but in spite of the 
presence of different proteins in this class, it seems that only few SNAPs and NSF are 
required to disassemble them in eukaryotes (Jahn and Scheller, 2006; Clary et al., 1990). 
This process includes 4 different steps (Fig.4.8.1): 
1. Up to four αSNAP binds the cis-SNARE complex anchored to the plasma 
membrane; 
2. NSF binds the αSNAP:SNAREs generating the 20S complex where both D1 and D2 
domain are tightened and N-terminal is immobilized due to its interaction with 
the complex; in the proposed model two N-terminal domains bind to one αSNAP. 
3. The ATP hydrolysis is the key event where NSF starts to disassemble the SNAREs 
and a collection of four different events have been proposed as different 
molecular states in which the complex is twisted and stretched for the 
disassemble. 
4. Multiple ATP hydrolysis events that produce a large conformational changes of 
NSF between ATP- and ADP-bound states. Here, a combination of movements 
through D1 changes, that turn to a more open conformation, and pulling forces 
by N-terminal domains towards the sides of NSF, result in the dissociation of 
SNARE complex into individual proteins. Two N-terminal domains go from top to 
side of the D1 ring. 
The mechanism described above is the most recently proposed in the literature where 
cryo-EM was used to highlight the conformational changes between ATP- and ADP- state 
(Zhao et al., 2015). Even if it is well known that NSF can adopt those two different 
conformational states, intermediate species and the detailed ATP hydrolysis mechanism 
lack. Moreover, the number of subunits that must hydrolyze ATP remains unclear: 
studies suggest that the complex disassembly is induced by only one round of ATP 
hydrolysis (Ryu et al., 2015), as few as 10 (Shah et al., 2015) or at least 50 (Cipriano et al. 
2013) molecules of ATP are needed per disassembly reaction. All these observation try 
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to clarify the process, but more detailed studies will be necessary shed light into the 
mechanism, which, at present, remains substantially unclear. 
 
 Fig.4.8.1 | Model of the SNARE complex disassembly: The model consists of four different 
steps in which alpha-SNAP binds the SNARE complex on the plasma membrane, then NSF is 
recruited and the complex is disassembled by pulling the complex. Colors are the same as above 
(Adapted from Zhao et al., 2015). 
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5. Aim of the Project 
The research project of this thesis aims at identifying novel substrates of LRRK2 kinase 
activity. LRRK2 phosphorylation affects vesicle trafficking at the presynaptic site and its 
PD-related mutations lead to cytotoxicity and neurodegeneration (Greggio et al., 2006; 
Heo et al., 2010). Moreover, PD is characterized by an impairment of vesicle trafficking 
at early stages and a number of LRRK2 interactors are presynaptic proteins (Belluzzi et 
al., 2012). 
Since alteration of vesicle recycling is likely to represent a crucial step in PD that triggers 
neurodegeneration, understanding whether LRRK2 can regulate vesicle-related 
processes through its kinase activity is a key aspect. N-ethylmaleimide Sensitive Fusion 
(NSF) protein has been found as a putative LRRK2 interactor (Piccoli et al., 2011). NSF is 
an ATPase responsible for SNARE complex disassembly, allowing correct vesicle recycling 
(Zhao and Brunger, 2015). After validating that recombinant human Flag-NSF is an active 
ATPase, we divided the project into three main objectives: i) to investigate the 
NSF:LRRK2 interaction; ii) to test whether NSF is a substrate of LRRK2 kinase activity by 
MS/MS analysis and iii) to study effects of phosphorylation on both NSF ATPase activity 
and SNARE complex disassembly. 
Rab GTPases play a key role in vesicular sorting among all cellular compartments 
(Grosshans et al., 2006). Recent studies highlighted a possible interaction between 
Rab7L1 and Lrrk2 (Beilina et al., 2014). Indeed, Rab7L1 overexpression suppressed the 
LRRK2 G2019S mutation-induced neurite length phenotype (MacLeod et al., 2013). 
Considering that neurotransmitter release is one frequently altered aspect in 
neurodegenerative diseases and Rab7L1 was also found associated with a higher PD-risk, 
another aim of this work was to evaluate whether Rab7L1 is a substrate of LRRK2 kinase 
activity. In this scenario, an abnormal phosphorylation of Rab7L1 due to LRRK2 G2019S 
mutation could results in impaired vesicle sorting inside neurons. 
The identification and validation of LRRK2 putative substrates is fundamental to shed 
light into LRRK2 physiological function, providing insights into the mechanisms that 
appear altered in PD. To date, LRRK2 kinase activity has been considered the most 
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tempting therapeutic target in PD (Kethiri and Bakthavatchalam, 2014). However, 
pharmacological compounds against LRRK2 kinase activity have been shown to produce 
severe side effects (Baptista et al., 2013; Luerman et al., 2014). Thus, identification of 
novel LRRK2 substrates might represent alternative targets to block the downstream 
effects of pathogenic LRRK2. 
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6. Materials and Methods 
6.1 Plasmids And Constructs 
NSF protein, conjugated with a Flag-tag, was cloned in pcDNA3 vector (Sigma-Aldrich, St. 
Louis, MO, USA) and the construct was already present in our laboratory. NSF N-
terminal, D1 and D2 domains were cloned into p3XFLAG-CMVTM-7.1 vector (Sigma-
Aldrich, St. Louis, MO, USA) and amplified using forward primers with NotI overhang and 
reverse primers with KpnI overhang as following: 
N-Domain (1–205aa): forward 5′-AAGCTTGCGGCCGCCTTCGCGGGCCGGAGC-3′ and 
reverse 5′-TCGAC TGGTACCTTAGCGATTTTCCTTGGTTTT-3′ 
D1 domain (206-477aa): forward 5′-AAGCTTGCGGCCGCCCAATCAATTATCAATC-3′ and 
reverse 5′-TCGACTGGTACCTTATCTCGTCACTTGCAGGC-3′ 
D2 domain (478-744aa): forward 5′-AAGCTTGCGGCCGCCGGAGACTTCCTTGCTTC-3′and 
reverse 5′-TCGACTGGTACCTCAATCAAAATCAAGGGG-3′. 
NSF mutants were generated using the QuickChange mutagenesis kit (Agilent 
Technologies, CA, USA) according to the manufacturer’s instructions. All plasmids were 
validated by restriction analysis and DNA sequencing. 
pCHMWS 3xFlag-tagged LRRK2 wild-type, K1906M and G2019S have been previously 
described (Civiero et al., 2012). Rab proteins used (Rab7, Rab7L1, Rab9, Rab11 and 
Rab32) were cloned into p3XFLAG-CMVTM-7.1 by our collaborators at the University of 
Granada (group of Dr. Sabine Hilfiker), that generated also all the site directed point 
mutants. 
 
6.2 Cell Culture And Transfection  
Human embryonic kidney cells (HEK293T) were cultured in Dulbecco's modified Eagle's 
medium (DMEM, Thermo Fisher, Waltham, MA USA) supplemented with 10% v/v fetal 
bovine serum (FBS, Thermo Fisher, Waltham, MA USA), penicillin (100 Units/ml) and 
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streptomycin (100 μg/ml) (Life Technologies) at 37°C and 5% CO2. HEK293T were 
transiently transfected using linear polyethylenimine (PEI, Polysciences) with ratio 
DNA:PEI 1:2. 40 μg of DNA were dissolved in 1 ml of OPTI-MEM (Thermo Fisher, 
Waltham, MA USA) and 80 µl of PEI (40 µM) were added to 1 ml of OPTI-MEM. After 5 
minutes of incubation, the two solutions were mixed together. After 20 minutes, to 
allow the formation of DNA/PEI complexes, the mix was added directly to the cells in 
150 mm Petri dishes and used after 48-72 hours.  
 
6.3 Protein Purification From Mammalian HEK293T Cells 
6.3.1 Human Flag-tagged NSF  
Human NSF, its mutants and single domains with an N-terminal Flag-tag, were purified 
from HEK293T cells after transient transfection as described above. Cells were 
resuspended in 1 ml of a Lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 
2.5 mM Na4P2O7, 1 mM beta-glycerophosphate, 1mM Na3VO4, Protease Inhibitor 
Mixture (Sigma-Aldrich, St. Louis, MO, USA)) and then lysed with 5 cycles of freezing and 
thawing in liquid nitrogen. Cell lysate was collected after centrifugation at 18000xg for 
40 minutes at 4°C. The supernatant was incubate overnight with 40 µl of Anti-Flag M2 
Affinity gel (Sigma-Aldrich, St. Louis, MO, USA) at 4°C. After centrifugation, the 
supernatant was discarded and the beads with Flag-tagged proteins were washed with 1 
ml of different buffers: WB1 (20 mM Tris-HCl pH 7.5, 500 mM NaCl) twice, WB2 (20 mM 
Tris-HCl pH 7.5, 350 mM NaCl) twice, WB3 (20 mM Tris-HCl pH 7.5, 150 mM NaCl) six 
times. The protein was then eluted by incubating the beads with 200 µl of WB5 or 
directly in the Kinase assay buffer (25 mM Tris-HCl pH 7.5, 5 mM beta-glycerophosphate, 
2 mM DTT, 0,1 mM Na3VO4, 10 mM MgCl2 supplemented with 0.007% Tween® 20) with 
150 ng/µl 3xFlag peptide and mixing the sample for about 2 hours. The sample was 
centrifuged to pellet the resin and the supernatant was collected. 
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6.3.2 Human Flag-tagged LRRK2 wt/G2019S and Flag-tagged Rab 
proteins 
1% Tween-20 was added to the Lysis buffer (composition described above) and samples 
were hold on ice for 30 minutes. Beads were washed with buffers with different 
concentration of Tween-20 added: WB1 (20 mM Tris-HCl pH 7.5, 500 mM NaCl, 1% 
Tween-20) twice, WB2 (20 mM Tris-HCl pH 7.5, 350 mM NaCl, 1% Tween-20) twice, WB3 
(20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Tween-20) twice, WB4 (20 mM Tris-HCl pH 
7.5, 150 mM NaCl, 0.1% v/v Tween-20) twice, and WB5 (20 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 0.02% v/v Tween-20) twice. Elution was done as described above. 
 
6.4 Bacterial Cell Colture 
For the experiments, two different bacterial E. coli cell lines were used: DH5α, to obtain 
DNA plasmids, and BL21 for protein’s purification. Cells were grown in Luria-Bertani 
broth (LB), composed by: tryptone 1% w/v, yeast extract 0.1% w/v, NaCl 0.1% w/v and 
then deionazed H2O to the final volume. For selection of positive clones, ampicillin 
(Sigma-Aldrich) was used between 50 and 100 μg/ml. 
 
6.4.1 Recombinant alpha-SNAP production  
Rat αSNAP cloned in pET28 plasmid in fusion with a His-tag was a kind gift of Dr. 
Reinhard Jahn (Max-Planck-Institute, Göttingen). αSNAP was subsequently expressed in 
E. Coli in BL21(DE3) strain. Bacteria were grown at 37°C to an OD at 600nm of 0.4-0.6, 
then induced with 0.25 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4 hours. 
Cells were then harvested by centrifugation and the pellet of 250 ml of culture was 
resuspended in 5-10 ml of Tris-HCl pH 8.0. Phenylmethylsulfonyl fluoride (PMSF) 100μM 
and a cocktail of protease inhibitors were added to the cells 1:100 (v/v) that were 
subsequently subjected to one French Press cycles (Constant Systems Ltd). The cell 
homogenate was centrifuged 30 minutes at 4°C and the supernatant loaded onto a Co2+ 
affinity column and eluted with a 0-500 mM linear gradient of imidazole at a flow rate of 
0.5 ml/min. Protein solution was dialyzed in Tris-HCl 20 mM pH 7.5, NaCl 150 mM. 
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6.4.2 Recombinant SNARE complex production  
Soluble SNARE complex was obtained by co-expression of wild type SNAP-25A, syntaxin-
1A and His-tagged VAMP2(1-96) using the Duet expression system (Novagen) in E. Coli in 
BL21(DE3) strain. VAMP2(1-96)-His6-TEV pACYC-Duet and syntaxin-1A/SNAP-25A pET-
Duet were a kind gift of Prof. A. Brunger (Stanford University, California) (Cipriano et al., 
2013). Bacteria were grown at 37°C to an OD at 600nm of 0.6-0.8, then induced with 0.5 
mM IPTG for 4 hours. Cell pellets of 250 ml of culture were suspended in 10 ml of 50 
mM Tris-HCl, pH 8.0, 300 mM NaCl, 20 mM imidazole and 0.5 mM Tris(2-
carboxyethyl)phosphine (TCEP) (SNARE buffer), supplemented with PMSF 100μM and 
protease inhibitors cocktail. Cell were lyses by two French Press cycles (Constant 
Systems Ltd) and the lysate was clarified by centrifugation for 1 hour at 15000g at 4°C. 
The supernatant was loaded onto a 1-ml Ni2+ affinity column, washed with 20 ml of 
SNARE buffer containing 7.5 M urea and then with 20 ml of SNARE buffer. The complex 
was then eluted with SNARE buffer containing 350 mM imidazole. After elution, SNARE 
complex was subjected to size exclusion chromatography using a Superdex 200 10/300 
(GE Healthcare) that was equilibrated with 50 mM Tris-HCl, pH 7.5, 100 mM NaCl. The 
SNARE complex was checked and quantified by SDS-PAGE. 
 
6.5 Sds-Page And Determination Of Protein Concentration  
The desired amount of each sample was denatured by adding Sample Buffer, Laemmli, 
to a final 1X concentration (obtained by diluting 4X stock solution: 200 mM Tris-HCl pH 
6.8, 8% w/v SDS, 400 mM DTT, 40% v/v glycerol and Bromophenol Blue to reach the 
desired colour intensity) and heated at 95°C for 10 minutes. Proteins were separated by 
Poly-Acrylamide Gel Electrophoresis (PAGE) in denaturing conditions, dependent on the 
presence of SDS. Gels were prepared with the opportune percentage of acrylamide 
(between 7.5 and 13%) according to the size of the proteins analyzed. For Flag-tagged 
NSF, NSF mutants and both LRRK2 wild type and G2019S, we used gels with 7.5% v/v 
acrylamide. For NSF N-terminal, D1 and D2 domains, Rab proteins, αSNAP and the 
SNARE complex with 13%. Protein were separated by electrophoresis in Tris-Glycine-SDS 
Running Buffer (25mM Tris Base, 250mM Glycine, 0.1% w/v SDS). The SHARPMASS™ V 
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PLUS Prestained Protein Ladder (EuroClone) was loaded in a separate lane of the gel to 
estimate the approximate molecular weight of proteins. After running, samples were 
stained in agitation with Coomassie Brilliant Blue (0.25% w/v Brilliant Blue R-250 Sigma-
Aldrich, 40% v/v ethanol, 10% v/v acetic acid and water) for 45 minutes and destained in 
agitation with a Destaining Solution (10% v/v isopropanol, 10% v/v acetic acid and 
water) that was replaced several times. Gels were finally kept in a 10% v/v acetic acid 
solution in agitation to remove all the background staining. Proteins were quantified by 
comparison with different known concentrations of BSA (Bovine Serum Albumin) loaded 
on the same gel each time and the quantification was done with ImageJ software. 
 
6.6 Western Blot Analysis 
After SDS-PAGE gel electrophoresis, protein samples were transferred on a 
polyvinylidene fluoride (PVDF) membrane (Bio-Rad), previously activated in methanol, 
through the Trans-Blot® Turbo™ Transfer System (Bio-Rad) in semi-dry conditions, with 
the 1X Trans-Blot® Turbo™ Transfer Buffer (obtained diluting 5X Trans-Blot® Turbo™ 
Transfer Buffer, 20% v/v ethanol and deionized water), at 25V for 20 minutes. PVDF 
blots were then soaked for 40 minutes in 5% w/v skimmed milk dissolved in TBST buffer 
(20mM Tris-HCl pH 7.4; 150 mM NaCl; 0.1% v/v Tween-20) in order to saturate non-
specific binding sites for proteins on the membranes. After, membranes were incubated 
with primary antibodies added to a 5% w/v skimmed milk dissolved in TBST solution for 
1 hour at room temperature or over-night at 4°C. Membranes were subsequently 
washed with TBST (4x10 minutes) to remove the excess of antibody not bind to proteins 
or bound in a non-specific manner. Membrane was then incubated for 1 hour at room 
temperature with Horseradish-Peroxidase (HRP)-conjugated secondary antibodies, 
diluted in 5% w/v skimmed milk in TBST. Incubation with secondary antibody was 
followed by washes in TBST (4x10 minutes). Primary and secondary antibodies were 
used at the following dilutions:  
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Antibody Dilution 
Anti-Flag® M2-Peroxidase (Sigma-Aldrich) 1:40000 
Mouse Anti-β-Tubulin (OriGene Technologies) 1:10000 
Rabbit Anti-NSF (Cell Signaling, Danvers, MA, USA) 1:2000 
Rabbit Anti-LRRK2 (C41-2, Abcam, Cambridge, UK) 1:1000 
Rabbit Anti-LRRK2 phospho-T2483 (MJF-R8, Abcam, Cambridge, UK) 1:2000 
Rabbit Anti-Mouse-Peroxidase (Sigma-Aldrich) 1:80000 
Goat Anti-Rabbit-Peroxidase (Sigma-Aldrich) 1:16000 
 
After washes, membranes were removed from TBST and incubated with Amersham™ 
ECL™ Western Blotting Detection Reagents (GE Healthcare) containing a substrate of 
HRP for Enhanced ChemiLuminescence (ECL). The visualization of the signal was 
detected employing the Amersham™ Hyperfilm ECL (GE Healthcare Waukesha, WI, USA), 
successively processed with developer and fixing solutions (Kodak® Developer and 
Replenisher and Kodak® Fixer and Replenisher, Sigma-Aldrich). Densitometric analysis 
was carried out using Image J software. 
 
6.7 Primary Neuronal Cultures 
Primary cortical neurons were obtained from E19 (embryonic days 19) mice with the 
Papain Dissociation System (Worthington Biochemical Corporation): brains were 
dissected from skull and olfactory bulbs, brainstems and meninges were removed. 
Cortices were then transferred to a separate dish containing cold Hank’s BalancedSalt 
Solution (HBSS, Sigma-Aldrich), cut into smaller pieces and large fragments of tissue 
were broken up by pipetting. Dissociated tissue was transferred into Papain solution 
(one bottle of Papain, containing 199 Units -Worthington- was dissolved in 5ml of Earle’s 
Balanced Salt Solution or EBSS, purchased from Sigma-Aldrich, and 250 μl of 0.1% w/v 
DNAse, Sigma-Aldrich, previously resuspended in 500 μl of EBSS, were added to this 
solution). The suspension was incubated for 40 minutes at 37°C and mixed by inversion 
every 10 minutes. After trituration, the mixture was centrifuged for 5 minutes at 1000 
rpm. The supernatant was discarded and cells were resuspended in 3 ml of STOP 
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solution (250 μl of DNAse solution, 600 μl of 15.5mg/ml Papain Inhibitor, Worthington, 
and 5.4 ml of EBSS) and incubated at room temperature for 10 minutes. This permits the 
largest fragments precipitate by gravity. Later, the supernatant was slowly pipetted into 
5 ml of 10/10 solution (0.1 g of Bovine Serum Albumin, BSA, and 0.1 g of Trypsin 
Inhibitor, both purchased from Sigma-Aldrich, in 10ml EBSS). After a 10 minutes spin at 
800 rpm, the cell pellet was finally resuspended in warm Neurobasal medium (Life 
Technologies) supplemented with 5% v/v FBS, 2% v/v of B27 supplement (Invitrogen), 
0.5 mM Glutamine (Life Technologies), penicillin and streptomycin and 2.5 μg/ml 
fungizone (Life Technologies). 1x106 cells/coverslip were pleated in 2 ml of medium on 
12 mm coverslip pre-treated with poly-D-lysine. After 10 days, neurons were washed 
with phosphate buffer saline (PBS) solution and fixed with paraformaldehyde (PFA) 4% 
for 30 minutes. PFA was removed and coverslip was washed three times with PBS. Cells 
were permeabilized using PBS with 0.1% Triton X-100 at room temperature and 
incubated in PBS with 5% fetal bovine serum (FBS) for 30 minutes both. Using the same 
buffer, neurons were then incubated with primary antibodies: a rabbit anti-NSF (1:100, 
D31C7Cell Signaling) and a mouse anti-LRRK2 (1:50, N231B/34 EMD Millipore (Davies P 
et al., 2013)) with overnight incubation. After three washes in PBS, cells were incubated 
with goat secondary antibodies linked to Alexa Fluor-488 and -568 (Life Technologies) at 
1:200 dilution for 1 hour at room temperature. Coverslips were washed three times with 
PBS and mounted on a microscope slide (Thermo Scientific) with Mowiol (Calbiochem) 
supplemented with 1 μg/μl Hoechst33258 stain (Life Technologies). Images were 
acquired with Zeiss LSM 700 confocal microscope. 
 
6.8 Pull-Down Assays 
To perform pull-down assays, NSF domains and full length NSF were purified after 
transient transfection from HEK293T cells. Cells were harvested in 500 µl of Lysis buffer 
(50 mM Tris-HCl pH 7.5, 1 mM EDTA, 2.5 mM Na4P2O7, 1 mM beta-glycerophosphate, 1 
mM Na3VO4, 0.27 M Sucrose, 1% Triton X-100, Protease Inhibitor Mixture (Sigma-
Aldrich, St. Louis, MO, USA)). The cell lysate was then centrifuged at 18000xg for 30 
minutes at 4°C and further incubated overnight with 20 µl of Anti-Flag M2 Affinity gel 
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(Sigma-Aldrich, St. Louis, MO, USA) at 4°C. After centrifugation, the supernatant was 
discarded and the beads with NSF proteins were washed 3 times with 1 ml of a Washing 
buffer (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.27 M Sucrose, 250 mM NaCl, 0.02% Triton 
X-100) and resuspended in 100 µl of the same buffer. An aliquot of suspension was 
collected and proteins were loaded on an SDS-PAGE gel. Concentration were quantified 
measuring the intensity of the band against known BSA standards with ImageJ software. 
Proteins were subsequently adjusted to the same concentration (2 µM). During the 
incubation time, we lysed the adult mouse brain with 5 ml of the same Lysis buffer. We 
quantified the protein content with BCA assay. After overnight incubation at 4°C 
between brain lysate (600 µl, ∼3 mg/ml concentrated) and resins, we removed the 
supernatant and wash the resin with 1 ml of Washing buffer used above. Resins were 
then boiled with sample buffer, loaded into a Mini-PROTEAN® TGX™ Precast Gels (Bio-
Rad), run in Tris-Glycine-SDS running buffer and transferred onto PVDF membranes. 
Specific antibodies were used to detect the presence of the proteins. 
 
6.9 Size Exclusion Chromatography (SEC) And Dot Blot Analysis 
Flag-NSF was transfected into HEK293T cells, as described before, in a 100 mm Petri dish 
for 48h. Cells were resuspended in 500 µl of lysis buffer containing 1 % (v/v) Tween-20 
and different ATP concentrations: 0, 0.09 and 1 mM were used. Cell lysates were 
centrifuged at 100000 g and supernatants were separated on a Superdex 200 column 
(Ge Healthcare, Waukesha, WI, USA) pre-equilibrated with TBS buffer supplemented 
with 1% v/v Tween-20. The flow rate used was 0.5 ml/min. Fractions of 0.5 ml were 
collected and spotted (1 µl) onto a nitrocellulose membrane and analysed by dot blot. 
The membrane was blocked with 10% w/v skimmed milk in TBST (composition described 
in Western blot analysis section) and incubated with mouse monoclonal anti-Flag M2-
peroxidase (Sigma-Aldrich, St. Louis, MO, USA) dissolved in TBST with 10% milk. 
Immunoproteins were visualized using ECL (GE, Healthcare, Waukesha, WI, USA). 
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6.10 Transmission Electron Microscopy (TEM) 
Purified flag-tagged NSF and its mutants proteins, at a concentration of 235 nM, were 
incubated with 1 mM ATP and 4 mM MgCl2.  A total of 0.5 ng of protein was adsorbed 
few minutes to a glow-discharged carbon-coated copper grid, washed with deionized 
water, and stained with 1% uranyl acetate. Images were collected using a Fei Tecnai T12 
electron microscope equipped with a LaB6 filament and operated at an acceleration 
voltage of 100 kV. 
 
6.11 In Vitro Kinase Assay 
Purified NSF and all its domains were eluted in kinase assay buffer (0.007% v/v Tween-
20). They were incubated with LRRK2 G2019S protein dissolved in the same buffer for 1 
hour at 30 °C in the presence of 33P-ATP (1 µCi) and 2.5 µM cold ATP. After SDS-PAGE, 
proteins were transferred on PVDF membrane and the incorporated 33P-ATP was 
detected by autoradiography by Phospho-Imager system (Cyclone, Perkin-Elmer). The 
same membranes were probed with anti-Flag antibody for total protein loading and 
analysed using ImageJ software.  
 
6.12 ATPase Enzymatic Assay  
We employ Malachite Green enzyme assay to measure NSF ATPase activity. The amount 
of inorganic phosphate was quantified at a fixed time-point measuring the absorbance 
at 640 nm, through spectrophotometer. The assay was adapted from the method of 
Lanzetta et al., 1979. The Malachite Green Stock solution used for the assay was a 
mixture of two different solutions (one with 34 mg Malachite Green oxalate salt (Sigma-
Aldrich. St. Louis, MO, USA) into 40 ml HCl 1M and the other with 1 g (NH4)2MoO4 
(Sigma-Aldrich, St. Louis, MO, USA) into 14 ml HCl 4M to a final volume of 100 ml with 
distilled water and then filtered through 0,45 nm. The concentration of human NSF used 
for the ATPase assay was 36 nM (hexamer) with different ATP concentration. Reactions 
were performed at 37°C and followed for 120 minutes. The time point aliquots collected 
(20 µl) were mixed with 150 µl of Malachite Green stock solution until the solution 
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became homogenous. Absorbance was measured at a wavelength of 640 nm using a 
corresponding Malachite Green solution as blank. Next, values were converted into 
µmol of free Pi in solution using a standard curve. The reported values for the kinetic 
constants (Km, kcat and Vmax) were obtained by data fitting using the Michaelis-Menten 
kinetic model (Y = Vmax*S/(Km + [S])).  
 
6.13 Reverse Phase Hplc (RP-HPLC) ATPase Assay 
To determine the ATPase activity of NSF through RP-HPLC, ATP (500 or 700 µM) was 
added to 0.2 µM 3xFlag-NSF wt. Proteins were purified as previously described and 
incubated at 37°C in kinase buffer (composition described above). At the reported time-
points, aliquots (20 µl) were collected up to final reaction time of 120 minutes. The 
samples were then heated for 3 minutes at 95°C with 0.1 M of EDTA to stop the reaction 
and then stored at -80°C. RP-HPLC was used to monitor the total amount of ATP and 
ADP present in any given sample. Nucleotides were separated on a Jupiter 5u C4 300A 
(Phenomenex) column using an Agilent HP 1100 HPLC, pre-equilibrated with 50 mM 
NaH2PO4 pH 6.5, 10 mM Tetra-n-butylammonium bromide and 4% ACN. The flow-rate 
used was 0.5 ml/min and the amount of the nucleotide was evaluated by measuring the 
area of the peak at 256 nm. To convert this value to the Pi generated by the reaction, a 
standard curve (in the ADP concentration range from … to …) was used. ADP 
concentrations detected in the assay were plotted as a function of time and interpolated 
with a linear regression using GraphPad Prism 5. 
 
6.14 Flag-NSF HEK293 Stable Overexpressing Cell Line 
HEK293 cells were plated on a 150 mm Petri dish. Transfection was performed with 40 
µg DNA with ratio DNA:PEI 1:2, as described above. Therefore, cells were selected by 
culturing them in medium supplemented with the antibiotic geneticin (G418). After 24 
hours, single clones of cells found positive to transfection, as reveled by the acquired 
resistance against G418, were transposed into 96-wells plate, 48-wells plate, 24-wells 
plate and 6-wells plate subsequently. Finally, positive clones able to growth through all 
 63 
 
Chapter II Materials and Methods 
selective steps, were moved to T-75 flask. To confirm that Flag-NSF was stably 
expressed, cell lysates were analyzed by Western blot analysis and immunofluorescence 
with anti-Flag antibody, as described in paragraph 6.5 and 6.13. 
 
6.15 Immunofluorescence 
HEK293 cells stably expressing NSF were plated on 12 mm glass coverslips pre-treated 
with poly-D-lysine. Next, cells were washed with PBS solution and fixed for 30 min at 
room temperature (RT) with 4% paraformaldehyde (PFA). PFA was removed and 
coverslips were washed three times with PBS. Cells were permeabilized with 0.1% Triton 
X-100 in PBS for 30 min at RT and incubated in blocking solution (5% FBS in PBS) for 30 
min. The cells were incubated for 1 hour at RT with a mouse anti-Flag M2 primary 
antibody (1:200, Sigma Aldrich). After three washes in PBS, cells were incubated with 
goat secondary antibodies linked to Alexa Fluor-568 (Life Technologies) at 1:200 dilution 
for 1 hour at room temperature. Coverslips were washed three times with PBS and 
mounted on a microscope slide (Thermoscientific) with Mowiol (Calbiochem) 
supplemented with 1 μg/μl Hoechst33258 stain (Life Technologies). Images were 
acquired with Leica 5000B microscope. 
 
6.16 SNARE Disassembly Assay  
The SNARE disassembly protocol used followed a method previously described (Cipriano 
et al., 2013). The assay buffer used was the Kinase buffer (composition described 
above). Subsequently 1.5 µM αSNAP, 480 nM SNAREs, 24 nM NSF (hexamer 
concentration) phosphorylated or not by LRRK2 G2019S (ratio NSF:LRRK2 20:1, 1 hour at 
30°C) were added in presence of 2 mM ATP to start the reaction (final assay volume 240 
µl). At defined time points, an aliquot (20 µl) was collected and loaded on SDS-PAGE gel 
without boiling the samples to preserve the SDS-resistant SNARE complex. The complex 
runs as a single band on SDS-PAGE and the intensity of the band was measured and 
normalized to the value at time zero. The experiments were performed in triplicate up 
to a reaction time of 150 minutes. 
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6.17 Circular Dichroism (Cd) 
CD measurements were carried out on a JASCO J-810 spectropolarimeter. The CD 
spectra were acquired and processed using the J-700 software for Windows. All 
experiments were done at room temperature using an optical path length of 0.2 cm. The 
wavelength range of the measurements was 197–250 nm, using a bandwidth of 2 nm 
and a time constant of 8 s at a scan speed of 50 nm/min. The signal to noise ratio was 
improved by accumulating four scans for each sample. Spectra were acquired using 
purified proteins in 20 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.007% Tween®20 (as 
collected from the last purification step) using the same buffer with 3xFlag peptide as a 
control. All the spectra are reported in terms of mean residue molar ellipticity (deg cm2 
dmol−1). Protein concentrations in the samples were determined by SDS-PAGE and all 
the spectra were normalized for the measured protein concentration. 
 
6.18 Intrinsic Fluorescence Measurements 
The protein concentration of the sample used in the fluorescence experiment inside the 
sample was 0.9 µM in 20 mM Tris/HCl buffer (pH 7.5) with 150 mM NaCl buffer. 
Fluorescence emission spectra were recorded on a Cary Eclipse fluorescence 
spectrophotometer (Varian, Agilent Technologies, Santa Clara, CA) using the Cary Eclipse 
program. Sample measurements were carried out using optical path length of 10 mm. 
Fluorescence spectra were obtained using an excitation wavelength of 295 nm (Em = 
330 nm), with an excitation bandwidth of 5 nm and slit width of 10 nm. Emission spectra 
were recorded between 300-400 nm at a scan rate of 30 nm/sec.
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7. LRRK2 phosphorylates NSF 
enhancing its ATPase activity and 
SNARE complex disassembly rate 
7.1 LRRK2 Kinase Activity Influences Synaptic Vesicle Dynamics 
As described in the introduction, LRRK2 is widely expressed in several cell types, but the 
majority of the studies focused on neurons, since mutations in Lrrk2 gene are linked to 
both familial and sporadic forms of PD (Singleton et al., 2013). It has been previously 
demonstrated that LRRK2 inhibition impacts the presynaptic site leading to impaired SV 
trafficking and neurotransmitter release (Cirnaru et al., 2014). These findings suggest a 
possible role of LRRK2 catalytic activity in SV fusion cycle. In collaboration with Dr 
Giovanni Piccoli (University of Trento), we asked whether altered LRRK2 kinase activity 
leads to defects in SV dynamics (Belluzzi, Gonnelli et al., 2016; Appendix). To this aim, we 
used the sypHy (Synaptophysin-pHluorin) assay. This method of analysis is useful to 
monitor the behavior of SV cycle and it is based on a sensitive pH-fluorescent reporter.  
The reported is quenched in presence of an acid environment (vesicle lumen), but 
becomes fluorescent upon vesicle fusion, since it is exposed to a more basic pH 
(Granseth et al., 2006). We investigated the role of LRRK2 kinase activity in neurons in 
two complementary models using 1) primary cortical culture in presence or absence of a 
specific LRRK2 inhibitor (GSK2578215A), as a negative control, and 2) primary cortical 
neurons from BAC hG2019S transgenic mice, previously demonstrated to have LRRK2 
G2019S overexpression and an increased LRRK2 kinase activity (Melrose et al., 2010). 
First, we confirmed that GSK2578215A was efficient at inhibiting LRRK2 kinase activity in 
our paradigm by Western blot analysis using an antibody against phosphor-Ser935, a 
well-known LRRK2 constitutively phosphorylated residue used as readout of LRRK2 
kinase activity (Dzamko et al., 2010). Of interest, GSK2578215A did not provoke 
alterations in LRRK2 stability as showed in Appendix Fig.S1 a and b. To monitor the 
impact of LRRK2 inhibition or pathological mutation on SV trafficking, we used two 
different stimuli: 1) 40 AP (action potential) to mobilize SV of the ready releasable pool 
(RRP) and 2) 300 AP to mobilize the reserve pool. After the application of the stimulus, 
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we measured the time to return to the baseline and the decay in sypHy fluorescence 
corresponding to the exo- and endocytosis efficiency. Our results (Appendix, Fig.1) 
showed that the presence of GSK2578215A  increased value of tau for both upstroke 
and decay, suggesting an impaired exo-endocytosis. In contrast, BAC hG2019S neurons 
exhibited a faster kinetic (decreased  decay) at both two stimuli (ΔF40/F0 and 
ΔF300/F0) as show in Appendix, Fig.1 C. To better clarify the impact of LRRK2 G2019S 
pathological mutation and its role in synaptic vesicle dynamics we used a 
complementary approach. BAC hG2019S neurons were transduced at DIV4 (days in 
vitro) with viruses expressing GFP to track neuronal processes and assessed at DIV14., 
Briefly, cell medium was supplemented with antibodies directed against the 
intravesicular domain of synaptotagmin 1, which is internalized when vesicle fusion 
occurs. Afterwards, cells were fixed with PFA and exposed to an antibody against 
synaptophysin, used as counterstaining. A positive signal for both antibodies means that 
vesicle undergo to a correct exo-endocytic cycle. As shown in Appendix Fig.1 e, BAC 
hG2019S neurons are characterized by an increased number of positive clusters. 
However, the total number of SV pools was not altered in BAC hG2019S neurons 
(Appendix Fig. S1 d). Taken together, these results indicate that LRRK2 kinase activity 
plays a key role in SV dynamics and regulates SV fusion. 
 
7.2 Expression And Purification Of Recombinant Human Flag-
Tagged NSF 
Given the observed effects of LRRK2 kinase activity on synaptic vesicle trafficking, we 
decided to explore potential LRRK2 presynaptic substrates. A number of putative 
presynaptic proteins have been previously identified to be able to interact with LRRK2 
(Piccoli et al., 2014). We chose to explore the relationship between LRRK2 and NSF, an 
AAA+ ATPase, since LRRK2 kinase activity appears involved in the control of a step of the 
exo-endocytosis (paragraph 7.1) and NSF plays a pivotal role in SNARE complex 
disassembly and, hence, SV endocytosis (Zhao and Brunger, 2015). Moreover, NSF 
activity is tightly controlled by phosphorylation (Liu et al., 2006; Matveeva et al., 2001) 
and the ATPase has been found to accumulate in neuronal intranuclear inclusion bodies, 
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similar to Lewy Bodies, a pathological hallmark of PD (Pountney et al., 2008). Thus, to 
assess whether NSF is a LRRK2 substrate we first set out to find the optimal conditions to 
purify human recombinant NSF. 
As reported in the introduction, NSF belongs to the AAA+ (ATPases Associated with 
various cellular Activities) superfamily of proteins and it is responsible of the SNARE 
complex disassembly during vesicle recycling. Until now structural studies have been 
focused on recombinant Chinese Hamster (Cricetulus Griseus) NSF purified from E. coli 
(Chang et al., 2012; Zhao et al., 2015), whilst no studies are available on human NSF. Our 
aim was to first purify human NSF from mammalian HEK293T cells and then characterize 
it biochemically. Although the sequence alignment of C. Griseus and Human NSF reveals 
an identity of 98% between the two proteins (Fig.7.2.1), we reasoned that expressing 
and purifying recombinant NSF from mammalian cells would be important in terms of 
post-translational modifications that E. coli cannot provide. 
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Hum_NSF   1  MAGRSMQAARCPTDELSLTNCAVVNEKDFQSGQHVIVRTSPNHRYTFTLKTHPSVVPGSI  60 
             MAGRSMQAARCPTDELSL+NCAVV+EKD+QSGQHVIVRTSPNH+Y FTL+THPSVVPGS+ 
CrG_NSF   1  MAGRSMQAARCPTDELSLSNCAVVSEKDYQSGQHVIVRTSPNHKYIFTLRTHPSVVPGSV  60 
 
Hum_NSF  61  AFSLPQRKWAGLSIGQEIEVSLYTFDKAKQCIGTMTIEIDFLQKKSIDSNPYDTDKMAAE  120 
             AFSLPQRKWAGLSIGQEIEV+LY+FDKAKQCIGTMTIEIDFLQKK+IDSNPYDTDKMAAE 
CrG_NSF  61  AFSLPQRKWAGLSIGQEIEVALYSFDKAKQCIGTMTIEIDFLQKKNIDSNPYDTDKMAAE  120 
 
Hum_NSF 121  FIQQFNNQAFSVGQQLVFSFNEKLFGLLVKDIEAMDPSILKGEPATGKRQKIEVGLVVGN  180 
             FIQQFNNQAFSVGQQLVFSFN+KLFGLLVKDIEAMDPSILKGEPA+GKRQKIEVGLVVGN 
CrG_NSF 121  FIQQFNNQAFSVGQQLVFSFNDKLFGLLVKDIEAMDPSILKGEPASGKRQKIEVGLVVGN  180 
 
Hum_NSF 181  SQVAFEKAENSSLNLIGKAKTKENRQSIINPDWNFEKMGIGGLDKEFSDIFRRAFASRVF  240 
             SQVAFEKAENSSLNLIGKAKTKENRQSIINPDWNFEKMGIGGLDKEFSDIFRRAFASRVF 
CrG_NSF 181  SQVAFEKAENSSLNLIGKAKTKENRQSIINPDWNFEKMGIGGLDKEFSDIFRRAFASRVF  240 
 
Hum_NSF 241  PPEIVEQMGCKHVKGILLYGPPGCGKTLLARQIGKMLNAREPKVVNGPEILNKYVGESEA  300 
             PPEIVEQMGCKHVKGILLYGPPGCGKTLLARQIGKMLNAREPKVVNGPEILNKYVGESEA 
CrG_NSF 241  PPEIVEQMGCKHVKGILLYGPPGCGKTLLARQIGKMLNAREPKVVNGPEILNKYVGESEA  300 
 
Hum_NSF 301  NIRKLFADAEEEQRRLGANSGLHIIIFDEIDAICKQRGSMAGSTGVHDTVVNQLLSKIDG  360 
             NIRKLFADAEEEQRRLGANSGLHIIIFDEIDAICKQRGSMAGSTGVHDTVVNQLLSKIDG 
CrG_NSF 301  NIRKLFADAEEEQRRLGANSGLHIIIFDEIDAICKQRGSMAGSTGVHDTVVNQLLSKIDG  360 
 
Hum_NSF 361  VEQLNNILVIGMTNRPDLIDEALLRPGRLEVKMEIGLPDEKGRLQILHIHTARMRGHQLL  420 
             VEQLNNILVIGMTNRPDLIDEALLRPGRLEVKMEIGLPDEKGRLQILHIHTARMRGHQLL 
CrG_NSF 361  VEQLNNILVIGMTNRPDLIDEALLRPGRLEVKMEIGLPDEKGRLQILHIHTARMRGHQLL  420 
 
Hum_NSF 421  SADVDIKELAVETKNFSGAELEGLVRAAQSTAMNRHIKASTKVEVDMEKAESLQVTRGDF  480 
             SADVDIKELAVETKNFSGAELEGLVRAAQSTAMNRHIKASTKVEVDMEKAESLQVTRGDF 
CrG_NSF 421  SADVDIKELAVETKNFSGAELEGLVRAAQSTAMNRHIKASTKVEVDMEKAESLQVTRGDF  480 
 
Hum_NSF 481  LASLENDIKPAFGTNQEDYASYIMNGIIKWGDPVTRVLDDGELLVQQTKNSDRTPLVSVL  540 
             LASLENDIKPAFGTNQEDYASYIMNGIIKWGDPVTRVLDDGELLVQQTKNSDRTPLVSVL 
CrG_NSF 481  LASLENDIKPAFGTNQEDYASYIMNGIIKWGDPVTRVLDDGELLVQQTKNSDRTPLVSVL  540 
 
Hum_NSF 541  LEGPPHSGKTALAAKIAEESNFPFIKICSPDKMIGFSETAKCQAMKKIFDDAYKSQLSCV  600 
             LEGPPHSGKTALAAKIAEESNFPFIKICSPDKMIGFSETAKCQAMKKIFDDAYKSQLSCV 
CrG_NSF 541  LEGPPHSGKTALAAKIAEESNFPFIKICSPDKMIGFSETAKCQAMKKIFDDAYKSQLSCV  600 
 
Hum_NSF 601  VVDDIERLLDYVPIGPRFSNLVLQALLVLLKKAPPQGRKLLIIGTTSRKDVLQEMEMLNA  660 
             VVDDIERLLDYVPIGPRFSNLVLQALLVLLKKAPPQGRKLLIIGTTSRKDVLQEMEMLNA 
CrG_NSF 601  VVDDIERLLDYVPIGPRFSNLVLQALLVLLKKAPPQGRKLLIIGTTSRKDVLQEMEMLNA  660 
 
Hum_NSF 661  FSTTIHVPNIATGEQLLEALELLGNFKDKERTTIAQQVKGKKVWIGIKKLLMLIEMSLQM  720 
             FSTTIHVPNIATGEQLLEALELLGNFKDKERTTIAQQVKGKKVWIGIKKLLMLIEMSLQM 
CrG_NSF 661  FSTTIHVPNIATGEQLLEALELLGNFKDKERTTIAQQVKGKKVWIGIKKLLMLIEMSLQM  720 
 
Hum_NSF 721  DPEYRVRKFLALLREEGASPLDFD  744 
             DPEYRVRKFLALLREEGASPLDFD 
CrG_NSF 721  DPEYRVRKFLALLREEGASPLDFD  744 
Fig.7.2.1 | Protein blast alignment: The result of full-length sequence alignment between 
Human NSF (Hum_NSF) and Cricetulus Griseus NSF (CrG_NSF) displays an identity on 732/744 
residues (98%) among the three different domain (N-terminal 1-205, yellow; D1 206-487, red; D2 
488-744, green). 
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We first validated recombinant human Flag-tagged NSF full-length, purified according to 
the procedures described in materials and methods. The flag tag is a short amino-acid 
peptide (DYKDDDDK), fused to human NSF at the N-terminal, widely used in a variety of 
cell types, including bacteria, yeast and mammalian cells. Furthermore, flag-tagged 
proteins have the advantage that can be purified by immunoprecipitation from the cell 
lysate using beads conjugated with antibodies and then eluted from the resin by 
competition with an excess of Flag peptides. Starting from 20x106 cells, we obtained 
about 60 µg of highly pure monomeric human NSF at a concentration of 0.3 mg/ml 
(Fig.7.2.2 A). Since SDS-PAGE gel electrophoresis allows to detect only denatured NSF 
due to the presence of both sodium dodecyl sulfate (SDS) and dithiotreitol (DTT), we 
subsequently monitored the ability of purified proteins to assemble into hexamers. A 
common feature of all the AAA+ proteins is the Walker A motif, whose function is 
necessary for ATP binding and conformational changes (Hanson and Whiteheart, 2005). 
For this reason, to assess the capability of NSF to undergo from monomeric to 
homoexameric structure, we incubated the purified protein with 1 mM ATP and 4 mM 
MgCl2. Based on the Cryo-EM structure of Chinese Hamster NSF recently published 
(Chang et al., 2012 e mechanicistic), we monitored the presence of hexamers in solution 
by Transmission Electron Microscopy (TEM). As shown in Fig.7.2.2 B, the presence of a 
structural transition into oligomeric state denotes the solubility of the protein and 
confirms that human flag-tagged NSF is able to form hexamers in the presence of ATP. 
 
 
 
 
 72 
 
Chapter III Results 
 
Fig.7.2.2 | Purification of recombinant human flag-NSF: (A) Purified human NSF separated on 
SDS-PAGE and quantified by comparison with different concentration of BSA (Bovine Serum 
Albumin); (B) (A) Purified human NSF separated on SDS-PAGE and quantified by comparison with 
different concentration of BSA (Bovine Serum Albumin); (B) Representative TEM micrograph of 
purified NSF with 1 mM ATP and 4 mM MgCl2 reveals the presence of hexamers as highlighted in 
the large onset. (scale bar 50 nm). 
 
In addition, we exploited size exclusion chromatography (SEC) to further monitor the 
ability of flag-tagged NSF to oligomerize upon ATP addition. To this aim, different 
amounts of ATP were added to the cell lysates and NSF-containing lysates were 
subsequently loaded into a Superdex200 gel filtration column (Fig.7.2.3).  The elution 
profile of NSF was then monitored by a dot blot analysis collecting all the 
chromatographic fractions. As shown in Fig.7.2.3, the addition of the nucleotide causes a 
shift in the position of NSF elution peak toward shorter retention times, suggesting an 
increased hydrodynamic radius of the protein in presence of ATP. Moreover, the entity 
of the shift of the NSF chromatographic peak is different as a function the ATP 
concentration. The presence of an intermediate peak at 90 µM of ATP between 0 and 1 
mM suggests that NSF may assemble into intermediate species before acquiring its 
hexameric conformation. Supporting this finding, early studies indicate that NSF can 
form trimers and that the two ATP binding sites (D1 and D2) possess different affinities 
for the nucleotide (Whiteheart et al., 1994; Matveeva et al., 1997).  
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Fig.7.2.3 | SEC profile of cell lysates overexpressing flag-NSF adding different ATP 
concentration: Size exclusion chromatography fractions of HEK293T expressing flagged-NSF 
spotted onto nitrocellulose membrane and probed with anti-flag antibody; SEC profile of cell 
lysates adding different ATP concentrations in the Lysis buffer. 
 
Interestingly, Flag-NSF purified with M2-Flag agarose beads binds endogenous NSF, as 
indicated by the presence of an extra band with an approximate molecular weight of the 
endogenous protein (82 kDa) and that is recognized by an antibody against NSF but not 
by the anti-flag antibody (Fig.7.2.4). 
 
 
Fig.7.2.4 | Co-purification of endogenous NSF: western-blot analysis to validate the presence of 
endogenous NSF co-purification with recombinant human NSF using anti-flag and anti-NSF 
antibodies. 
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Taken together, these experiments support the notion that recombinant human flag-
NSF purified from HEK293T cells is soluble and correctly folded. 
 
7.3 Catalytic Properties Of Recombinant Human Flag-NSF 
Having established that recombinant human NSF purified is correctly folded and able to 
form its functional hexameric structure, the next step was to evaluate NSF ATPase 
activity. We set up two complementary assays to monitor the catalytic activity of NSF: 1) 
a Malachite Green Enzyme assay and 2) an isocratic reversed-phase HPLC (RP-HPLC)-
based assay. The latter, provides a direct measurements of ATP to ADP conversion by 
monitoring the areas of the peaks corresponding to the two nucleotides.  The Malachite 
Green is a colorimetric assay that measures the inorganic phosphate (Pi) free in solution, 
released from ATP during the reaction (Lanzetta et al., 1979). Thus, it is an indirect 
measurement influenced by several aspects, such as Pi already present in the reaction 
buffer and/or produced by other sources (i.e. contaminating GTPases/ATPases). 
However, this assay has the advantage of being faster and scalable, since it measures 
the absorbance (at a wavelength of 640 nm) of the reaction at a given time (Fig.7.3.1). 
 
 
Fig.7.3.1 | Pi free in solution measured with Malachite Green assay: Schematic 
representation of the Malachite Green enzyme assay, on top, and the concentration of Pi free in 
solution as a function of time ([ATP] = 0.5 mM). Aliquots were collected as a function of time and 
subtracted by a control purification of untransfected cells. Velocities of the reactions (slopes) 
were calculated by linear regression using GraphPad Prism 5 software. 
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To validate the Malachite Green assay, we performed it in parallel with the HPLC-based 
assay, which provides a direct measurement of the ATP consumption and concomitant 
ADP formation, but has the limitation of requiring long running times and it cannot be 
implemented in a high-throughput fashion. For the Malachite Green assay, we collected 
aliquots of the reaction at different time points and evaluated the Pi formation by 
measuring the absorbance at 640 nm, as show in Fig.7.3.1. For the RP-HPLC assay, we 
detected the variation of ATP and ADP over time by injecting aliquots of the reaction 
collected at different time points (Fig.7.3.2). Both assays confirmed that human flag-tag 
NSF purified from mammalian cells is an active ATPase: as shown in Fig.7.3.2 B and 7.3.1, 
the amount of ADP and the concentration of Pi in solution increased as a function of the 
reaction time. 
 
 
Fig.7.3.2 | Isocratic RP-HPLC assay: (A) Reaction profile of the two different nucleotide peaks 
over time ([ATP] = 0.7 mM). The ATPase activity of NSF was evaluated measuring the area under 
the peak of ADP (B). Aliquots were collected as a function of time and subtracted a control 
purification of untransfected cells. Velocities of the reactions (slopes) were calculated by linear 
regression using GraphPad Prism 5 software. 
 
We then identified the best purification conditions to maximize the ATPase activity of 
NSF in vitro. Specifically, we tested if the presence Tween-20 has a negative effect on 
NSF catalytic activity. For this reason, we purified NSF in parallel with i) lysis buffer 
containing 1% of detergent, a purification protocol routinely used to purify LRRK2, and ii) 
with repeated freeze/thaw cycles. This new tested protocol was used because it is a 
gentle process of lysing cells and it can help maintaining the protein folding. After having 
validated, with a BCA assay, that 5 cycles are enough to disrupt plasma membranes, we 
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found that the ability of NSF to hydrolyze ATP is higher when purification is carried out 
using the freeze/thaw procedure. As shown in Fig.7.3.3 A, the rate of the reaction is 
higher and this suggest that the presence of the detergent may affect the correct 
protein folding which results in a lower rate of ATP to ADP hydrolysis as highlighted in 
Fig.7.3.3 B. 
 
 
Fig.7.3.3 | Impact of Tween-20 on NSF ATPase activity: (A) Concentration of Pi free in solution 
with different amount of the substrate reveal that the rate of the reaction decrease in presence 
of the detergent, as highlight in (B) fitting slopes with Michaelis-Menten equation (NSF+Tween-
20 Vmax=1.24 µmol/min; NSF Vmax=2.32 µmol/min). 
 
Based on these observations, all the subsequent NSF purifications were carried out using 
a freeze/thaw protocol and the ATPase activity of NSF was measured using the 
Malachite Green assay. 
Next, we determined the KM of NSF using the Malachite Green enzyme assay. The KM 
represents the concentration of substrate required to reach half of the reaction 
maximum velocity (Vmax) and provides an indication of the affinity of the substrate for 
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the enzyme. We monitored this value by comparing proteins at different days post-
purification at 4°C. We found that the value of the Km did not change, however the 
Vmax substantially decreased (Fig.7.3.4 B). This phenomenon suggests that a fraction of 
the protein progressively becomes inactive, but the fraction of active NSF has unaltered 
affinity for the substrate (Fig.7.3.4 A). Collecting all the data obtained from independent 
experiments with different amount of ATP, we showed that human NSF possesses a Km 
of 180±10 μM. 
 
 
Fig.7.3.4 | Km of recombinant flag-NSF: The values of Km (A) and Vmax (B) calculated for NSF on 
different days after purification, keeping the protein at 4°C. Km value was equal to 180±10 µM 
and did not change in function of days, suggesting that this corresponds to its affinity for the 
substrate. 
 
Taken together, these observations indicate that recombinant human Flag-NSF full 
length purified from mammalian HEK293T cells is an active ATPase. 
 
7.4 Generation Of Stable Cell Line Expressing Human Flag-NSF 
To optimize the purification procedure, we attempted to bypass transient transfection – 
which requires large amounts of transfection reagents - by generating HEK293T cell lines 
stably expressing human NSF. To this end, we took advantage of the presence within the 
NSF-coding plasmid of the Neomycin gene, which confers resistance to the antibiotic 
geneticin. After transfection, resistant cells were selected by culturing them in the 
selective medium containing geneticin (G418). We isolated three clones and tested them 
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for NSF expression. As indicated by western blot analysis in Fig.7.4.1 A, only one clone 
expressed Flag-NSF. Moreover, immunofluorescence analysis with confocal microscopy 
revealed that 100% of cells overexpressed Flag-NSF, indicating that the selection worked 
(Fig.7.4.1 B). We next compared the amount of the protein that we were able to purify 
from HEK cells either transiently transfected or stably expressing NSF. 
 
 
Fig.7.4.1 | NSF stable cell line: (A) Western-blot analysis on lysates from different clones of 
HEK293 cell line reveal the presence of flagged NSF stably expressed, on top, and its ability to 
interact with endogenous NSF. (B) Immunofluorescence microscopy. Red staining against Flag-
tag show that human Flagged-NSF was ubiquity expressed in stably transfected HEK293 cells. 
 
While we could purify NSF stably expressed in HEK293 cells, the total amount of protein 
recovered was about 75% lower compared to that obtained from cells transiently 
transfected (Fig.7.4.2). This result highlights that although these cells maybe useful to 
perform some cellular and biochemical evaluations, transient NSF expression is required 
to obtain a purification yield suitable for using the protein in enzymatic assays. 
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Fig.7.4.2 | Purification of flag-NSF from HEK293 cells: Comparison of purified human NSF 
derived from both transient transfection using HEK293T cells and stable HEK293 cells. Proteins 
were separated on SDS-PAGE and quantified by comparison with different concentration of BSA 
(Relative beads, named with “-r”, were loaded as a control of correct elution on the gel). 
 
 
7.5 LRRK2 Interacts With NSF In Vitro 
Previous studies reported that LRRK2 can interact with proteins at the presynaptic site, 
modulating endosome maturation, microtubules formation and SNARE complex 
assembly with consequences on neurotransmitter release and vesicle recycling (Matta et 
al., 2012; Yun et al., 2013; Cho et al., 2014; Yun et al., 2015). A presynaptic protein that 
was demonstrated to interact with the WD40 domain of LRRK2 is NSF (Piccoli et al., 
2011). Here, the aim was to confirm the interaction between these two proteins at the 
endogenous level and to map the domains involved in this interaction. In collaboration 
with Drs. Antonella Marte and Franco Onofri (University of Genova), we found that 
LRRK2 binds NSF in purified synaptosomes (Belluzzi, Gonnelli et al., 2016; Appendix Fig.2 
a). 
Next, we evaluated the interaction between LRRK2 and NSF in primary neurons using an 
antibody against LRRK2 already validated in the literature in hippocampal neurons 
(N231B/34; Davies et al., 2013). As show in Fig.7.5.1, LRRK2 and NSF largely co-localize, 
and co-localization is enriched within clusters along neurites. 
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Fig.7.5.1 | LRRK2 interacts with NSF: Immunofluorescence of primary cortical neurons stained 
for endogenous LRRK2 (green) and endogenous NSF (red) (scale bar is 10 μm). 
 
Next, we asked which domain(s) of NSF is responsible for the interaction. To this aim, we 
performed pulldown assays in presence of flag-tagged NSF full-length and all its three 
domains (N-ter 1-205, D1 206-487 and D2 488-744) also cloned with an N-terminal Flag-
tag. Proteins were purified from HEK293T cells with Flag-conjugate beads and incubated 
at equimolar concentrations with a mouse brain lysate. As expected, full-length NSF 
pulls-down endogenous LRRK2, confirming the interaction. Moreover, we found that 
LRRK2 co-precipitates in presence of N-terminal and D2 domain, but not with the D1 
domain (Fig.7.5.2). These data indicate that LRRK2 binds NSF at N-terminal and D2 
domains. 
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Fig.7.5.2 | LRRK2 pull-down assays: (A) Human flag-tagged NSF full-length or its domains 
purified from HEK293T and bound to M2 flag resin were incubated with a mouse brain lysate. (B) 
Pull-down reveals the interaction between LRRK2 and N and D2 domains (n=2). (C) Schematic 
representation of NSF full-length and the three different domains. 
 
 
7.6 LRRK2 Phosphorylates NSF In Vitro 
Having validated the interaction between LRRK2 and NSF, we next assessed whether NSF 
is also a substrate of LRRK2 kinase activity. To test this, full-length NSF was incubated 
with LRRK2 at a 1:10 ratio LRRK2:NSF with 33P-ATP in kinase conditions. To evaluate if 
NSF is a specific substrate of LRRK2 kinase activity, the wild-type, the kinase dead 
mutant (K1906M) and the pathogenic G2019S form were used. The latter mutation is 
well known to increase LRRK2 kinase activity and this was also confirmed by enhanced 
its autophosphorylation compared to the wild-type (Fig.7.6.1). The M1906M is instead 
devoid of autophosphorylation as expected. Importantly, both LRRK2 wild-type and 
G2019S proteins were able to phosphorylate NSF (Fig.7.6.1). Moreover, NSF was not 
phosphorylated by the kinase dead mutant or in the presence of the LRRK2 inhibitor 1 
(IN-1; Deng et al., 2011). The fact that we did not see any signal in presence of the kinase 
dead form of LRRK2 and upon IN-1 addition, supports the notion that NSF is a LRRK2 
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specific substrate in vitro and allows us to rule out that the observed phosphorylation is 
not due to the presence of other kinases co-purified with NSF, but depends on LRRK2. In 
addition, Fig.7.6.1 indicates also that 33P incorporated by NSF in presence of the gain-of-
function G2019S mutant is higher compared to the wild-type, as expected. 
 
 
Fig.7.6.1 | NSF is a substrate of LRRK2 kinase activity: NSF is efficiently phosphorylated by full-
lenght LRRK2 wild-type and to a greater extend by LRRK2 G2019S. Moreover, any signal was 
detected upon incubation with kinase dead mutant (K1906M) of LRRK2 and the presence of IN-
1, supporting the notion that this NSF is a specific substrate of LRRK2 kinase activity. 
 
To follow up these observations, we next calculated the stoichiometry of the reaction 
using different forms of LRRK2, including the N-terminal truncated LRRK2-G2019S 
(LRRK2-G2019S970-2527), which has been previously shown to be hyperactive (Lewis, 
2012). By measuring the phosphate incorporation, calculated with a calibration curve of 
known concentrations of 33P-ATP (Fig.7.6.2 C), we found that the stoichiometry of 
phosphorylation was about 0.04, 0.1 and 0.4 moles of phosphate per mole of 
monomeric NSF in presence of LRRK2 wild-type, G2019S and LRRK2-G2019S970-2527 
respectively. Referring these stoichiometry values to hexameric NSF, 24% of NSF-
hexamers possesses at least one phosphorylation in the presence of LRRK2 wild-type, 
60% in the presence of LRRK2 G2019S and 240% (on average 2.4 monomers within each 
hexamer) in the presence of LRRK2-G2019S970-2527. Percentages are reported in Fig.7.6.2 
B. Thus, we concluded that LRRK2 phosphorylates NSF in vitro and the phosphorylation 
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stoichiometry in the presence of hyperactive LRRK2 is sufficient to imply the presence of 
at least one phosphorylated monomer per hexamer. 
 
 
Fig.7.6.2 | Measurements of 33P incorporated by NSF: (A) NSF in vitro phosphorylation by the 
hyperactive form of LRRK2 G2019S970-2527 and (B) percentage of moles 33P incorporated by NSF 
upon LRRK2 wild-type, kinase dead, G2019S (referred to Fig.7.6.1) and G2019S970-2527 form using 
a (C) calibration curve with known 33P-ATP concentrations (CPM=counts per million). 
 
We next took advantage of NSF isolated domains to attempt mapping the domain(s) 
where this phosphorylation occurs. We therefore performed kinase assays in the 
presence of NSF full-length, N-terminal, D1 and D2 in the same conditions (1:10 ratio 
LRRK2:NSF/domains with 33P-ATP). The assay revealed that, in addition to NSF full-
length, only the D2 domain was phosphorylated, whilst no phosphorylation was 
observed for the other domains of NSF upon LRRK2-G2019S970-2527 incubation (Fig.7.6.3). 
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Fig.7.6.3 | LRRK2 phosphorylation occurs in the D2 domain: In vitro kinase assays using NSF full-
length and all its domains incubated with LRRK2 GST-LRRK2970-2527. The presence of a signal in the 
lane with D2 domain suggest phosphorylation preferentially occurs within this domain. 
 
This result supports the hypothesis that the LRRK2 kinase activity-dependent regulation 
of synaptic vesicle dynamics might be mediated by NSF phosphorylation. 
 
7.7 LRRK2 Phosphorylates NSF At Threonine-645 
Starting from the results obtained with kinase assays, we next performed mass 
spectrometry analysis to identify possible LRRK2 phosphorylation sites within NSF. To 
this aim, in collaboration with Dr. Giorgio Arrigoni (Dept of Biomedical Science, 
University of Padova), we applied phosphopeptide enrichment coupled with liquid 
chromatography/tandem mass spectrometry (LCMS/MS) analysis. Specifically we 
incubated purified NSF, pretreated with alkaline phosphatase to eliminate possible 
cellular phosphorylation sites, with LRRK2-G2019S970-2527 (to maximize the stoichiometry 
of phosphorylation). The sequence coverage before phosho-peptide enrichment was 
about 80% and three independent analyses consistently enriched the peptide 
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639KLLIIGTTSR648, indicating the presence of one phosphorylation event (Fig.7.7.1). To 
confirm this peptide as a candidate for bearing the LRRK2 phospho-site, we repeated the 
MS analysis in presence of both LRRK2 wild-type and G2019S and found that they were 
able to phosphorylates NSF within this peptide. Moreover, this phosphorylation did not 
occur in the presence of LRRK2 kinase dead form or IN-1. For these reasons, the 
639KLLIIGTTSR648 peptide appeared a very good candidate being within the D2 domain, 
although the exact residue phosphorylated - among Thr-645, Thr-646 and Ser-647 - 
could not be discriminated by the software. 
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Fig.7.7.1 | LC-MS/MS analysis of NSF phosphorylated by LRRK2: (A) Sequence coverage of NSF 
phosphorylated by LRRK2. (B) Manually annotated MS/MS spectrum relative to the 
monophosphorylated peptide KLLIIGTTSR from NSF. Charge: +2, Monoisotopic m/z: 591.33636 
Da (+0.03 mmu/+0.04 ppm respect to the theoretical m/z),   MH+: 1181.66545 Da. Identified 
with Mascot with an IonScore of 60 (Exp Value of 2.5E-005). The presence of the fragment y2 
suggests that the phosphorylation site is probably not located at the level of the serine residue. 
The fragmentation pattern is compatible with a phosphorylation at T645 or T646. 
 
To confirm the MS result and map the phospho-site within the 639KLLIIGTTSR648 peptide, 
we next generated phospho-deficient alanine mutants by site directed mutagenesis of 
all the possible residues that could be the substrate of the serine-threonine kinase 
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activity of LRRK2. Specifically, three different Flag-NSF mutants were generated by 
substituting the two threonine or the serine with an alanine (T645A, T646A and S647A). 
The mutated proteins were expressed and purified from HEK293T cells with the same 
protocol described above for the wild-type NSF (Fig.7.7.2). 
 
 
Fig.7.7.2 | Purification of recombinant NSF and its mutants: Purified human NSF wild-type, 
T645A, T646A and S647A mutants separated on SDS-PAGE and quantified by comparison with 
different concentration of BSA (Bovine Serum Albumine). 
 
Kinase assays were then performed under the same conditions, incubating LRRK2-
G2019S with NSF wild-type, T645A, T646A or S647A respectively. As evidenced in 
Fig.7.7.3, we found that the alanine substitution of Threonine-645 resulted in a 50% 
reduction of 33P incorporation compared to wild-type, T646A and S647A mutants 
(Fig.7.7.3). Bands were quantified by densitometry and 33P signal normalized by the total 
protein concentration (Coomassie blue staining on the PVDF membrane). Thus, 
phosphorylation occurs at T645 and this phosphorylation accounts for the 50% of the 
total LRRK2-mediated phosphorylation on NSF measured in kinase assays. 
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Fig.7.7.3 | Kinase assay on NSF mutants: (A) In vitro kinase assays with 3xFlag-LRRK2 G2019S 
and NSF wild-type or non-phosphorylable mutants T645A, T646A and S647A at 1:10 ratio 
LRRK2:NSF. (B) Quantification of 33P incorporated by NSF (autoradiography in A upper panel) 
controlled for total NSF (NSFTOT, Coomassie staining (CCB) in A lower panel) from n=4 
independent experiments (bars represent the mean ± SEM). One way-ANOVA with Bonferroni’s 
post-test (**p<0.01). 
 
As discussed in the introduction, NSF is a substrate of Pctaire1 and Protein Kinase C 
(PKC) and phosphorylation by these kinases results in impairment on NSF 
hexamerization and alpha-SNAP binding respectively (Liu et al., 2006; Matveeva et al., 
2001). To test whether phosphorylation on T645 is specific for LRRK2 or instead can be 
achieved by other kinases, both NSF wild-type and T645A were incubated with PKC, 
expressed and purified with Flag-affinity purification from HEK cells. As shown in 
Fig.7.7.4, PKC efficiently phosphorylates NSF, as expected, and 33P incorporation was 
similar for wild-type and T645A, suggesting that T645A is a specific LRRK2 
phosphorylation site. 
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Fig.7.7.4 | NSF T645A mutation does not alter PKC phosphorylation: In vitro kinase assays with 
PKC and NSF (1:10, PKC:NSF). On the left, upper panel shows a high exposure image where 
autophosphorylation of PKC can be observed. Middle panel represent a low exposure 
phosphoscreen. Lower panel shows a coomassie of the same membrane to normalize for protein 
loading. On the right, quantification of radioactivity incorporated by NSF wild-type and T645A 
(n=3 independent experiments). 
 
Taken together, these experiments indicate that NSF is a robust substrate of LRRK2 
kinase activity in vitro and that phosphorylation occurs preferentially at T645. The fact 
that the phosphorylation signal was not completely abolished, suggest that there might 
be an additional site(s) phosphorylated by LRRK2. 
 
7.8 LRRK2 Mediated Phosphorylation Increases NSF ATPase 
Activity 
Once identified that NSF is a substrate of LRRK2 kinase activity, the next step was to 
investigate whether this phosphorylation has functional consequences on the ATPase 
activity of NSF. In contrast to NSF, purification of recombinant LRRK2 from HEK293T cells 
requires the presence of Tween-20 in the lysis buffer. One possibility is that LRRK2 is 
stabilized by the detergent, as it has been shown to interact with membranous 
structures inside the cell. We first identified the optimal reaction conditions at which 
both NSF and LRRK2 display their maximal activity, since we needed to pre-incubate NSF 
with LRRK2 (or only buffer) to allow phosphorylation, before proceeding with the 
ATPase assays. The activity of NSF was evaluated with the Malachite Green enzyme 
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assay adding different concentration of Tween-20 to the reaction buffer. LRRK2 activity 
was determined by monitoring the auto-phosphorylation of Thr-2483 using a specific 
antibody (Davies et al., 2013). As shown in Fig.7.8.1, the presence of the detergent is 
necessary for the activity of LRRK2 and the concentration of Tween-20 at which both 
proteins display maximum activity is 0.007%. This value corresponds to the detergent 
CMC (critical micelle concentration), suggesting that the presence of micelles in solution 
are required to maintain an enzymatically active LRRK2. Importantly, NSF ATPase activity 
is preserved at a low concentration of detergent, therefore the subsequent assays were 
performed with the presence of Tween-20 at its CMC concentration. 
 
 
Fig.7.8.1 | Evaluation of the optimal detergent concentration: Optimal Tween-20 concentration 
for the reactions was evaluate within ability of LRRK2 to phosphorylate itself measuring the 
intensity of the band with an antibody against one of its auto-phosphorylation site (Thr-2483). At 
the same time, the activity of human NSF, using the same concentration of detergent, was 
evaluate measuring the V0 of the reaction with the Malachite Green Enzyme assay. 
 
NSF was treated with LRRK2-G2019S970-2527 at a ratio NSF:LRRK2 = 20:1 or alone in the 
kinase buffer at 30°C for 1 hour and 30 minutes in the presence of 50 μM ATP which is 
sufficient to support LRRK2 phosphorylation and minimizes interference with the 
subsequent ATPase assay. We incubated 500 nM of NSF (monomer) and then performed 
ATPase assays at a final NSF concentration of 36 nM (hexameric) based on previous 
studies that employed this concentration to monitor NSF activity (Cipriano et al., 2013; 
Vivona et al., 2013). We used the Malachite Green enzyme assay, to measure the kinetic 
parameters of NSF and to evaluate if they change upon LRRK2 phosphorylation. Pi 
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release over time was measured in NSF-phosphorylated and NSF-unphosphorylated. As 
summarized in Fig.7.8.2, we found that the kinetic parameters of the reaction calculated 
for recombinant human flag-tagged NSF increased of about 2-fold upon LRRK2 
phosphorylation. 
 
 
Fig.7.8.2 | LRRK2 phosphorylation increase the ATPase activity of NSF: (A)NSF ATPase activity 
was assessed with a Malachite green assays at 36 nM NSF (hexamer) at different ATP 
concentration to calculate the kinetic parameters of NSF (red, NSF) and NSF phosphorylated by 
LRRK2-G2019S970-2527 (blue, NSF-LRRK2 ΔG2019S). Malachite Green assay was repetead for 
LRRK2-G2019S970-2527 (pink, LRRK2 ΔG2019S) as a control. Data were fitted with the Michaelis-
Menten kinetic model to determine kinetic constants (n=3). (B) Kinetic parameters obtained 
from the experiment show in A. Data reveal that NSF increases its activity within 2-fold upon 
LRRK2 ΔG2019S phosphorylation. 
 
We then repeated the experiment in presence of the different NSF mutants and 1.4 mM 
ATP to evaluate whether the abolishment of the phosphorylation site would prevent the 
observed increased ATP activity observed upon LRRK2 phosphorylation. Interestingly we 
found that both T645A and T646A mutants display a low basal activity independently of 
phosphorylation, whereas S647A mutant has a similar ATPase activity compared to wild-
type form (Fig.7.8.3). These results suggest that T645 and T646 residues may play a key 
role in NSF activity, since mutations into alanine provoke impairment of ATPase activity. 
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Fig.7.8.3 | ATPase activity of NSF wild-type and all mutants upon LRRK2 phosphorylation: Pi 
generated by ATP hydrolysis in the presence of NSF wild-type, NSFT645A NSFT646A NSFS647A pre-
phosphorylated or not by LRRK2 ΔG2019S (P-) was measured with the Malachite Green Assay at 
120 min with an initial concentration of ATP of 1.4 mM (NSFWT vs NSFT645A **p<0.01; NSFWT vs P-
NSFWT ***p<0.001; NSFT645A vs P-NSFT645A p>0.05, not significant, n.s.; NSFT646A vs P-NSFT646A 
p>0.05, n.s.; NSFS647A vs P-NSFS647A **p<0.01; one-way ANOVA, Bonferroni’s post-test, n≥3). 
UT=untrasfected cells subjected to Flag-affinity purification to monitor background activity (n=1; 
excluded from the statistical analysis). 
 
To rule out the possibility that these differences in the activity of NSF mutants may be 
due to an incorrect folding of the protein, we compared the circular dichroism (CD) and 
fluorescence properties of NSF wild-type, T645A, T646A and S647A mutants. As shown 
in Fig.7.8.4 B, all the proteins exhibit similar CD spectra showing a prevalent alpha-helix 
conformation. Moreover, intrinsic fluorescence values are also similar without 
differences in wavelength of the maximum emission value of the tryptophan peak 
(Fig.7.8.4 A).  
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Fig.7.8.4 | Intrisic fluorescence and CD spectra of NSF wild-type and mutants: (A) Protein 
concentration used for Intrinsic Fluorescence measurements was 0.9 µM (Ec = 295 nm; Em = 330 
nm). (B) CD spectra were normalized by protein concentration previously measured with an SDS-
PAGE gel and reveal  that all proteins are predominantly folded in alpha-helix conformation. 
 
One final piece of evidence is that both T645A and T646A mutants are both able to form 
hexamers in solution as indicated by Transmission Electron Microscopy (TEM) in 
Fig.7.8.6. These results show that the alanine mutation in Thr-645 (as well as in the 
adjacent residue) does not alter the overall folding and the ability of NSF to goes from 
monomeric conformation. 
 
 
Fig.7.8.6 | NSF mutant form hexamers in solution: TEM micrograph of both NSF T645A and 
T646A mutant with 1 mM ATP and 4 mM MgCl2. Images reveal the typical hexameric structures 
showed above for NSF wild-type in Fig.7.2.2 (scalebar 50 nm). 
 
We then looked at the position of these sites within the C. griseus NSF structure, which 
presents a 98% amino acid identity with the human sequence and all the three residues 
are conserved among the two species (Fig.7.2.1). The peptide 639KLLIIGTTSR648 is outside 
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the Walker A motif involved in nucleotide binding (543GPPHSGKTA551), and the PDB 
structure of the D2 domain highlights a possible role of these residues in mediating 
nucleotide binding (Fig.7.8.5), therefore mutations in these sites could compromise 
nucleotide binding, thus the ATPase activity of NSF. 
 
 
Fig.7.8.5 | 3D structure of NSF D2 domain complexed with ATP: ATP-dependent 
oligomerization D2 domain of NSF upon ATP (green) binding. D2 quaternary structure was solved 
using X-ray diffraction method with a resolution of 1.9 Å (PDB code: 1NSF). In figure residues 
T645-T646-S647 are yellow-labelled within the monomer (dark red). 
 
Taken together, these data indicate that LRRK2 phosphorylation increase NSF ATPase 
activity and that T645 is a key site for the enzymatic activity of NSF. 
 
7.9 Phosphorylation Increases Also The SNARE Complex 
Disassembly Rate 
The physiological role of NSF inside neurons is to disassemble the SNARE complex and 
this phenomenon is an ATP-mediated process. Starting from the evidence collected so 
far, we next evaluated whether the altered ATPase activity measured in the presence of 
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NSF phosphorylated by LRRK2 would also reflect a different SNARE complex disassembly 
rate. Based on published methods, we co-expressed recombinant syntaxin, SNAP-25 and 
6xHis-VAMP in E. coli (Vivona et al., 2013) and purified the SNARE-complex already 
assembled by IMAC affinity purification followed by size exclusion chromatography. The 
complex is SDS-resistant and eluted as a single band corresponding of its expected 
molecular weight (68 kDa). Upon heating, the three components of the complex 
dissociate as shown in Fig.7.9.1. 
 
 
Fig.7.9.1 | SDS-PAGE gel of purified SNARE complex: the purified SDS-resistant SNARE complex 
(68 kDa) was obtained by co-expression of Syntaxin, SNAP-25 and 6xHis-VAMP in E. Coli 
BL21(DE3) strain, either boiled (+) and not (-) to disassemble the three single components. 
 
To test the hypothesis that LRRK2 phosphorylation of NSF affects SNARE complex 
disassembly rate, we incubated the assembled SNARE complex (480 nM) together with 
alpha-SNAP (1.5 μM), the adaptor protein that permits NSF-SNARE binding, and NSF (24 
nM) upon LRRK2 phosphorylation or not at 37°C. Reaction started when 2mM of ATP 
were added to the reaction mix. We then monitored the dissociation of the SNARE 
complex over time by measuring the intensity of the corresponding band at 68 kDa. As 
shown in Fig.7.9.2, we found that NSF phosphorylated by LRRK2 G2019S displayed a 
higher efficiency in disassembling the SNARE complex compared to unphosphorylated 
NSF. 
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Fig.7.9.2 | SNARE complex disassembly rate is higher when NSF is phosphorylated: (A) 
Representative SDS-PAGE gels (CBB, coomassie brilliant blue) of SNARE complex incubated for 
increasing time with NSF phosphorylated or not by LRRK2-G2019S970-2527 in the presence of the 
co-factor alpha-SNAP. (C) Quantification of n=3 independent experiments. Time points are 
relative to t=0 which was set at 100% (two-way ANOVA with Bonferroni’s post-test, 
***p<0.001). 
 
These data support the notion that the altered catalytic activity of NSF due to LRRK2 
phosphorylation has a downstream effect on SNARE complex disassembling. 
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8. Rab7L1 is a substrate of LRRK2 
kinase activity 
In the previous section, paragraph 7.1, we discussed the importance of LRRK2 kinase 
activity in synaptic vesicle trafficking. Among all the putative LRRK2 interactors at the 
presynaptic site, we focused on NSF, an AAA+ ATPase responsible for SNARE complex 
disassembly, and, thus vesicle endocytosis. We demonstrated that NSF co-localizes with 
LRRK2 inside primary cortical neurons (Fig.7.5.1) and pulls-down endogenous LRRK2 
(Fig.7.5.2). Moreover, NSF is a substrate of LRRK2 kinase activity in vitro and, 
phosphorylation preferentially occurs at Thr-645 (Fig.7.7.3). We speculate that abnormal 
NSF phosphorylation due to LRRK2 mutation could represent one of the pathways 
compromised in LRRK2-linked PD, leading to neurodegeneration via impairments in the 
exo- and endocytic machinery. Thus, understanding how LRRK2 kinase activity regulates 
its presynaptic substrates is key to shed on into LRRK2 pathological function with 
potential impact in the development of novel therapeutic strategies against PD.  
Several studies linked LRRK2 to vesicular trafficking events. In particular, there is 
growing evidence that LRRK2 interacts with Rab proteins (MacLeod et al., 2013; Gomez-
Suaga et al., 2014; Dodson et al., 2014; Waschbusch et al., 2014). As discussed in the 
introduction, Rabs are a class of small monomeric GTPases localized in different cellular 
compartments that regulate a number of vesicle transport events.  
Recently, genome-wide association studies (GWAS) highlighted a correlation between 
variants of the Rab7L1 gene, localized within the PARK16 locus, and PD-risk (Beilina et 
al., 2014). The authors also showed that overexpression of Rab7L1 is linked to a higher 
risk of PD in humans. Another group found instead that overexpression of Rab7L1 gene 
significantly rescued the LRRK2 G2019S PD-related neurite length phenotype, but did 
not alter neurite length in case of LRRK2 wt overexpression (MacLeod et al., 2013). It is 
possible that in the pathologic context, LRRK2 and Rab7L1 play adverse roles in vesicular 
trafficking. Rab7L1 has been shown to localize in association with the trans-Golgi 
apparatus and is implicated in vesicular sorting (Berger et al., 2009; Spanò et al., 2011), 
even though its precise function in neurons remains unknown. Furthermore, LRRK2 has 
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been shown to interact with Rab5B (Heo et al., 2010), Rab7 (Dodson et al., 2012) and 
functionally with Rab9, which promotes retromer-dependent recycling from late 
endosomes to the Golgi (Dodson et al., 2014). 
We can make two hypotheses on the mechanism of LRRK2 regulation of Rabs activity: i) 
LRRK2 could directly regulate the GTPase activity of Rab proteins via phosphorylation or 
ii) it could alter the association between Rabs and their GEFs and/or GAPs, leading to 
impairment in vesicle sorting. 
 In this scenario, our aim was to test the first hypothesis, i.e. whether LRRK2 
phosphorylates any relevant Rab protein. 
 
8.1 LRRK2 Efficiently Phosphorylates Rab7L1 
Over 60 Rab proteins (molecular weight about 26 kDa) are present in eukaryotic cells 
and some of them are known to be part of LRRK2 interactome. While pathological  
LRRK2 activity might compromise the endosome-lysosomal pathways, the molecular 
mechanism behind LRRK2-dependent Rab regulation is unknown. In collaboration with 
Dr. Sabine Hilfiker (Instituto de Parasitologia y Biomedicina "Lopez-Neyra", CSIC, 
Granada, Spain) who previously showed that LRRK2 delays degradative receptor 
trafficking by impeding late endosomal budding through decreasing Rab7 activity 
(Gomez-Suaga et al., 2014), we investigated whether LRRK2 acts on Rabs through 
phosphorylation. Thus, we focused on several Rab proteins, which are known to interact 
with LRRK2 or are related to neurodegeneration. As for NSF, impairment of vesicle 
sorting could be the consequence of an altered phosphorylation of these GTPases due to 
LRRK2 pathological mutations. We selected several Rab proteins from different 
subcellular compartments: 
1. Rab7. It is implicated in late endosome (LE) to Lysosome trafficking and 
overexpression of a PD-related pathological mutation of LRRK2 results in a 
decreased level of active Rab7. This was observed in fibroblast from PD patients 
carrying G2019S LRRK2 mutation, important for LE trafficking (Gomez-Suaga et 
al., 2014); 
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2. Rab7L1. Rab7L1 gene lies within the PARK16 locus, a non-familial PD risk-
associated locus, composed by five different genes: SLC45A3, NUCKS1, RAB7L1, 
SLC41A1, and PM20D1. As described before, previous studies show that 
overexpression of Rab7L1, but not other genes in this locus, is able to rescue 
LRRK2 G2019S pathological phenotype (MacLeod et al., 2013); 
3. Rab9. It regulates trafficking between LE and both trans-Golgi network (TGN) and 
autophagosome in mammalian cells. Studies in Drosophila demonstrated that 
LRRK2 co-localize with Rab9 at the LE membrane suggesting a regulation in its 
membrane recruitment (Dodson et al., 2014); 
4. Rab11. It was found associated with early endosomes (EE) regulating vesicular 
trafficking through recycling of EEs to the trans- Golgi network (TGN). Rab11 has 
been implicated in different neurodegenerative disorders, such as Alzheimer’s 
disease and Huntington’s disease (Bhuin and Roy, 2015), and therefore it might 
be also associated to PD, even though to date an interaction with LRRK2 has not 
been demonstrated; 
5. Rab32. It is necessary for TGN organization with influences on endosomal 
trafficking and autophagy. Studies show that Rab32 and LRRK2 co-localize in 
recycling endosomes and an overexpression of Rab32 decreases the amount of 
LRRK2 in mitochondria and lysosome containing fractions (Waschbusch et al., 
2014). 
To test whether any of these Rabs are substrates of LRRK2 kinase activity, we purified all 
these proteins with a Flag-tag from mammalian HEK293T cells, following the same 
protocol previously optimized for LRRK2 (Fig.8.1.1). 
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Fig.8.1.1 | Purification of recombinant Flag-Rab proteins from HEK293T cells. Purified human 
LRRK2 wt, G2019S mutant and Rab proteins separated on SDS-PAGE and quantified by 
comparison with different concentration of BSA (Bovine Serum Albumine). 
 
Subsequently, we performed kinase assays in which proteins were incubated with both 
LRRK2 wild-type and G2019S form for 1 hour at 30°C at a 1:10 ratio of LRRK2:Rab(s) with 
33P-ATP. Incubation was performed with both LRRK2 wild-type and G2019S form to 
evaluate whether phosphorylation was enhanced in “pathological” conditions. 
Moreover, to verify that the phosphorylation signal detected was specifically due to 
LRRK2 activity and not to the presence of other kinases co-purified with Rabs, we added 
a LRRK2 spefic inhibitor, GSK2578215A (2 µM), as control. As shown in Fig.8.1.2, we 
found that only Rab7L1 is a clear substrate of LRRK2 kinase activity in vitro. 
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Fig.8.1.2 | LRRK2 phosphorylates Rab7L1. In vitro kinase assays between Flagged-Rab proteins 
and LRRK2 highlighted that only Rab7L1, among the tested Rabs, is efficiently phosphorylated by 
both LRRK2 wild-type and G2019S forms. The lower panel shows the same samples loaded on 
SDS-PAGE. 
 
Thus, among the Rab proteins tested here, Rab7L1 is the only GTPase that appears to be 
phosphorylated by LRRK2. Given the previously reported genetic and functional 
interaction of LRRK2 and Rab7L1, this result appeared particularly interesting. Thus, an 
outstanding question is whether the Rab7L1 function(s) relevant for disease is regulated 
through phosphorylation by LRRK2. In this regard, the G2019S pathological mutation 
could abnormally phosphorylate Rab7L1 altering its GTPase activity, similar to what we 
observed for NSF, and, in turn, cause neurodegeneration. 
To identify the residue within Rab7L1where this phosphorylation occurs, we performed 
MS analysis on purified Flag-tagged Rab7L1 protein after incubation with LRRK2 G2019S 
in the presence or absence of GSK2578215A as a control (in collaboration with Dr 
Giorgio Arrigoni, University of Padova). 
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8.2 Mass Spectrometry Analysis Identified A Phospho-Site In The P-
Loop Region 
As we previously did for NSF, we performed phosphopeptide enrichment coupled with 
liquid chromatography/tandem mass spectrometry (LCMS/MS) analysis on purified 
Rab7L1 upon LRRK2 G2019S phosphorylation. The incubation of Rab7L1 and LRRK2 was 
conducted with the same ratio and conditions of the kinase assay showed in Fig.8.1.2. 
Also in this case, GSK2578215A was added as a negative control. Interestingly, MS 
analysis identified the 10VLVVGDAAVGKTSLVQR26  peptide as phosphorylated by LRRK2. 
Specifically, threonine-21 appeared the most likely to be phosphorylated (99-100% Post-
Translational Modifications (PTM) Site probability) while phosphorylation on the 
adjacent residue, serine-22, resulted lower (45-75% PTM Site probability; Fig.8.2.1). 
Importantly, these sites were not found in the controls (reaction at t=0 and reaction 
conducted in the presence of inhibitor). 
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Fig.8.2.1 | LC-MS/MS analysis of Rab7L1 phosphorylated by LRRK2 G2019S: (A) Sequence 
coverage of Rab7L1 phosphorylated by LRRK2 G2019S (56.16%). In the large onset, the sequence 
with the peptide that was found phosphorylated. The signal highlight that LRRK2 G2019S 
phosphorylates Rab7L1 at T21 (75%-99% PTM Site Probabilities) and S22 (45%-75% PTM Site 
Probabilities). (B) Manually annotated MS/MS spectrum relative to the monophosphorylated 
peptide 10VLVVGDAAVGKTSLVQR26 from Rab7L1. Charge: +2, Monoisotopic m/z: 896.4913 Da. 
Four different samples have been prepared to discriminate possible unspecific phospho-site. We 
stopped the reaction at different time points (after 10 minutes and 60 minutes), but there were 
no differences in the spectrum signal. In addition, the peptide 10VLVVGDAAVGKTSLVQR26 was not 
detected as phosphorylated in the control and in presence of GSK2578215A inhibitor. This 
means that LRRK2 G2019S preferentially phosphorylates Rab7L1 at T21.  
 
Noteworthy, Thr-21 is located in the P-loop region, near the K residue that mediates GTP 
binding. The nucleotide binding motif contains the consensus sequence 20GXXXXGKTS27, 
which is conserved among Rab proteins (Fig.8.2.2). This finding supports the hypothesis 
of a regulatory mechanism exerted by LRRK2, that, by modulating Rab7L1 GTP binding, 
might be able to influence its GTPase activity. Moreover, an altered phosphorylation 
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pattern of Rab7L1 in the neuron due to the presence of LRRK2 G2019S pathologic 
mutant could cause impairment in the trans-Golgi network activity. 
 
 
Fig.8.2.2 | Multiple sequence alignment. The P-loop region (yellow) involved in nucleotide 
binding, is a highly conserved motif among Rab proteins. In particular, the alignment highlights 
that Rab proteins carry a conserved 25VGKTS28 sequence (red) and interestingly, the Thr-21 of 
Rab7L1 (blue), identified through phosphopeptide enrichment, is located inside this motif. 
 
Next, to validate MS data, we generated by site-directed point mutation an 
unphosphorylable Rab7L1 mutant substituting Thr-21 with an alanine (Rab7L1-T21A) 
and phospho-mimetic mutants (Rab7L1-T21D and T21E). We also generated a second 
mutant by replacing Ser-22 with an alanine (Rab7L1-S22A) and the corresponding and 
phospho-mimetic mutants (Rab7L1-S22D and S22E). 
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8.3 Rab7L1 Possesses Possible Alternative Phosphosites 
To validate the phospho-MS data, we purified Rab7L1 and its mutants (T21A, D and E 
and S22A, D and E) from mammalian HEK293T cells with the same protocol previously 
described. Fig.8.3.1 shows the result of protein purification. Of note, T21D, T21E and 
S22D mutants displayed the presence of bands at higher molecular weights, which 
possibly suggests the formation of aggregate(s). This hypothesis is also supported by the 
fact that the amount of all purified Rab7L1 mutants was lower than the wild-type form. 
 
 
Fig.8.3.1 | Purification of Rab7L1 and all its mutants. Purified human LRRK2 G2019S 
mutant with Rab7L1 wild-type and all its mutants separated on SDS-PAGE. In presence of site 
directed mutations in Thr-21 and in S22D, there are bands corresponding to possible aggregates 
at 130, 70 and 55 kDa respectively. Of interest, this feature is highly present upon aminoacid 
substitution with aspartate (D). 
 
Kinase assays were then performed with the different Rab7L1 mutants incubated for 1 
hour at 30°C with 33P-ATP at a 1:50 ratio of LRRK2:Rab(s)  to maximize the signal of the 
substrate. Moreover, the large amount of substrate should result in a higher specificity 
for LRRK2 G2019S mediated phosphorylation. 
As shown in Fig.8.3.2, the phosphorylation signals of Rab7L1 mutants were not 
abrogated in T21A or S22A mutants. This was completely unexpected since the MS 
analysis identified one single phospho-peptide which was enriched only upon incubation 
with LRRK2 G2019S (both after 10 and 60 minutes incubation with the kinase) but not 
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when the inhibitor was added to the reaction or when the reaction was analyzed at t=0. 
Phosphoscreen signals were quantified by densitometry and highlighted a non 
significant tendency towards a decrease in phosphorylation between wild-type and 
S22A, S22D and S22E. This may suggest that S22 has some degree of phosphorylated but 
that another site(s), within a different peptide not phosho-enriched, contributes for the 
majority of the signal observed. Of interest, the T21A, T21D, T21E and S22D mutants 
display additional bands at higher molecular weight that are also substrates of LRRK2 
G2019S. These bands correspond to those previously detected in SDS-PAGE (Fig.8.3.1), 
suggesting they might be Rab7L1 aggregates. Of note, upon substitution of the two 
residues with aspartate (D) or glutamate (E), we observed a difference in the 
phosphorylation pattern of these bands by LRRK2 G2019S. As shown in Fig.8.3.2, the 
signal of incorporated 33P in these bands is higher in Rab7L1-T21D, -T21E and -S22D than 
in the other forms. 
 
Fig.8.3.2 | Kinase assay on Rab7L1 mutants. (A) In vitro kinase assays with Flagged-Rab7L1 wt 
and all its mutants incubated with LRRK2-G2019S at 1:50 ratio LRRK2-G2019S:Rab(s). (B) 
Quantification of 33P incorporated by Rab proteins (autoradiography) normalized by total 
amount of proteins ([Rab(s)]tot, IB against Flag-tag) from n=2 independent experiments. 
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Taken together, while these results confirm that Rab7L1 is a substrate of LRRK2 kinase 
activity, we were not able to validate the MS results. One likely explanation could be 
that the phospho-peptide contributing to the majority of the observed phosphorylation 
was not processed (i.e. tryspin did not cut at the appropriate length for MS analysis). 
Thus, it is likely that additional LRRK2 phosphorylation site(s) are present within Rab7L1 
sequence, that were not detected.  
To try and overcome this pitfall, we next purified Rab7L1 with the freeze/thaw method. 
This should allow achieving a milder lysis, thus preserving Rab7L1 conformation to avoid 
possible unspecific phosphorylation due to partial misfolding. Since we previously 
demonstrated that the presence of Tween-20 impairs NSF ATPase activity, we decided 
to use the same protocol for Rab7L1, to see if there were differences on its 
phosphorylation signal. As shown in Fig.8.3.3, the amount of Rab7L1 purified without 
Tween-20 is slightly higher than in presence of the detergent, probably because this 
method is important to preserve a correct protein folding. 
 
 
Fig.8.3.3 | Comparison between the different purification protocols. The amount of purified 
Rab7L1 is higher without adding Tween-20 in the Lysis buffer (Rab7L1 (Tween-20) = 1.7 µg; 
Rab7L1 (Freeze&Thaw) = 3.3 µg; starting from 20x106 cells). Proteins were separated on SDS-
PAGE and quantified by comparison with different concentrations of BSA (Bovine Serum 
Albumine).  
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Next, we incubated LRRK2 G2019S together with Rab7L1 obtained with the two 
methods of purification for 1 hour following the same conditions described for the 
previous experiments. Of interest, in absence of Tween-20, 33P incorporation appeared 
lower (Fig.8.3.4). This might be the result of a more specific phosphorylation. 
 
Fig.8.3.4 | Kinase assay on Rab7L1. In vitro kinase assay between LRRK2 G2019S and Rab7L1, 
purified with and without Tween-20, reveals that the absence of detergent decreases the 
amount of 33P incorporation signal, suggesting a more specific phosphorylation (n=3). 
 
This result is in accordance with data obtained from NSF experiments. Also in this case 
the phosphorylation could be more specific due to a proper folding of the protein. 
Another set of samples was prepared for MS analysis in presence of GSK2578215A or 
not. The different purification protocol used (freeze/thaw), and, hopefully, a higher 
percentage of sequence coverage, will allow to clearly identify the major phospho-site(s) 
of Rab7L1 upon incubation with LRRK2 G2019S.  
Once identified the site(s), the following aims will be to understand the impact of this 
phosphorylation on Rab7L1 GTPase activity and cellular function. If we can demonstrate 
that LRRK2-mediated phosphorylation of Rab7L1 is physiologically relevant, we will have 
in hand another cellular pathway that could be compromised in pathological condition 
and, in turn, lead to neurodegeneration. 
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9. Discussions and Conclusions 
Neurodegenerative disorders result from the impairment of complex cellular processes 
that leads to loss of neuronal functionality and eventually to cell death. Among these, 
Parkinson’s disease (PD) results from a specific neurodegeneration that mainly affects 
neurons in the midbrain region. In fact, the PD pathological hallmarks are the loss of 
dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the presence of 
intracellular proteinaceous inclusions called “Lewy bodies” (LB) in surviving neurons 
(Damier et al., 1999; Frank et al., 2007). The etiology of PD remains unclear but it seems 
to be linked to a combination of factors, i.e. environment, genetics and aging (Dauer and 
Przedborski, 2013). Although PD is typically sporadic, several PD-related genes have 
been identified (Van Den Eeden et al., 2003). However, the molecular mechanisms 
underlying neurodegeneration in PD is still an open question. Accumulating evidence 
indicates that neuronal dysfunction through impairment of synaptic vesicle trafficking 
might represent an early event that triggers neurodegeneration. The molecular 
mechanisms that cause defects in synaptic vesicle dynamics remain however to be 
determined, being exo- and endocytosis highly regulated processes that require precise 
interactions among many proteins (Südhof, 2004).  
In 2004, two studies identified mutations in the Lrrk2 (PARK8) gene associated with 
familial forms of PD (Paisan-Ruiz et al., 2004; Zimprich et al., 2004) and, at present,  
autosomal dominant mutations in Lrrk2 are the most common genetic cause of late-
onset PD (Singleton et al., 2013). To date, both the physiological role and the neurotoxic 
properties of LRRK2 are poorly understood. A large variety of possible functions have 
been linked to LRRK2 and its pathological role during neurodegeneration (Zhu et al., 
2006; Giasson et al., 2006; MacLeod et al., 2006; Plowey et al., 2008; Belluzzi et al., 
2012; Greggio, 2012; Rivero-Ríos et al., 2015). The factors that have challenged the 
investigation of LRRK2 are i) its complex multi-domain structure, ii) the possible 
pleiotropic activity of LRRK2 and iii) the variety of models used that resulted in a large 
body of in vitro and in vivo studies present in the literature. Further complexity emerges 
in the evaluation of the function of LRRK2 in the context of the several pathological 
mutations identified. In this frame, the G2019S mutation induces a higher kinase activity 
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of LRRK2, which is likely to affect putative effector proteins (Gilks et al. 2005; Greggio 
and Cookson, 2009). Thus, the identification of a more specific role of LRRK2 at the 
presynaptic site is crucial to understand the early events in neurodegeneration, being 
that deregulation of synaptic vesicle trafficking seems to occur prior to the onset of 
motor symptoms (Fernandez-Chacon et al., 2004; Burre et al., 2010). Identification of 
substrates of LRRK2 kinase activity at the presynaptic site is the first step to unravel the 
molecular pathways in which LRRK2 is involved. This, in turn, will allow understanding 
which cellular pathways are deregulated by PD-related mutations of LRRK2. A large body 
of evidence supports a role of LRRK2 at the presynaptic compartment. Among these, 
LRRK2 has been found to interact with several proteins involved in vesicle recycling 
(Piccoli et al., 2011). Moreover, LRRK2 kinase activity has been described as regulating 
both synaptic vesicle exo- and endocytosis (Cirnaru et al., 2014) possibly via 
phosphorylation of presynaptic proteins, such as Snapin and EndophilinA (Yun et al., 
2013; Matta et al., 2012). Furthermore, BAC hG2019S transgenic mice display a faster 
synaptic vesicle trafficking (Belluzzi, Gonnelli et al., 2016; Appendix). In my research 
project, I focused on the identification of two possible LRRK2 substrates at the 
presynaptic site. The first one is the N-ethylmaleimide Sensitive Fusion (NSF) protein, an 
ATPase responsible of the SNARE complex disassembling. The second substrate tested 
here is the small GTPase Rab7L1, which is encoded by Rab7L1 gene within PARK16, a 
non-familial PD risk-associated locus. Rab7L1 was demonstrated to interact with LRRK2 
to promote the clearance of Trans-Golgi derived vesicles (Beilina et al. 2014) and its 
overexpression suppresses the LRRK2-related phenotype (MacLeod et al., 2013). 
As presented in the Results section, NSF and LRRK2 efficiently co-localize along neurites 
and we showed by pull-down assays that NSF is able to interact with endogenous LRRK2. 
Furthermore, we provided evidence that NSF is not only an interactor, but also a 
substrate of LRRK2 kinase activity in vitro. Previous studies showed that NSF is a target 
of other kinases and phosphorylation affects its activity. More in detail, Pctaire1 and PKC 
are both able to phosphorylate NSF modifying its oligomerization process and 
interaction with alpha-SNAP:SNAREs complex, respectively (Liu et al., 2006; Matveeva et 
al., 2001). In our study, we demonstrated that LRRK2 G2019S phosphorylation occurs at 
NSF-T645. Further analysis indicated that NSF has an increased ATPase activity upon 
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LRRK2 G2019S phosphorylation. This result is in agreement with previous studies, since 
phosphorylation appeared to be a critical modification for NSF activity. LRRK2-mediated 
phosphorylation on NSF could be an important process to tune its ATPase activity. 
Accordingly, we found that T645A is characterized by a reduced endogenous ATPase 
activity. The D2 domain of NSF is responsible for its structural changes (Matveeva et al., 
1997). ATP binding occurs at the D2 domain within the Walker A motif, in which 
nucleotide binding is responsible for the NSF structural transition into hexamer. In this 
state, NSF is an active ATPase. Structural studies demonstrate that T645 is located in the 
beta-strand S4 (aa 639-646), which contributes to hexamer stability through interaction 
with alpha-helix H5 (Yu et al., 1998). For this reason, T645 might play a key role in 
mediating NSF oligomerization and consequently ATP hydrolysis, so the predicted key 
role of this residue for NSF activity supports the outcome of our results. We predict that 
the PD-related hyperactive form of LRRK2, G2019S mutant, might abnormally 
phosphorylate this residue resulting in an altered NSF ATPase activity, thus SNARE 
complex disassembly. Further investigation is necessary to better clarify how the impact 
of LRRK2 phosphorylation at T645 directly alters NSF hexamerization. To this end, we 
could monitor NSF hexameric conformation with Transmission Electron Microscopy 
(TEM) and evaluate whether oligomerization is altered in presence of a mutation that 
mimic phosphorylation (T645D/E). To cast these molecular data on isolated proteins in 
the contest of the living neuron,, we reasoned that the process regulated by LRRK2 may 
be the SNARE complex disassembly. An increased NSF phosphorylation would result in a 
higher ATPase activity and a faster SNARE complex disassembly rate, which may lead to 
impairment in the normal synaptic vesicle trafficking. Accordingly, our data support a 
faster SNARE complex dissociation when NSF is phosphorylated by LRRK2. Future studies 
should also be directed at understanding whether this enhanced disassembling kinetic 
occurs also in the cellular context in the presence of PD-related LRRK2 mutations. 
An altered SV sorting at the presynaptic site could derive from impairment in vesicle 
recycling. Coherently, many intracellular trafficking events are mediated by Rab 
proteins, a large family of monomeric small GTPases, which regulate the endosome 
maturation (Novick et al., 1997; Ng and Tang, 2008). To date, there is growing evidence 
that LRRK2 interacts with Rab proteins (Wallings et al., 2015). In the second part of this 
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work, we investigated which among the several Rab proteins maybe substrates of LRRK2 
kinase activity. Specifically, we selected Rabs from different cellular compartments, 
which are known to interact with LRRK2 and are related to neurodegeneration, i.e. Rab7 
(Gomez-Suaga et al., 2014), Rab7L1 (MacLeod et al., 2013), Rab9 (Dodson et al., 2014), 
Rab11 (Bhuin and Roy, 2015) and Rab32 (Waschbusch et al., 2014). In our studies, kinase 
assays revealed that only Rab7L1 is a substrate of LRRK2 kinase activity. This feature is in 
agreement with recently published studies, which revealed a physical and functional 
interaction between Rab7L1 and LRRK2 (Beilina et al., 2014; MacLeod et al., 2013). 
Rab7L1 gene lies within the PARK16 locus, a non-familial PD risk-associated locus. In 
particular, an accumulation of the mannose phosphate receptor, a retromer component, 
is a typical consequence of LRRK2 G2019S mutations, which is efficiently recovered by 
Rab7L1 (MacLeod et al., 2013). Being LRRK2 a kinase, the first aspect in the regulatory 
mechanism that we investigated was phosphorylation. Therefore, we decided to run 
phospho-peptide enrichment and mass spectrometry analysis on Rab7L1 after 
incubation with LRRK2 G2019S. The MS results revealed that LRRK2 G2019S-mediated 
phosphorylation occurs preferentially on the residue T21 of Rab7L1. The region in which 
T21 lies is the highly conserved nucleotide binding region among GTPases (P-loop, 
20GXXXXGKTS27). Thus, phosphorylation of T21 is predicted to alter GTP binding, with 
possible consequence on the activation of Rab7L1 downstream effectors. To validate the 
MS data, phosphorylation deficient mutants were generated at residues T21 and S22, 
which was also indicated as possible phosphorylation site, but with lower probability. 
Unexpectedly, we did not see significant differences in radioactivity incorporation 
between Rab7L1 witld-type and non-phosphorylatable mutants. This result could be 
explained by 1) the presence of additional phospho-site(s) not phospho-enriched with 
more favorable stoichiometry compared to P-T21; 2) the ability of Rab7L1 mutants to 
co-purify with kinases that can phosphorylate them (i.e. PKA or PKC, very active and 
poorly selective out of the tightly regulated cellular context); 3) the interchangeable 
phosphorylation between T21 and S22, in which case a double T21/S22 alanine mutant 
should rule out this possibility. We also aim to repeat MS analysis on proteins purified 
without detergent, since they display a lower, but possibly more specific 
phosphorylation.  
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Chapter IV Discussions and Conclusions 
Accumulating evidence supports a model where LRRK2 and Rab7L1 impairment leads to 
altered intracellular vesicle sorting at the level of the trans-Golgi network and retromer 
complex. Of interest, only Rab7L1 overexpression, among the gene within the PARK16 
locus, is able to rescue LRRK2 cellular defects, suggesting functional interaction between 
the two proteins (MacLeod et al., 2013). Rescue of mutant LRRK2 phenotypes can be 
achieved also with overexpression of VPS35, a retromer component. Mutations in VPS35 
have been linked to familial inherited and idiopathic forms of PD (Follett et al., 2014). 
Dysfunction of VPS35 affects normal vesicle sorting between retrograde transport and 
Golgi that may end in the onset of PD. It is possible that PD-related defects in LRRK2 and 
RAB7L1 impact other aspects of vesicular trafficking besides retromer function. 
Future studies are necessary to confirm these results in a cellular contest. 
Understanding whether NSF and Rab7L1 phosphorylation are relevant in the 
pathogenesis of PD might provide new targets against vesicle sorting impairment, 
biomarkers for early PD diagnosis and, in turn, more opportunities to find effective 
therapies to halt or slow PD progression. 
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LRRK2 phosphorylates pre-synaptic
N-ethylmaleimide sensitive fusion (NSF)
protein enhancing its ATPase activity and
SNARE complex disassembling rate
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Abstract
Background: Lrrk2, a gene linked to Parkinson’s disease, encodes a large scaffolding protein with kinase and
GTPase activities implicated in vesicle and cytoskeletal-related processes. At the presynaptic site, LRRK2 associates
with synaptic vesicles through interaction with a panel of presynaptic proteins.
Results: Here, we show that LRRK2 kinase activity influences the dynamics of synaptic vesicle fusion. We therefore
investigated whether LRRK2 phosphorylates component(s) of the exo/endocytosis machinery. We have previously
observed that LRRK2 interacts with NSF, a hexameric AAA+ ATPase that couples ATP hydrolysis to the disassembling of
SNARE proteins allowing them to enter another fusion cycle during synaptic exocytosis. Here, we demonstrate that
NSF is a substrate of LRRK2 kinase activity. LRRK2 phosphorylates full-length NSF at threonine 645 in the ATP binding
pocket of D2 domain. Functionally, NSF phosphorylated by LRRK2 displays enhanced ATPase activity and increased rate
of SNARE complex disassembling. Substitution of threonine 645 with alanine abrogates LRRK2-mediated increased
ATPase activity.
Conclusions: Given that the most common Parkinson’s disease LRRK2 G2019S mutation displays increased kinase
activity, our results suggest that mutant LRRK2 may impair synaptic vesicle dynamics via aberrant
phosphorylation of NSF.
Keywords: Parkinson’s disease, Leucine-rich repeat kinase 2, N-ethylmaleimide sensitive fusion, Presynapse,
Phosphorylation
Background
Leucine-rich repeat kinase 2 (LRRK2) is a large kinase
with protein-to-protein interaction domains and dual en-
zymatic activities. The catalytic core includes a ROC (Ras
Of Complex) domain with GTPase activity, followed by a
COR (C-terminus Of ROC) domain likely involved in pro-
tein dimerization, and a serine-threonine kinase domain
[1–3]. Mutations in Lrrk2 cause late-onset autosomal
dominant Parkinson’s disease (PD) [4, 5], whereas more
common variants around the Lrrk2 locus act as risk fac-
tors for disease [6, 7]. As the most common G2019S mu-
tation increases kinase activity in vitro and in vivo by ~3
fold, LRRK2 is being intensively explored as a pharmaco-
logical target for the treatment of PD [8]. Several sub-
strates of LRRK2’s kinase activity have been reported,
however few of these have been extensively validated at a
physiological level [9]. There is, therefore, an increasing
interest in identifying LRRK2 substrates and cellular path-
ways compromised during pathological conditions that
could serve as therapeutic alternatives to directly targeting
LRRK2 kinase activity. LRRK2 has been found associated
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with various membrane structures, including synaptic ves-
icles (SV) [10–15]. Multiple studies on different experi-
mental models support a role for LRRK2 at the synapse.
Mutant LRRK2 rodent models display defects in neuro-
transmission [16–19], and LRRK2 overexpression or
knockdown results in impaired SV endocytosis/exocytosis
[15, 20]. We recently showed that LRRK2 binds SV via
interaction with a number of presynaptic proteins [21]
and that its kinase activity modulates these interactions
and impacts on SV dynamics [22]. Among the LRRK2
interactors identified, we found N-ethylmaleimide sensi-
tive factor (NSF), which is involved in the fusion of SV or-
chestrated by SNARE (Soluble NSF-Attachment protein
REceptor) proteins. During membrane fusion, vesicular
and target SNAREs assemble into an alpha-helical trans-
SNARE complex that juxtaposes the two membranes to-
gether to catalyze membrane fusion. NSF is the ATPase
that catalyzes the release of SNARE complexes, thus
allowing SV endocytosis and the next cycle of fusion [23].
Notably, NSF activity is tightly controlled by phosphoryl-
ation/dephosphorylation [24–26]. In the present study,
using dynamic assays of SV cycling, we found that SV fu-
sion is altered by LRRK2 kinase function, suggesting com-
ponents of the exo/endocytic machinery may be a target
of LRRK2 kinase activity. Given that LRRK2 interacts with
NSF, we assessed whether NSF is a substrate for LRRK2
kinase activity. We found that LRRK2 can efficiently phos-
phorylate NSF in vitro, with phosphorylation primarily oc-
curring at T645. Importantly, phosphorylated NSF
displays enhanced ATPase activity and increased rate of
SNARE complex disassembling in vitro. Our data impli-
cate LRRK2 kinase activity in the regulation of SV exo/
endocytosis by phospho-modulation of NSF activity and
suggest that pathological LRRK2 may disturb SV dynam-
ics via aberrant phosphorylation of NSF.
Results
LRRK2 kinase activity influences synaptic vesicle dynamics
We recently reported that inhibition of LRRK2 kinase
activity causes impairment in synaptic vesicles (SV) dy-
namics, indicating a role for LRRK2 catalytic activity in
SV fusion cycle [22]. To further determine the role of
LRRK2 kinase activity at the presynapse, we performed
dynamic assays of SV taking advantage of the sypHy
assay in two complementary models: a) primary cortical
cultures in the presence or absence of the LRRK2 inhibi-
tor GSK2578215A (GSK in, 0.2 μM, 2 h), a brain pene-
trant, selective LRRK2 inhibitor (IC50 10 nM) [27]; b)
primary cortical neurons obtained from BAC hG2019S
mice characterized by higher LRRK2 kinase activity [28].
GSK treatment induced LRRK2 dephosphorylation at
Ser935, as predicted (Additional file 1: Figure S1-b), but did
not cause protein destabilization (Additional file 1:
Figure S1a–c), whereas BAC hG2019S neurons
displayed increased LRRK2 expression due to the presence
of the transgene (Additional file 1: Figure S1a-b-c).
Synaptophysin-pHluorin (sypHy) is a pH-sensitive fluores-
cent reporter that, by analogy with the original synap-
topHluorin (synaptobrevin-pHluorin), is quenched in the
acidic intracellular space of the SV and will only become
fluorescent upon SV fusion, when the contents of the SV
is exposed to the more basic pH of the extracellular space
[29]. As shown in Fig. 1, at the onset of the stimulus, exo-
cytosis caused a rapid increase in sypHy fluorescence,
which after cessation of the stimulus, slowly returned to
baseline (Fig. 1a–b). The first stimulus, 40 AP, is predicted
to mobilize SV belonging to the ready releasable pool,
while 300 AP is sufficient to trigger the fusion of SV be-
longing to the total recycling pool [29]. Furthermore, the
kinetics describing the on-set and the decay of the fluores-
cence are correlated to the efficiency of the exocytotic and
endocytotic mechanism, respectively [29]. Interestingly,
while we measured a significant impairment of SV fusion
(decreased fluorescence) in the presence of GSK upon ei-
ther 40 or 300 AP stimuli, BAC hG2019S neurons were
characterized by a higher answer following the two stimu-
lations (ΔF40/F0 and ΔF300/F0 respectively, Fig. 1c). Fur-
thermore, while upon acute pharmacological inhibition
the time taken for fluorescence decay was extended, τ
decay was decreased in hG2019S cells (Tau decay, Fig. 1c).
To further assess a role for LRRK2 in the SV cycle, we
took advantage of the exo/endocytic assay previously re-
ported [20, 21]. Using this approach, we previously dem-
onstrated that acute pharmacological blockade of LRRK2
kinase activity impairs SV recycling [22]. Building upon
these data, BAC hG2019S cortical cultures were trans-
duced at DIV4 with control viruses co-expressing GFP to
track neuronal processes and assayed at DIV14. Briefly,
we exposed living cultures to rabbit polyclonal antibodies
directed against the intravesicular domain of synaptotag-
min1, which are internalized inside the vesicle lumen
upon SV recycling [30]. Vesicles within GFP positive pro-
cesses were then monitored via laser confocal microscopy.
The vesicles appeared as clusters either synaptotagmin
and synaptophysin positive (i.e. cycling vesicles) or only
synaptophysin positive (Fig. 1d). The analysis showed that
BAC hG2019S cultures are characterized by a significant
increase in the number of synaptotagmin and synaptophy-
sin positive clusters (Fig. 1e). The total number of synaptic
contacts, however, remained unaltered despite any
pharmacological treatments (Additional file 1: Figure
S1d). Taken together, these results indicate that LRRK2
kinase activity is involved in the regulation of SV fusion.
LRRK2 interacts with NSF
Having found that LRRK2 kinase activity influences
SV fusion, we next asked what the molecular mecha-
nisms behind this phenotype might be. We had
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previously demonstrated that LRRK2 interacts with
the vesicle fusing ATPase NSF through its WD40
domain [21].
We first confirmed LRRK2 and NSF interaction at the
endogenous level in synaptosomal preparations. Using
co-immunoprecipitation with endogenous proteins from
Fig. 1 LRRK2 kinase activity modulates synaptic vesicle fusion. a We recorded synaptophluorin fluorescence from DIV14 wild-type cortical neurons
treated with DMSO (control) or treated with LRRK2 inhibitor GSK2578215A (GSK in, 0.2 μM, 2 h) and from cortical neurons obtained from BAC hG2019S
mice (hG2019S). Representative snapshots were taken at DIV16 from 1 Hz recordings at rest (0), after 40 action potential stimulation (40AP), after 300 action
potential stimulation (300AP) and upon neutralization with 50 mM NH4Cl to reveal total fluorescence (Fmax). Panels size is 113 × 113 μm. b The graph
shows representative pattern of fluorescence. Y-axis reports ΔF/F0 at the given time point (second). c The graphs report the increase in fluorescence after
40AP (ΔF40/F0) and 300AP (ΔF300/F0) and the kinetic of signal after 300AP expressed as time constant describing the increase (tau upstroke) and decay
(tau decay) of fluorescence. Data are expressed as mean ± SEM, n = 4, at least 50 boutons from minimum five neurons were analyzed for
experiment (* p < 0.05; ** p < 0.01 versus control, ANOVA). d The exo/endocytotic assay was performed at DIV14 on wild-type and BAC
hG2019S cortical neurons infected at DIV4 with virus expressing GFP. Cycling SV appears as synaptotagmin (s-tagmin) positive clusters
along neuron processes. Total SV pool was revealed by staining with anti-synaptophysin antibodies upon fixation and permeabilization.
Images show signals acquired for synaptotagmin, synaptophysin and their superimposition plus GFP (merge). Panel size is 28 × 4 μm. (e) The percentage
of s-tagmin and s-physin positive clusters within the totality of s-physin positive clusters reflects the pool of cycling vesicles. Data are expressed as mean ±
SEM, n= 4, at least 7 neurons were analyzed for experiment (** p< 0.01 Student’s t-test)
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rat synaptosomes, we observed that LRRK2 efficiently co-
precipitates NSF (Fig. 2a). Next, we dissected the do-
main(s) of NSF involved in binding LRRK2. To this aim,
we cloned human full-length NSF (aa 1–744) and its dif-
ferent domains, namely N domain (aa 1–205), D1 domain
(aa 206–487) and D2 domain (aa 488–744) in fusion with
a N-terminal Flag-tag and purified the proteins from
HEK293T cells. Proteins bounds to Flag-conjugated beads
were adjusted to equal molar concentrations and subse-
quently incubated with a mouse brain lysate. As shown in
Fig. 2b, full-length NSF pulls-down endogenous LRRK2.
Interestingly, N and D2 domains, but not D1, also pull-
down endogenous LRRK2 (Fig. 2b). To further confirm
the interaction between LRRK2 and NSF, we used size
exclusion chromatography (SEC) to fractionate HEK293T
lysates expressing Flag-NSF or co-expressing Flag-NSF
and 2xMyc-LRRK2, followed by dot blot analysis. As
shown in Fig. 2c, NSF elutes between 11 and 17.5 mL.
Interestingly, in the presence of LRRK2, NSF elution pro-
file shifts toward shorter retention times (elution peak be-
tween 10 and 16.5 mL) suggesting the formation of a
complex with higher molecular weight than NSF alone
(Fig. 2c). We also evaluated the cellular localization of en-
dogenous NSF and LRRK2 in primary neuronal cultures
and found that the two proteins largely co-localize, and
co-localization is enriched within clusters along the neur-
ites (Fig. 2d). Collectively these data indicate that LRRK2
and NSF form a complex in the cell.
Fig. 2 LRRK2 interacts with NSF. a Extracts of purified cortical synaptosomes were incubated with anti-LRRK2 antibodies or rabbit IgG. The
immunocomplexes were sedimented with protein G-Sepharose and the samples were resolved by SDS-PAGE and analyzed by immunoblotting with
anti NSF and anti LRRK2 antibodies. Immunoblotting against synaptotagmin 1 (S-tagmin1), synaptophysin (S-physin) and synaptobrevin (S-brevin) were
performed to confirm purity of synaptosomal preparation. b Flag-NSF full-length or domains (N, D1, D2) purified from HEK293T and bound to M2 flag
resin were incubated with a mouse brain lysate. Samples were subjected to immunoblotting using anti-LRRK2 (MJFF2) or stained with Coomassie to
show flag inputs. c Size exclusion chromatography fractions of HEK293T expressing ectopic flag-NSF alone or together with 2xMyc-LRRK2 spotted onto
nitrocellulose membrane and probed with anti-flag antibody (n = 3 independent experiments). d Immunofluorescence of primary cortical neurons
stained for endogenous LRRK2 and endogenous NSF (scale bar is 10 μm)
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LRRK2 phosphorylates NSF in D2 domain
LRRK2 affects SV dynamics via its kinase activity
(Fig. 1a–c) [22]. Therefore, we hypothesized that NSF
could be a substrate of LRRK2 and, as such, be involved
in the LRRK2 kinase dependent regulation of SV. To test
this hypothesis, we performed in vitro kinase assays
using recombinant LRRK2 and NSF purified from mam-
malian cells. We first validated recombinant human NSF
biochemically. NSF purified as described in the methods
section folds into hexamers when loaded with 1 mM
ATP as evidenced by negative-stain transmission elec-
tron microscopy (TEM) (Additional file 1: Figure S2a).
Of interest, Flag-tagged NSF purified with Flag affinity
resin co-precipitates endogenous NSF as indicated by
the presence of a band corresponding to endogenous
NSF (Additional file 1: Figure S2b), further supporting
the notion that Flag-NSF forms oligomers. To verify
that purified NSF is functional, we measured ATP to
ADP hydrolysis rate by isocratic reverse-phase HPLC
(Additional file 1: Figure S2c-d) and malachite green
colorimetric assay (Additional file 1: Figure S2e). NSF
efficiently hydrolyzes ATP to ADP over time under
these purification and assay conditions.
Having validated recombinant human full-length NSF,
we next purified soluble 3xFlag-LRRK2 wild-type, the
hyperactive clinical mutant G2019S and the kinase dead
K1906M from HEK293T cells and subsequently incubated
these purified proteins with full-length NSF in kinase assay
conditions [31]. As shown in Fig. 3a, at a 1:10 ratio of
LRRK2:NSF, we observe robust phosphorylation of NSF by
LRRK2. Importantly, in the presence of LRRK2 K1906M
or upon addition of 1 μM LRRK2 IN-1 inhibitor, NSF
phosphorylation corresponds to the background levels ob-
served for NSF alone, confirming that the incorporation of
Fig. 3 LRRK2 phosphorylates NSF. a In vitro radioactive kinase assays of 3x-Flag LRRK2 wild-type, K1906M (kinase dead) and G2019S (hyperactive)
and flag-NSF purified from HEK293T cells at 1:10 ratio. Radioactivity incorporated was revealed by autoradiography (upper panel) and total proteins
loaded by flag immunoblotting (lower panels). LRRK2 inhibitor IN-1 was used at 1 μM concentration to confirm LRRK2 specific phosphorylation on
NSF. b In vitro kinase assays as in (a) with the hyperactive GST-LRRK2970–2527 fragment. c Quantification of moles of 33P incorporated by NSF using
a calibration curve with known concentration of 33P-ATP. d In vitro kinase assays as in (a) using NSF full-length or domains as substrates of LRRK2 GST-
LRRK2970–2527 kinase activity at 1:10 ratio LRRK2:NSFs. Radioactivity incorporated was revealed by autoradiography (upper panel) and total proteins loaded
by coomassie brilliant blue (CBB) staining for NSF (middle panel) or LRRK2 immunoblotting (lower panel). e In vitro radioactive kinase
assays of 3xFlag-LRRK1 or 3xFlag-LRRK2 and Flag-NSF as substrate at 1:10 ratio. Left panel is an example of autoradiography and right
panel represents the corresponding immunoblot of total loading
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radioactive phosphate is genuinely due to LRRK2 kinase
activity (Fig. 3a). We confirmed LRRK2-mediated phos-
phorylation of NSF using the hyperactive G2019S-
LRRK2970–2527 fragment (Fig. 3b). The stoichiometry of
phosphate incorporation, measured using a calibration
curve with different concentrations of 33P-ATP, is approxi-
mately 0.04 moles of phosphate per mole of monomeric
NSF in the presence of LRRK2 wild-type, 0.1 in the pres-
ence of G2019S and 0.4 with an artificial truncated variant
characterized by higher activity, G2019S-LRRK2970–2527
(Fig. 3c). The low value for this stoichiometry, when taken
in the context of a hexameric NSF complex, is sufficient to
imply the presence of at least one phosphorylated mono-
mer per hexamer. The reaction reached a plateau after 1-
hour incubation (Additional file 1: Figure S3a-b), likely
due to inactivation of LRRK2 under assay conditions as
previously reported [32].
To define the region(s) of NSF phosphorylated by
LRRK2, we performed kinase assays in the presence
of NSF full-length or isolated domains. While we
failed to detect any phosphorylation when N and D1
domains were incubated with G2019S-LRRK2970–2527,
we were able to measure phosphate incorporation in
the D2 domain (Fig. 3d). Importantly, NSF is not a
substrate of the cognate protein LRRK1 under these
assay conditions (Fig. 3e), suggesting that this phos-
phorylation event is specific to LRRK2. In toto, these
results indicate that LRRK2 likely phosphorylates the
D2 domain of NSF.
LRRK2 phosphorylates NSF at threonine 645
We next set out to identify NSF phosphorylation site(s)
targeted by LRRK2. To achieve this, we used phospho-
peptide enrichment coupled with liquid chromatography/
tandem mass spectrometry (LC-MS/MS) analysis on puri-
fied NSF pretreated with alkaline phosphatase to eliminate
possible cellular phosphorylation sites, and subsequently
phosphorylated by LRRK2 in vitro. Under the experimen-
tal conditions used, we were able to achieve ≈ 80 % NSF
sequence coverage (Additional file 1: Figure S4a) and
identified the peptide 639KLLIIGTTSR648 as a bona fide
phospho substrate. The MS analysis could not discrimin-
ate whether single/multiple phosphorylation occurred at
T645, T646 or S647 or whether these sites may be multi-
phosphorylated (Additional file 1: Figure S4b). This phos-
phopeptide was enriched following incubation with wild-
type and G2019S LRRK2, but not in control samples
(LRRK2 kinase dead or in the presence of 1 μM IN-1) in-
dicating it contains specific LRRK2 phosphorylation
site(s). We next validated the MS data by site-direct muta-
genesis and in vitro kinase assays. Wild-type and
phospho-deficient NSF mutants T645A, T646A and
S647A were expressed and purified in HEK293T cells and
subsequently incubated in vitro with catalytically ac-
tive LRRK2 under phosphorylation permissive condi-
tions. T645A displayed ~50 % reduction of 33P
incorporation compared to NSF wild-type, T646A and
S647A (**p < 0.01, One-Way ANOVA with Bonferro-
ni’s post-test) (Fig. 4). Since NSF is also phosphory-
lated by PKC but within a different residue (S237)
[26], we next assessed whether PKC is able to phos-
phorylate NSF at T645 to rule out any promiscuous
effect. As shown in Additional file 1: Figure S5, we
confirm that PKC efficiently phosphorylates NSF in
vitro, but NSFT645A exhibits similar 33P incorporation
as NSF wild-type, suggesting that T645 is a LRRK2
specific phospho-site. Overall, our data indicate that
T645 is a LRRK2 phosphorylation site within NSF.
Fig. 4 LRRK2 phosphorylates NSF at T645. a In vitro kinase assays with 3xFlag-LRRK2 G2019S and NSF wild-type or non-phosphorylatable mutants
T645A, T646A and S647A mutants at 1:10 ratio LRRK2:NSF. The G2019S hyperactive mutant was used to maximize 33P incorporation. b Quantification
of 33P incorporated by NSF (autoradiography, upper panel) controlled for total NSF (NSFTOT, coomassie staining, lower panel) from n = 4 independent
experiments (bars represent the mean ± SEM). One way-ANOVA with Bonferroni’s post-test (**p < 0.01)
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LRRK2-mediated phosphorylation increases NSF ATPase
activity
We next investigated whether LRRK2 mediated phos-
phorylation of NSF has a functional consequence on its
ATPase activity. We first identified the optimal detergent
concentrations at which both LRRK2 and NSF display max-
imal catalytic activity (0.007 % of polysorbate 20, the critical
micelle concentration of the detergent; Additional file 1:
Figure S6). Subsequently, full-length NSF was exposed to
LRRK2-G2019S970–2527 or buffer in kinase assays condi-
tions (with 50 μM ATP to minimize interference with the
subsequent ATPase assay) for 30 min. As shown in Fig. 5a,
NSF phosphorylated by LRRK2 exhibits increased ATPase
activity (Km= 355 ± 50 μM; kcat = 40 ± 11 min
−1; Vmax =
0.95 ± 0.22 μmol/min, from n = 4 independent purifica-
tions) compared to unphosphorylated NSF (Km = 178 ±
12 μM; kcat = 19 ± 4 min
−1; Vmax = 0.37 ± 0.07 μmol/min,
from n = 4 independent purifications). Given that we identi-
fied threonine 645 as a bona fide LRRK2 target, we next
assessed the ATPase activity of NSFT645A, along with NSF
wild-type, NSFT646A and NSFS647A, pre-treated with
LRRK2-G2019S970–2527 or buffer control in kinase assay
conditions. As shown in Fig. 5b, NSFT645A displays
impaired ability to hydrolyze ATP and, importantly,
activity could not be restored when NSFT645A is pre-
phosphorylated by LRRK2. Interestingly, the neighbor-
ing T646 mutated to alanine also exhibits impaired
ATPase activity that cannot be recovered by LRRK2
phosphorylation, whereas NSFS647A, two residues
apart from T645, displays ATPase activity similar to
wild-type, and this activity is enhanced by LRRK2
phosphorylation. These results strongly indicate that
T645 and T646 are critical for NSF catalytic activity.
To rule out that NSFT645A impaired activity was due
to partial unfolding, we used circular dichroism (CD) and
fluorescence spectroscopy to compare the secondary struc-
tures of NSF wild-type and NSFT645A. Tryptophan fluores-
cence is similar among wild-type and NSFT645A (Additional
file 1: Figure S7a). CD spectra also confirm that the overall
folding is maintained (Additional file 1: Figure S7b). In
addition, TEM imaging confirms that NSFT645A retains the
ability to form hexamers (Additional file 1: Figure S7c).
Taken together, these data indicate that NSF phosphory-
lated by LRRK2 possesses enhanced ATPase activity and
T645 is a crucial site for enzymatic catalysis.
LRRK2-mediated phosphorylation of NSF increases the
rate of SNARE complex disassembling
NSF-mediated ATP hydrolysis promotes disassembly of
the SNARE complex [33]. Given that NSF phosphoryl-
ation by LRRK2 increases its ATPase activity (Fig. 5), we
next postulated that this also impacts upon the rate of
SNARE complex dissociation. To test this, we monitored
the kinetic of SNARE complex disassembling in vitro as
previously described [34, 35]. We co-expressed in E. coli
recombinant soluble syntaxin, SNAP-25 and 6xHis-
VAMP and purified the assembled complex by IMAC af-
finity purification followed by size exclusion chromatog-
raphy [35]. As shown in Additional file 1: Figure S8, the
complex elutes as single band corresponding to the ex-
pected molecular weight for the soluble SNARE complex
(68 kDa), which is dissociated into the three SNARE
components upon heating. To assess whether LRRK2
phosphorylation on NSF impacts the rate of SNARE
complex disassembling in vitro, we incubated SNARE
complex (480 nM) with 1.5 μM of alpha-SNAP, an es-
sential co-factor, and 24 nM of NSF (phosphorylated or
not by LRRK2) in the presence of 2 mM of ATP, and
Fig. 5 Phosphorylated NSF exhibits enhanced ATPase activity. a NSF ATPase activity was assessed with a Malachite green assays at 36nM NSF and
increasing concentrations of ATP substrate (up to 1.4 mM) in the presence of NSF alone, NSF pre-phosphorylated by LRRK2-G2019S970–2527 (ΔG2019S) or
LRRK2-G2019S970–2527 (ΔG2019S) alone (NSF:LRRK2 20:1). Data were fitted with the Michaelis-Menten kinetic model to determine kinetic constants.
b Phosphate generated by ATP hydrolysis in the presence of NSF wild-type, NSFT645A NSFT646A NSFS647A pre-phosphorylated or not by ΔG2019S was
measured with the Malachite Green Assay at 120 min with an initial concentration of ATP of 1.4 mM (NSFWT vs NSFT645A **p < 0.01; NSFWT vs
P-NSFWT ***p < 0.001; NSFT645A vs P-NSFT645A p > 0.05, non significant, n.s.; NSFT646A vs P-NSFT646A p> 0.05, n.s.; NSFS647A vs P-NSFS647A **p < 0.01; one-
way ANOVA, Bonferroni’s post-test, n≥ 3). UT = untrasfected cells subjected to Flag-affinity purification to monitor background activity (n= 1; excluded
from the statistical analysis)
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subsequently analyzed the kinetic of SNARE complex dis-
appearance over 150 min. Under these assay conditions,
NSF phosphorylated by LRRK2 displayed a markedly in-
creased efficiency in disassembling SNARE complex com-
pared to non-phosphorylated NSF (Fig. 6a–b). These data
further support the notion that LRRK2-mediated phos-
phorylation increases NSF catalytic activity with conse-
quent acceleration of the disassembly of SNARE complexes
in vitro.
Discussion
Identification of heterologous substrates of LRRK2 kin-
ase activity is essential for understanding the cellular
pathways deregulated in PD caused by mutations in this
gene [3]. Here we provided evidence that the presynaptic
ATPase NSF is a substrate of LRRK2 kinase activity, and
that phosphorylated NSF displays enhanced ATP hy-
drolysis and SNARE complex dissociation activity
in vitro.
Multiple lines of evidence support a role of LRRK2 at
the presynaptic compartment. We previously found that
LRRK2 controls SV storage and mobilization within the
recycling pool [20] and that this process is dependent on
LRRK2 kinase activity [22]. Synaptosomes treated with
LRRK2 inhibitors exhibit decreased evoked glutamate
release [22] whereas elevated glutamate release and syn-
aptic transmission were observed in LRRK2 G2019S
knock-in mice [16]. Altogether, these data indicate that
LRRK2 kinase may play an important role in modulating
a step of the exo-endocytic pathway. LRRK2 is a com-
plex kinase with several protein interaction domains,
which was shown to assemble multiprotein complexes
during signal transduction [11]. At the presynapse,
LRRK2 interacts with several proteins [21]. Moreover,
accumulating literature suggests that LRRK2 regulates
SV dynamics via phosphorylation of presynaptic pro-
teins, such as Snapin, and EndophilinA [36–38]. The
present work provides evidence that NSF is not only an
interactor but also a substrate of LRRK2 in vitro. Re-
cently, another LRRK2 interactor, the ribosomal protein
s15, has been shown to serve as LRRK2 substrate [39],
further emphasizing the value of examining LRRK2
interacting proteins as potential kinase substrates.
Here, we demonstrated that LRRK2 phosphorylates
NSF at T645. The functional consequence of this is that
NSF hydrolyses ATP faster when phosphorylated by
LRRK2 at this residue. The physiological relevance of
this finding is further supported by the observed in-
creased rate of SNARE complex disassembling in the
presence of phosphorylated NSF. Indeed, we found
T645A is characterized by a reduced endogenous
ATPase activity. Given that T645 is located within the
D2 domain of NSF, which is thought to be important for
NSF oligomerization via ATP binding [40], these results
are consistent with our current understanding of NSF
function. Specifically, T645 is part of the beta strand S4
(aa 639–646), which stabilizes the hexamer through
interaction with the neighboring alpha-helix H5 [41].
Therefore, T645 is predicted to be a key residue for pro-
tein oligomerization, which impacts the ability of the D1
domain to hydrolyze ATP. Clearly, further investigation
is merited to determine whether LRRK2 phosphorylation
at T645 directly alters NSF oligomerization.
Translating these findings into the neuronal context,
these data imply that LRRK2 may play a role in tuning
the kinetics of SV fusion by accelerating SNARE com-
plex dissociation via NSF phosphorylation. Previous
studies reported NSF as substrate of other serine-
threonine kinases: NSF is phosphorylated by Pctaire1 at
S569 in the D2 domain, and this phosphorylation re-
duces NSF oligomerization [25]; NSF is also phosphory-
lated by PKC in vitro at Ser-237 of the catalytic D1
domain which negatively regulate NSF binding to alpha-
SNAP-SNARE complexes (Additional file 1: Figure S5)
[26]. Therefore, both Pctaire1 and PKC appear to switch
off NSF activity. In our current study, we report multiple
strands of evidence that suggest that NSF phosphory-
lated by LRRK2 is more active in vitro, however it is still
unknown whether this is replicated in vivo. Wild-type
LRRK2 is characterized by a low basal activity that may
become pathologically relevant in the presence of gain
of function mutations. We predict that in the presence
of pathological hyperactive LRRK2 variant, SV endocyto-
sis may be abnormally fast. Such alteration could result
in 1) increased neurotransmitter release or 2) impaired
Fig. 6 Phosphorylated NSF exhibits increased rate of SNARE complex
disassembling in vitro. a Representative coomassie gels (CBB, coomassie
brilliant blue) of SNARE complex incubated for increasing time with NSF
phosphorylated or not by LRRK2-G2019S970–2527 in the presence of
the co-factor alpha-SNAP. b Quantification of n = 3 independent
experiments. Time points are relative to t = 0 which was set at
100 % (two-way ANOVA with Bonferroni’s post-test, ***p < 0.001)
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neurotransmitter release by accelerating SV endocytosis.
While the second hypothesis would fit with the reduced
dopamine release observed in mice expressing LRRK2
G2019S selectively in midbrain dopaminergic neurons
[42], increased glutamate release has been reported in
G2019S knock-in neurons [16] – consistent with the
first hypothesis. Thus, additional research is needed to
clearly identify the best representative model of LRRK2
function and dysfunction in the neuron.
We also provide robust evidence that the kinase activ-
ity of LRRK2 affects SV dynamics using two comple-
mentary models: LRRK2 inhibition and hyperactive
LRRK2 (BAC hG2019S) in primary cortical neurons.
The strong impairment of SV exo-endocytosis observed in
the presence of pharmacological inhibition (Fig. 1, [22])
suggests that a consequence of therapeutic LRRK2 kinase
inhibition might be alterations in the biology of the pre-
synaptic compartment, likely impairing neurotransmitter
release and synaptic function. These observations, to-
gether with the reported side effects in peripheral organs
[43] suggest that additional strategies should be consid-
ered to target pathological LRRK2 function.
Conclusions
In the present study, we report LRRK2 kinase as a posi-
tive regulator of NSF activity and SNARE complex disas-
sembling in vitro. Future studies should also be directed
at understanding whether this phosphorylation is rele-
vant in the pathogenesis of PD.
Methods
Animals, neuron cultures and drugs
Housing and handling of mice were carried out in com-
pliance with the guidelines established by the European
Community Council (Directive 2010/63/EU of March
4th, 2014) and approved by the Italian Ministry of
Health (IACUC 625). Non-transgenic wild-type and
LRRK2 BAC hG2019S mice, back-crossed on a C57BL/
6J strain, were obtained from Mayo Clinic (Jacksonville,
FL, USA) through a collaboration with Dr. Heather Mel-
rose [28]. Animals were kept following guidelines of
Ministry of Education, Universities and Research
(MIUR). Neuron cultures were prepared from either
mouse cortexes or hippocampi obtained from embryonic
day 15.5–16.5 mice (C57BL/6 J). High-density (750–
1000 cells/mm2) and medium-density (150–200 cells/
mm2) neuron cultures were plated and grown as de-
scribed on 12-well plastic tissue culture plates (Iwaki;
Bibby Sterilin Staffordshire, UK) or on 12 mm diameter
coverslips put into 24-well plastic tissue culture plates
(Iwaki) [44]. GSK-2578215A compound (Tocris Bio-
science, Bristol, UK) or DMSO were added to culture
media at the concentrations indicated through the text.
For immunocytochemistry, primary cultured neurons
were fixed with 4 % paraformaldehyde and probed with
primary rabbit anti-NSF (1:200, D31C7, Cell Signaling,
Danvers, MA, USA) and mouse anti-LRRK2 (1:200
N231B/34, NeuroMab, Davis, CA, USA) and secondary
anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor
568 (Thermo Fisher, Waltham, MA USA).
Plasmids and constructs
pCHMWS 3xFlag-tagged LRRK2 wild-type, K1906M and
G2019S, 2x-Myc LRRK2 constructs have been previously
described [31]. NSF constructs (full-length and domains)
were cloned into p3XFLAG-CMV-7.1 vector (Sigma-Al-
drich, St. Louis, MO, USA). NSF domains were amplified
using forward primers with NotI overhang and reverse
primers with KpnI overhang as following:
N-Domain (1–205): forward 5′-AAGCTTGCGGCCGC
CTTCGCGGGCCGGAGC-3′ and reverse 5′-TCGAC
TGGTACCTTAGCGATTTTCCTTGGTTTT-3′
D1 domain (206-477aa): forward 5′-AAGCTTGCGGC
CGCCCAATCAATTATCAATC-3′ and reverse 5′-TC
GACTGGTACCTTATCTCGTCACTTGCAGGC-3′
D2 domain (478-744aa): forward 5′-AAGCTTGCGGC
CGCCGGAGACTTCCTTGCTTC-3′ and reverse 5′-
TCGACTGGTACCTCAATCAAAATCAAGGGG-3′.
NSF mutants were generated using the QuickChange
mutagenesis kit (Agilent Technologies, CA, USA) accord-
ing to the manufacturer’s instructions. All plasmids were
validated by restriction analysis and DNA sequencing.
Cell culture and transfection
Human embryonic kidney cells (HEK293T) were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM,
Thermo Fisher, Waltham, MA USA) supplemented with
10 % fetal bovine serum (FBS, Thermo Fisher, Waltham,
MA USA) at 37 °C and 5 % CO2. HEK293T were transi-
ently transfected using linear polyethylenimine (PEI,
Polysciences) with ratio DNA:PEI 1:2. 40 μg of DNA
were dissolved in 1 ml of OPTI-MEM (Thermo Fisher,
Waltham, MA USA) and 80 μl of PEI (40 μM) were
added to 1 ml of OPTI-MEM. After 5 min of incubation
the two solutions were mixed together and incubated for
20 min to allow the formation of DNA/PEI complexes.
Then, the mix was added directly to the cells in Petri
dishes of 15 cm2 and used after 48–72 h.
Antibodies, SDS-PAGE and western blot analysis
Antibodies used for western blotting were as follows:
anti-Flag M2 (1:10000, Sigma-Aldrich, St. Louis, MO,
USA); anti-NSF (1:500, Cell Signaling, Danvers, MA,
USA); anti-LRRK2 (1:1000, C41-2, Abcam, Cambridge,
UK); anti-Synaptobrevin, anti-synaptophysin and anti-
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Synaptotagmin 1 (1:1000, Synaptic System, Göttingen,
Germany).
Between 10 and 20 μg of protein samples were dis-
solved in 4–20 % Tris-glycine polyacrylamide gels
(Biorad) in SDS/Tris-glycine running buffer. Precision
Plus molecular weight markers (Biorad) were used for
size estimation. Solubilized proteins were then trans-
ferred to polyvinylidenedifluoride (PVDF) membranes in
transfer buffer containing 10 % methanol. The PVDF
sheets were blocked in Tris-buffered saline plus 0.1 %
Triton (TBS-T) plus 5 % nonfat dry milk for 1 h at 4 °C
and then incubated overnight at 4 °C with primary anti-
body in TBS-T plus 5 % non-fat dry milk. The PVDF
membranes were washed in TBS-T (3 × 10 min) at room
temperature (RT) followed by incubation for 1 h at RT
with horseradish peroxidase-conjugated anti-mouse IgG.
Blots were then washed in TBS-T (4 × 10 min) at RT
and rinsed in TBS, and immunoreactive proteins were
visualized using enhanced chemiluminescence plus (ECL
+, GE Healthcare, Waukesha, WI, USA). Densitometric
analysis was carried out using Image J software.
Protein purification
Human NSF with a N-terminal Flag tag or NSF domains
were purified from HEK293T cells after transient trans-
fection as described above. Cells were resuspended in
1 ml of a lysis buffer (20 mM Tris–HCl pH 7.5, 150 mM
NaCl, 1 mM EDTA, 2.5 mM Na4P2O7, 1 mM beta-
glycerophosphate, 1 mM Na3VO4, Protease Inhibitor
Mixture (Sigma-Aldrich, St. Louis, MO, USA)) and then
lysed with 5 cycles of freezing and thawing in liquid ni-
trogen. The cell lysate was collected after centrifugation
at 18000xg for 40 min at 4 °C. The supernatant was in-
cubate overnight with 40 μl of Anti-Flag M2 Affinity gel
(Sigma-Aldrich, St. Louis, MO, USA) at 4 °C. After cen-
trifugation, the supernatant was discarded and the beads
with human NSF were washed with 1 ml of different
buffers: WB1 (20 mM Tris–HCl pH 7.5, 500 mM NaCl)
twice, WB2 (20 mM Tris–HCl pH 7.5, 350 mM NaCl)
twice, WB3 (20 mM Tris–HCl pH 7.5, 150 mM NaCl)
six times. The protein was then eluted by incubating the
beads with 200 μl of 20 mM Tris–HCl pH 7.5, 150 mM
NaCl or directly in the kinase assay buffer (25 mM
Tris–HCl pH 7.5, 5 mM beta-glycerophosphate, 2 mM
DTT, 0,1 mM Na3VO4, 10 mM MgCl2) with 150 ng/μl
3xFlag peptide and mixing the sample for about 2 h. The
sample was centrifuged to pellet the resin and the super-
natant was collected. Note that all the purification steps
were carried out in the absence of detergent, a condition
that resulted essential to maintain NSF folding and to de-
tect specific phosphorylation by LRRK2. Purified human
NSF was separated on SDS-PAGE and quantified by com-
parison with different concentrations of BSA (Bovine
Serum Albumin). Proteins were electrophoretically resolved
on 4–20 % Tris-glycine polyacrylamide gels (Biorad) using
SDS/Tris-glycine running buffer. To estimate the molecular
weight of proteins Precision Plus molecular weight marker
(Biorad) was used. After the run, proteins were stained with
Coomassie Brillant blue to enable the quantification with
ImageJ software.
Synaptosomes preparation and immunoprecipitation
Brains from adult rats were quickly removed and the
cerebral cortex dissected out at 4 °C. Purified synapto-
somes were prepared on Percoll gradients (Sigma-Al-
drich, St Louis, MO, USA) essentially according to
Nakamura et al. with minor modifications [45]. Briefly,
the tissue was homogenized in 14 volumes of 0.32 M su-
crose, Tris–HCl pH 7.4, using a glass-teflon tissue
grinder (clearance 0.25 mm, 12 up–down strokes in
about 1 min). The homogenate was centrifuged (5 min,
1000 g at 4 °C) to remove nuclei and debris and the
supernatant was gently stratified on a discontinuous Per-
coll gradient (2, 6, 10, and 20 % v/v in Tris-buffered su-
crose) and centrifuged at 33,500 g for 5 min at 4 °C.
The layer between 10 and 20 % Percoll (synaptosomal
fraction) was collected, washed by centrifugation and re-
suspended in RIPA buffer (NaCl 150 mM, Tris 50 mM
(pH 7.4), NP40 (1%v/v), SDS (0.1%v/v) and protease in-
hibitors). To precipitate the immunocomplexes the extract
was incubated for 2 h at RT with anti-LRRK2 antibodies
(10 μg/sample; MJFF C41-2, Abcam, Cambridge, UK) or a
control rabbit IgG (10 μg/sample; Sigma-Aldrich, St. Louis,
MO, USA) conjugated with 25 μl of settled prewashed
protein G-Sepharose beads (GE-Healthcare, Waukesha,
WI, USA). The eluted proteins were separated by SDS-
PAGE, transferred onto nitrocellulose membrane (GE-
Healthcare, Waukesha, WI, USA) and analyzed by
western-blotting with anti-LRRK2 and anti-NSF (Cell Sig-
naling, Danvers, MA, USA) antibodies. Western-blotting
with anti-synaptotagmin 1, anti-synaptophysin and anti-
synaptobrevin were performed to confirm purity of synap-
tosomal preparation.
Pull-down assays
NSF domains and full length NSF were purified after
transient transfection from HEK293T cells. Cells were
harvested in 500 μl of Lysis buffer (50 mM Tris–HCl
pH 7.5, 1 mM EDTA, 2.5 mM Na4P2O7, 1 mM beta-
glycerophosphate, 1 mM Na3VO4, 0.27 M Sucrose, 1 %
Triton X-100, Protease Inhibitor Mixture (Sigma-Al-
drich, St. Louis, MO, USA)). The cell lysate was then
centrifuged at 18000xg for 30 min at 4 °C. Subsequently,
the lysate was incubated overnight with 20 μl of Anti-
Flag M2 Affinity gel (Sigma-Aldrich, St. Louis, MO,
USA) at 4 °C. After centrifugation, the supernatant was
discarded and the beads with NSF proteins were washed
three times with 1 ml of a Washing buffer (50 mM
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Tris–HCl pH 7.5, 1 mM EDTA, 0.27 M Sucrose,
250 mM NaCl, 0.02 % Triton X-100) and resuspended in
100 μl of the same buffer. Proteins were loaded on an
SDS-PAGE gel and their concentration was quantified
measuring the intensity of the band against known BSA
standards with ImageJ software.
Proteins were subsequently adjusted to the same con-
centration (2 μM) and incubated with 600 μl mouse
brain lysate (2.5 mg/ml concentrated) overnight at 4 °C.
The day after, resins were boiled with sample buffer,
loaded into a SDS-PAGE gel and transferred onto PVDF
membranes.
Size Exclusion Chromatography (SEC) and dot blot
analysis
Flag-NSF alone or Flag-NSF and 2xmyc-LRRK2 trans-
fected HEK293T cells were lysed in 500 μl of lysis buffer
containing 0.06 % (v/v) Triton X-100 and centrifuged.
Cell lysates clarified were separated on a Superose 6 10/
300 column (Ge Healthcare, Waukesha, WI, USA) pre-
equilibrated with 20 mM Tris–HCl pH 7.5, 150 mM
NaCl and 0.06 % (v/v) Triton X-100. The flow rate used
was 0.5 ml/min. A calibration curve was produced using
the following proteins and relative elution volumes:
7.5 ml for Blue Dextran (void volume), 11.5 ml for
hemocyanin from Carcinus aestuarii (900 kDa), 12 ml
for thyroglobulin (669 kDa), 14 ml for ferritin (440 kDa)
and 12.5 ml for catalase (232 kDa). Fractions of 0.25 ml
were collected and spotted onto a nitrocellulose mem-
brane and analyzed by dot blot. The membrane was
blocked with 10 % milk in TTBS and incubated with
mouse monoclonal anti-Flag M2-peroxidase (Sigma-Al-
drich, St. Louis, MO, USA) or anti-myc (Roche) in TTBS
with 10 % milk. A secondary rabbit antibody (Sigma-Al-
drich, St. Louis, MO, USA) was used to stain the anti-
myc. Immunoproteins were visualized using ECL (GE,
Healthcare, Waukesha, WI, USA).
Electron microscopy
Purified NSF proteins were incubated with 1 mM ATP
and 2 mM MgCl2. A total of 15 ng of protein was
adsorbed few minutes to a glow-discharged carbon-
coated copper grid, washed with deionized water, and
stained with 1 % uranyl acetate. Images were collected
using a Fei Tecnai T12 electron microscope equipped
with a LaB6 filament and operated at an acceleration
voltage of 100 kV.
In vitro kinase assay
Purified NSFs eluted in kinase assay buffer were incu-
bated with LRRK2 proteins dissolved in kinase buffer for
1 h at 30 °C in the presence of 33P-ATP (1 μCi) and
10 μM cold ATP as previously described [31].
Incorporated 33P-ATP was detected by autoradiog-
raphy or by Phospho-Imager system (Cyclone, Perkin-
Elmer). The same membranes were probed with anti-
Flag antibody for total protein loading and analyzed
using ImageJ software.
SypHy assay
We infected DIV4 primary neurons with viruses express-
ing sypHy, a fusion construct of synaptophysin and
super ecliptic pHluorin [29]. At DIV14 neurons were
treated with DMSO (control) or GSK2578215A (0.2 μM,
2 h). Syphy positive boutons were assayed in a stimula-
tion chamber on the stage of a Zeiss Axiovert 200 M
equipped with a mono-chromator (Poly V) and a cooled
CCD camera (PCO, Imago QE), both from TILL pho-
tonics (Gräfelfing, Germany). The assay was carried out
as described previously [46]. Briefly, cells were sub-
merged in 500 μl of KRH buffer (125 mM NaCl, 5 mM
KCl, 1.8 mM CaCl2 2.6 mM MgSO4 5 mM Hepes,
pH 7.2) in presence of APV (2 μM, Sigma-Aldrich, St.
Louis, MO, USA) and CNQX (2 μM, Sigma-Aldrich, St.
Louis, MO, USA). SypHy was excited at 475 nm and its
fluorescence emission collected at 525 nm using a 60X,
1.1 NA water immersion objective. Images were ac-
quired every second for 200 s using TillVision software
(TILL Photonics). At frame 30, cells were stimulated
with 40 action potential (AP, 20Hz) then at frame 70
with 300 AP (20 Hz). Total fluorescence was measured
upon incubation with 50 mM NH4Cl. Quantitative mea-
surements of the fluorescence intensity at individual
boutons were obtained by averaging a selected area of
pixel intensities using ImageJ. Net fluorescence changes
(ΔF) were obtained by subtracting the average intensity
of the first 15 frames (F0) from the intensity of each
frame (Ft) for individual boutons and normalized F0
(ΔF/F0). The fluorescence increase and decay, reflect
exo- and endocytosis, respectively [29]. Both the fluores-
cence upstroke and decay were fitted with a single expo-
nential τ (τupstroke and τdecay respectively). Data are
expressed as mean ± SEM and statistical significance was
assessed by unpaired two-tailed Student’s t test (Graph-
Pad Prism).
Exo/endocytotic assay
The endocytosis assay to monitor SV recycling was per-
formed using rabbit polyclonal antibodies directed
against the intravesicular domain of synaptotagmin1
(Synaptic System), applied for 5 min at RT on the cul-
tures, as described previously [30]. Incubations with the
antibody (1:400) were performed in Tyrode solution
containing 124 mM NaCl, 5 mM KCl, 2 mM MgCl2,
30 mM glucose, 25 mM HEPES, pH 7.4 and 2 mM
CaCl2. After fixation and permeabilization, a synapto-
physin counter staining with mouse anti synaptophysin,
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1:400 (Sigma-Aldrich) visualized the totality of synaptic
vesicles. Acquired images were processed and quantita-
tively analyzed with ImageJ software as previously de-
scribed [47]. Briefly, cultures were infected at DIV4 with
GPF expressing viruses and assayed at DIV14 as in [22].
GFP positive processes were manually tracked and the
number of synaptotagmin and synaptophysin positive
clusters and synaptophysin positive clusters present in
the region of interest were automatically counted.
Proteins digestion
Approximately 2 μg of purified NSF pre-dephosphorylated
with alkaline phosphatase (Promega) and subsequently
phosphorylated or not with LRRK2 in the presence of
100 μM ATP were loaded into a SDS-precasted gel
(Biorad). Gel slices corresponding to purified NSF were ex-
cised, cut in smaller pieces, dehydrated with 100 μl of
acetonitrile (ACN) for 10 min, then dried under vacuum.
A protein reduction step was performed with 100 μl of
freshly prepared 10 mM Dithiothreitol (DTT, Fluka) in
50 mM NH4HCO3, at 56 °C. After 1 h DTT solution was
discarded and 100 μl of a freshly prepared solution of
55 mM iodoacetamide (Sigma-Aldrich, St. Louis, MO,
USA) in 50 mM NH4HCO3 was added to the gel pieces
for 45 min at room temperature and in the dark. Gel
pieces were washed 4 times (10 min each) alternating
100 μl of 25 mM NH4HCO3 and 100 μl of ACN, dried
under vacuum, and suspended in 20 μl of a sequencing
grade modified trypsin solution (Promega, 12.5 ng/mL in
25 mM NH4HCO3). Digestion was performed overnight at
37 °C. Peptides were extracted with three changes (50 μl
each) of 50 % ACN/0.1 % formic acid (FA, Fluka). Samples
were dried under vacuum and stored at −20 °C till the
phosphopeptide enrichment procedure was performed.
Enrichment of phosphopeptides
Phosphopeptides were enriched with home made micro-
columns of TiO2 as previously described [48]. TiO2
micro-columns were conditioned twice with 50 μl of
ACN and twice with loading buffer (80 % ACN/6 % tri-
fluoroacetic acid (TFA, Riedel-de Haën)). Samples were
suspended in 50 μl of loading buffer and slowly loaded
into the columns, which were then washed twice with
50 μl of loading buffer and twice with washing buffer
(0.1 % TFA). Phosphopeptides bound to TiO2 were
eluted with 50 μl of freshly prepared 5 % NH4OH and
subsequently with 50 μl of 50 % ACN/0.1 % FA. Samples
were immediately acidified by adding 5 μl of 100 % FA
and dried under vacuum.
Mass spectrometry analysis
Mass spectrometry analysis of phosphopeptides was per-
formed with a LTQ-Orbitrap XL mass spectrometer
(Thermo Fisher Scientific) coupled online with a nano-
HPLC Ultimate 3000 (Dionex-Thermo Fisher Scientific).
Samples were dissolved in 30 μl of 3 % ACN/0.1 % FA
and for every analysis 8 μl of sample were loaded at a
flow rate of 8 μl/min into a trap column (300 mm I.D.,
300 Å, C18, 3 mm; SGE Analytical Science). Samples
were injected into a home-made 10 cm pico-frit capillary
column (75 μm I.D., 15 μm tip; New Objective) packed
with C18 material (Aeris Peptide 3.6 um XB-C18, Phe-
nomenex). Peptides were separated using a linear gradi-
ent from 3 to 40 % of ACN/0.1 FA in 20 min at a flow
rate of 250 nl/min.
To increase the confidence in the identification of
phosphopeptides, the MS analysis of each sample was
performed with three different acquisition methods, as
reported in [49]. A MS2 data dependent acquisition (1
full-MS scan in the range 300–1700 Da on the Orbitrap
with a resolution of 60,000, followed by MS/MS spectra
acquired in the linear ion trap for the ten most abundant
ions); a MS3 neutral loss-triggered dependent acquisition
(one full-MS scan on the Orbitrap, followed by MS/MS
scans on the three most intense ions and by MS3 upon
detection of neutral loss of phosphoric acid in MS2 spec-
tra); a Multi Stage Acquisition (MSA) (1 full-MS scan at
a resolution of 60,000 followed by MS/MS scans on the
three most abundant ions with the activation of neutral
loss product without an additional isolation cycle).
Raw data files were analyzed with Proteome Discov-
erer software (version 1.4, Thermo Fisher Scientific) con-
nected to a Mascot Server version 2.2.4 (Matrix Science,
UK) and a SequestHT search engine version 28.0
(Thermo Fisher Scientific) against the Uniprot Human
Database (version 2013.11.13 used by SequestHT, ver-
sion 2014.04.16 used by Mascot). Trypsin was set as
digesting enzyme with up to two missed-cleavages. Car-
bamidomethyl cysteine was set as fixed modification,
while phosphorylation of Ser/Thr/Tyr and methionine
oxidation were set as variable modifications. Peptide and
fragment tolerance were 10 ppm and 0.6 Da respectively.
Percolator was used to calculate False Discovery Rate
(FDR) based on the search against the corresponding
randomized database. MS/MS spectra of phosphopep-
tides were manually inspected for confirmation and as-
signment of phosphorylation sites.
ATPase enzymatic assay
NSF ATPase activity was quantified using the Malachite
Green Assay by measuring the release of inorganic phos-
phate (Pi) due to the ATP hydrolysis with spectropho-
tometer. The assay was adapted from the method of
Lanzetta et al. [50]. The Malachite Green Stock solution
used for the assay was a mixture of two different solu-
tions (one with 34 mg Malachite Green oxalate salt
(Sigma-Aldrich. St. Louis, MO, USA) into 40 ml HCl
1 M and the other with 1 g (NH4)2MoO4 (Sigma-
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Aldrich, St. Louis, MO, USA) into 14 ml HCl 4 M to a
final volume of 100 ml with distilled water and then fil-
tered through 0,45 nm. The concentration of human
NSF used for the ATPase assay was 216 nM (36 nM
hexameric concentration) with different ATP concentra-
tion. Reaction was performed at 37 °C and followed for
120 min. The time point aliquots collected (20 μl) were
mixed with 150 μl of Malachite Green stock solution
until the solution became homogenous and the absorb-
ance measured at 640 nm using a corresponding Mal-
achite Green solution as blank. The values of absorbance
were then converted into μmol of free Pi in solution
using a standard curve. To reported values for the kin-
etic constants (Km, kcat and Vmax) were obtained by data
fitting with the Michaelis-Menten kinetic model (Y =
Vmax*S/(Km + [S])).
Reverse-phase HPLC ATPase assay
To determine the ATPase activity of NSF, 500 or
700 μM ATP was added to 0.2 μM 3xFlag-NSF wt. Pro-
teins were purified as previously described and incu-
bated at 37 °C for 1 h in the same kinase buffers and
conditions of the Malachite Green Assay. At the re-
ported time-points, aliquots (20 μl) were taken up to
120 min and heated for 3 min at 95 °C with 0.1 M of
EDTA to stop the reaction. Samples were stored at −80 °
C. Reverse Phase High-Performance Liquid Chromatog-
raphy (RP-HPLC) was used to monitor the amount of
ATP and ADP present in the sample. Nucleotides were
separated on a Jupiter 5u C4 300A (Phenomenex) col-
umn using an Agilent HP 1100 HPLC, pre-equilibrated
with 50 mM NaH2PO4 pH 6.5, 10 mM Tetra-n-
butylammonium bromide and 4 % ACN. The flow-rate
used was 0.5 ml/min and the amount of the nucleotides
was monitored measuring the increase in area of the
peak corresponding to ADP measured at 256 nm with a
total run time of 35 min. To convert this value to the Pi
released by the reaction, a standard curve generated with
different ADP concentration was used. ADP concentra-
tions detected in the assay were plotted as a function of
time and an equation was obtained through linear re-
gression with GraphPad Prism 5.
Recombinant alpha SNAP and SNARE proteins production
Rat alpha-SNAP cloned in pET28 plasmid in fusion with
a His-tag was a kind gift of Dr. Reinhard Jahn, Max-
Planck-Institute, Göttingen). Alpha-SNAP was subse-
quently expressed in E. Coli in BL21(DE3) strain. Bac-
teria were grown at 37 °C to an OD at 600 nm of 0.4–
0.6, then induced with 0.25 mM isopropyl β-D-1-thio-
galactopyranoside (IPTG) for 4 h. Cells were then har-
vested by centrifugation and the pellet of 250 ml of
culture was resuspended in 5–10 ml of Tris–HCl
pH 8.0. Phenylmethylsulfonyl fluoride (PMSF) 100 μM
and a cocktail of protease inhibitors were added to the
cells 1:100 (v/v) that were subsequently subjected to one
French Press cycles (Constant Systems Ltd). The cell
homogenate was centrifuged and the supernatant loaded
onto a Co2+ affinity column and eluted with a 0–
500 mM linear gradient of imidazole at 0.5 ml/min. Pro-
tein solution was dialyzed versus Tris–HCl 20 mM
pH 7.5, NaCl 150 mM.
Soluble SNARE complex was obtained by co-
expression of wild type SNAP-25A, of syntaxin-1A and
of His-tagged VAMP2(1–96) using the Duet expression
system (Novagen) in E. Coli in BL21(DE3) strain.
VAMP2(1–96)-His6-TEV pACYC-Duet and syntaxin-
1A/SNAP-25A pET-Duet were a kind gift of Prof. A.
Brunger (Stanford University, California) [34]. Bacteria
were grown at 37 °C to an OD at 600 nm of 0.6–0.8,
then induced with 0.5 mM IPTG for 4 h. Cell pellets of
250 ml of culture were suspended in 10 ml of 50 mM
NaPi, pH 8.0, 300 mM NaCl, 20 mM imidazole and
0.5 mM Tris(2-carboxyethyl)phosphine (TCEP) (SNARE
buffer), supplemented with PMSF 100 μM and protease
inhibitors cocktail. Cell were lyses by two French Press
cycles (Constant Systems Ltd) and the lysate was clari-
fied by centrifugation for 1 h at 15,000 g at 4 °C. The
supernatant was loaded onto a 1-ml Ni2+ affinity col-
umn, washed with 20 ml of SNARE buffer containing
7.5 M urea and then with 20 ml of SNARE buffer. The
complex was then eluted with SNARE buffer containing
350 mM imidazole. After elution, SNARE complex was
subjected to size exclusion chromatography using a
Superdex 200 10/300 (GE Helthcare) that was equili-
brated with 50 mM Tris–HCl, pH 7.5, 100 mM NaCl.
The SNARE complex was checked and quantified by
SDS-PAGE.
SNARE dissociation assay
As previously described [34] the SNARE dissociation as-
says were performed at 37 °C in 240 μl in a 1.5 ml
micro-tube. The assay buffer was composed of 25 mM
Tris–HCl pH 7.5, 5 mM β–glycerophosphate, 2 mM
dithiotreitol (DTT), 0.1 mM Na3VO4, 10 mM MgCl2
and 0.007 % polysorbate 20. Subsequently 1.5 μM
αSNAP, 480 nM SNAREs, 24 nM NSF (hexameric con-
centration) phosphorylated or not by LRRK2 (ratio
NSF:LRRK2 20:1) were added in the presence of 2 mM
ATP to start the reaction. At defined time points, an ali-
quot (20 μl) was collected and loaded into an SDS-
PAGE gel without boiling the samples: being the SNARE
complex is SDS-resistant, it runs as a single band on
SDS-PAGE gel. The intensity of each SNARE complex
band was calculated and normalized to its time zero.
The experiments were performed in triplicate up to
150 min of reaction.
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Circular Dichroism (CD)
CD measurements were carried out on a JASCO J-810
spectropolarimeter interfaced with a personal computer.
The CD spectra were acquired and processed using the
J-700 software for Windows. All experiments were done
at room temperature using an optical path length of
0.2 cm. The wavelength range of the measurements was
197–250 nm, using a bandwidth of 2 nm and a time
constant of 8 s at a scan speed of 50 nm/min. The signal
to noise ratio was improved by accumulating four scans.
Spectra were acquired using purified proteins in the elu-
tion buffer (20 mM Tris–HCl pH 7.5, 150 mM NaCl
and 0.007 % polysorbate-20) using the same buffer with
3xFlag peptide as a control. All the spectra are reported
in terms of mean residue molar ellipticity (deg cm2 dmol
−1). Protein concentrations in the samples were deter-
mined by SDS-PAGE and all the spectra were normal-
ized for the measured protein concentration.
Intrinsic fluorescence
Fluorescence emission spectra were recorded on a Cary
Eclipse fluorescence spectrophotometer (Varian, Agilent
Technologies, Santa Clara, CA) using the Cary Eclipse
program. Sample measurements were carried out using
optical path length of 10 mm. Fluorescence spectra were
obtained using an excitation wavelength of 288 nm, with
an excitation bandwidth of 5 nm and slit width of
10 nm. Emission spectra were recorded between 300
and 400 nm at a scan rate of 30 nm/sec. Spectra were
acquired using 80 nM proteins in 20 mM Tris/HCl buf-
fer (pH 7.5), 150 mM NaCl and 0.02 % Tween 20.
Statistical analysis
All quantitative data are expressed as mean ± SEM and rep-
resent at least three independent sets of experiments. Sig-
nificance of differences between two groups was assessed
by two-tailed unpaired t-test or one-way or two-way
ANOVA with Bonferroni’s post-test when more than two
groups were compared. Significance was set at p < 0.05.
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Figure S1. Expression and phosphorylation of LRRK2 in primary cortical neurons 
subjected to SypHy assays. (a) Cortical neurons from wild-type and BAC hG2019S mice 
were kept in culture until DIV14, treated or not with LRRK2 inhibitor GSK2578215A (GSK 
in, 0.2 M, 2h) and assayed for western blotting. Samples were processed to measure 
LRRK2 phosphorylation at Ser935, total LRRK2 and tubulin level. Graphs report P-Ser935 
level normalized on total LRRK2 level (b), total LRRK2 level normalized on tubulin amount 
(c). Data are expressed as mean ± SEM, n=3 (** p<0.01 versus control, ANOVA). (d) Total 
number of SV pools was not altered in BAC hG2019S neurons. The graph reports number 
of synaptophysin-positive clusters per 10 µm of GFP-positive process. 
 
 
 
Figure S2. Biochemical validation of recombinant human NSF. (a) Representative 
TEM micrograph of purified Flag NSF wild type (20 ng/µl) with 1 mM ATP and 4 mM MgCl2 
showed the typical hexameric structure (scale bar 50 nm). (b) Recombinant human NSF 
co-purifies with endogenous NSF as confirmed by western blot analysis with anti-flag and 
anti-NSF antibodies. (c) Isocratic RP-HPLC profile of the two different nucleotide peaks 
over time ([ATP] = 0.7 mM). The ATPase activity of NSF was evaluated also with the rate 
of inorganic phosphate (Pi) released measuring the area under the peak of ADP with RP-
HPLC (d) and with the Malachite Green Enzyme Assay ([ATP] = 0.5 mM) collecting 
aliquots as a function of time (n = 5) and subtracting a control purification of untransfected 
cells (e). Velocities of the reactions (slopes) were calculated by linear regression using 
GraphPad Prism 5 software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. LRRK2 phosphorylation of NSF occurs within the first 30 minutes. 
(a) In vitro kinase assays with LRRK2-G2019S970-2527 and NSF up to 240 minute reaction 
time. (b) Quantification of radioactivity incorporated by NSF over time. 
  
  
 
Figure S4. LC-MS/MS analysis of NSF phosphorylated by LRRK2. 
(a) Sequence coverage of NSF phosphorylated by LRRK2. (b) Manually annotated MS/MS 
spectrum relative to the monophosphorylated peptide KLLIIGTTSR from NSF. Charge: +2,   
Monoisotopic m/z: 591.33636 Da (+0.03 mmu/+0.04 ppm respect to the theoretical m/z),   
MH+: 1181.66545 Da. Identified with Mascot with an IonScore of 60 (Exp Value of 2.5E-
005). The presence of the fragment y2 suggests that the phosphorylation site is probably 
not located at the level of the serine residue. The fragmentation pattern is compatible with 
a phosphorylation at T645 or T646. 
  
 
 
 
Figure S5. PKC does not phosphorylate NSF at T645. 
(a) In vitro kinase assays with PKC and NSF (1:10, PKC:NSF). Upper panel shows a high 
exposure image where autophosphorylation of PKC can be observed. Middle panel 
represent a low exposure phosphoscreen. Lower panel shows a coomassie of the same 
membrane to normalize for protein loading. (b) Quantification of radioactivity incorporated 
by NSF wild-type and T645A (n=3 independent experiments). 
 
  
 
 
 
 
 
 
 
 
 
 
Figure S6. Evaluation of optimal detergent concentration for LRRK2 and NSF 
activities.  
Optimal polysorbate 20 concentration for the reactions was evaluate within ability of 
LRRK2 to phosphorylate itself measuring the intensity of the band with an antibody against 
one of its auto-phosphorylation site (T2483). At the same time, the activity of human NSF, 
using the same concentration of detergent, was evaluate measuring the V0 of the reaction 
with the Malachite Green Enzyme assay. 
 
 
 
 
 
Figure S7. NSF wild-type and T645A have similar overall folding and T645A forms 
hexamers. 
Recombinant human NSF wild type and NSFT645A were analyzed measuring the CD and 
Intrinsic Fluorescence Spectra. (a) CD spectra were normalized by protein concentration 
previously measured with an SDS-PAGE gel. (b) The protein concentration used for 
Intrinsic Fluorescence measurements was 0.9 µM. (c) Representative TEM micrograph of 
purified Flag NSF-T645A (20 ng/µl) with 1 mM ATP and 4 mM MgCl2 (scale bar 50 nm). 
 
 
 
 
 
 
 
 
Figure S8. Expression and purification of SDS-resistant SNARE complex. 
SDS-PAGE gel of the purified SDS-resistant SNARE complex (68 kDa) obtained by co-
expression of Syntaxin, SNAP-25 and 6xHis-VAMP in E. Coli BL21(DE3) strain, either 
boiled (+) and not (-) to disassemble the three single components. 
 
 
